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4ABSTRACT
This sub-thesis attempts to show the relevance of Bayesian ideas in biostatistics by 
focusing on selected problems. It consists of two chapters.
The first chapter presents several statistical models involving failure time data in the 
presence of noninformative right-censoring. These models are examined using Bayesian 
methods and the theory is illustrated by application to medical data. Point estimates and 
confidence regions are constructed for parameters and quantities of interest. Inferences 
based on vague priors are compared with analogous frequentist results. The fiducial 
approach stemming from these results is also investigated and shown to closely parallel the 
Bayesian argument. Some of the solutions presented illustrate the usefulness of Monte 
Carlo methods such as the Gibbs sampler. Some recent applications of the Bayesian 
paradigm in biostatistics are reviewed.
The second chapter examines a sequential phase ÜB clinical trial design developed by 
Thall and Simon (1992, 1993) to compare experimental and standard treatment response 
rates. The Bayesian stopping rules and analysis are based on posterior probabilities 
computed at each patient response, and the design is evaluated in terms of frequentist 
operating characteristics.
Thall and Simon's design requires the specification of strictly beta priors, which may not be 
appropriate in some situations. It is shown how this restriction can be relaxed via a 
discretizing approximation so as to permit continuous priors of any shape. Practical 
guidelines are offered for assessing the precision of this approximation.
All computations were performed using the statistical package Splus on Sun workstations. 
Some of the code is given in Appendix 3. Appendix 1 lists some notation, and proofs of 
selected results are presented in Appendix 2. An author index and a subject index are also 
provided.
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BAYESIAN SURVIVAL ANALYSIS
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1.1 SUMMARY
In this chapter, it is shown how the Bayesian paradigm can be applied to various problems 
involving failure time data. For some of the scenarios considered, results are compared, 
theoretically and by way of example, with those obtained using other approaches, in 
particular the classical frequentist and fiducial. Often, close if not complete agreement is 
found for some special case of the Bayesian procedure.
Some of the Bayesian solutions illustrate the use and importance of Markov Chain Monte 
Carlo methods such as Gibbs sampling, data augmentation and the Metropolis algorithm. 
Also illustrated are Newton-Raphson iteration, the EM algorithm, Laplace's method and the 
ratio of uniforms sampling technique. Rao Blackwell arguments are used to construct 
estimates of marginal posterior densities and moments. These estimates are compared with 
normal and lognormal approximations as well as with exact results obtained via numerical 
quadrature. The problem of predictive inference is addressed, and it is shown how 
unobserved shared covariate information can be accounted for in the form of frailty terms.
1.2 INTRODUCTION
The aim here is to focus on only a few examples. Hopefully, these will provide a useful 
guide for implementing the Bayesian philosophy in any biostatistical setting.
The Bayesian approach has many attractive features when compared with the frequentist. 
The frequentist typically requires asymptotic likelihood theory, and in biostatistics this is 
especially evident due to the complication brought about by censoring. This leads to only 
approximate solutions, the precision of which is an open question for small-to-medium 
sample sizes. Sometimes, the complexity of a model makes frequentist inference practically 
impossible without the application of questionable ad hoc rules. With the Bayesian
11
approach, however, inference always proceeds direcdy and 'exactly' from the posterior 
distribution, regardless of sample size and complexity.
On the other hand, this 'exactness' will often be only theoretically attainable, requiring non­
trivial amounts of computation as well as sophisticated mathematical techniques to achieve 
a reasonable degree of precision. This has in the past been one of the major hindrances to 
the acceptance of Bayesian methods, and even today computer technology has a long way 
to go before the computations involved in solving a complex Bayesian model can be 
considered feasible on a regular basis.
Perhaps more fundamentally, Bayesian inference always requires the specification of a 
prior distribution. When little is known a priori, this specification will be problematic. 
Although 'vague' priors have been suggested, these are conceptually unappealing because 
they are typically improper (i.e., integrate to infinity). Moreover, an improper prior can 
result in an improper posterior. Research is currently under way to determine when this 
happens. The question of what inference is possible in such a situation also needs to be 
addressed.
1.2.1 Outline
Section 1.3 gives a motivating example involving the estimation of an exponential hazard. 
It is shown how frequentist inference can in some situations be considered a special case of 
Bayesian methods. Markov Chain Monte Carlo techniques are introduced via the data 
augmentation algorithm. This algorithm is demonstrated by application to some leukemia 
remission time data.
Section 1.4 is concerned with the comparison of two exponential distributions. Here, a 
Bayesian treatment is compared with both frequentist large sample results as well as a 
fiducial approach based on these results. In an application to some lung cancer data, the 
fiducial approach is shown to provide a conceptual link between the other two. The 
usefulness of Laplace's method and ordinary Monte Carlo inference is illustrated, and the 
lung cancer data is reanalyzed according to a prognosis model incorporating covariate 
mortality information.
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Section 1.5 develops an exponential frailty model. This takes into account unobserved 
covariate information common to all members of the same group of individuals. Here, 
Monte Carlo methods are shown to be invaluable inferential tools, and the theory is applied 
to some kidney infection recurrence time data. It is shown how this data together with the 
model can be used to make predictive statements.
Section 1.6 reviews some other Bayesian models involving failure time data, and addresses 
the issue of nonparametric estimation.
Finally, Section 1.7 discusses the present and future roles of the Bayesian paradigm in 
biostatistics and highlights some outstanding problems associated with i t
13
1.3 ESTIMATING AN EXPONENTIAL HAZARD
To best clarify the issues involved in the Bayesian treatment of biostatistical problems, we 
will begin with the simplest possible example. The results and techniques established will 
form the basis for later sections.
Consider a study wherein n individuals are put on test and observed until they have all 
either failed or been right-censored. The censoring mechanism will throughout be assumed 
noninformative. This means that the times to censoring are independent of the failure times 
and have a probability distribution (possibly degenerate) which does not involve any 
unknown parameters defining the failure time’s distribution.
Suppose that the underlying survival distribution is exponential with (constant) hazard A, 
and that the survival times of the n individuals are independent. Then the likelihood (of A 
given the data) is 
L  = L(Aly) 
ocp(yU)
( i- i )
i=1
where:
, • • •, are the (unordered) observed times; 
f i t )  = Xe~^ (the failure time p.d.f.);
S{t) = e~^ (the failure time survivor function);
<5, is the indicator function for the ith individual failing (i.e., not being censored); 
y denotes the data, i.e. (*1, ^ ),•••,(*„,£„); and 
p( ) is used generally to indicate 'p.d.f. of (•).’
It follows from (1-1) that
L = Xde-vk,
where:
is the number of failures, and 
v = q+. • -+rn is the total time on test.
Unless otherwise specified, these symbols and notation will remain in effect throughout 
this treatise; see also Appendix 1 for a comprehensive list of abbreviations.
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Note that (1-1) is the appropriate form for the likelihood under various kinds of censoring 
(e.g., see Kalbfleisch and Prentice, 1980). These include Type I where the censoring time 
for each individual is fixed in advance, Type II where d is fixed in advance, and Random 
where the censoring time has a probability distribution. In a Bayesian analysis, this 
distinction is irrelevant because inference is based entirely on the product of prior and 
likelihood, each of which is identical in every case. However, the same cannot be said of 
frequentist methods, where inference depends on the distribution of the maximum 
likelihood estimator (m.l.e.). This fact constitutes a fundamental difference between the 
two approaches. In particular, it shows the Bayesian paradigm to be conceptually simpler.
Note also that (1-1) would need modification if some of the observations were left- 
censored (a different distinction). Such a situation is considered in Calabria and Pulcini 
(1990).
1.3.1 Frequentist solution
a
The m.l.e. of X is readily found to be X -  d /v  (the solution in X of <9logL / dX = 0). 
Inference under Type II censoring
Under Type II censoring, it can be shown (e.g., see Lawless, 1982) that
A  a
2vX = 2dX ! X ~ Xid- B follows (from 2dX / X thereby providing a pivotal quantity), that 
an exact and central 100(1 -  a)% confidence interval (Cl) for X is
z f A a /2 )  ^ ( l - « / 2 ) l
2v ’ 2v j
where Zv2(’) is the quantile function of the Zv distribution.
Other types o f censoring
For censoring other than Type II, the m.l.e. no longer has a simple distribution (although its 
realization is numerically the same), and accordingly (1-2) is not appropriate. However, 
several large sample results are available.
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The most basic is that (A -  A)^/(A) ~ 7/(0,1), where /(A) = - d2 logL/ dA2 = d / A2 is the 
observed Fisher information. From this it follows that an approximate 100(1- a)% Cl for 
A is
[ i ± & - \ \ - a / 2 ) y f d / v l  (1-3)
where d>-1() is the quantile function of the standard normal distribution.
A better approximation
Since A is strictly positive, however, a better Cl than (1-3) is obtained by first transforming 
to a parameter which can take on any real value. For convenience, let A - e P . Then 
(ß -  ß)^I(ß)  ~N ( 0,1), where I(ß) = - d 2\ogL / dß2 =ve^ is again the observed Fisher
A A
information (but under the reparameterization) and ß  = log A is the m.l.e. of ß. It follows 
that an approximate 100(1 -  a)% Cl for A is
[Äex v {± < S > -\\-a ll) l4 d )l  (1-4)
1.3.2 Bayesian solution
For convenience, we will here consider the class of priors (i.e., prior p.d.f.'s) defined by 
p(A)<* A >0,
where a e SR, b > 0, and a < 1 if b = 0.
This is a convenient choice because it includes the class of conjugate priors (in this case 
gamma distributions) as well as the improper Jeffreys prior p(A)ocl /A  (see Box and 
Tiao, 1973). In general, the Jeffreys prior is defined as proportional to the square root of the 
Fisher information and has the 'nice' properties of representing vagueness and of leading to 
solutions which are invariant under reparameterization. Also, conjugate priors allow 
mathematical tractability to be maintained, and are intuitively appealing in that the 
posterior is in the same class as the prior.
Given this class of priors, the posterior (i.e., posterior p.d.f.) is
Pa\y)
P(y)
~  p(X)p(y\X)
~ Xa~le~bk x A V vA 
_  ^(a+d)-lg-(b+v)X
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It follows that (Aly) ~ G(a + d,b + v), where G(rj, r) denotes the gamma distribution with 
mean 77 /  t. Inference now proceeds immediately from this result, irrespective of the type 
of censoring involved. However, there is some arbitrariness in deciding which summary 
statistics are most meaningful.
Point estimates
Two convenient point estimates for A are the posterior mean
XE = E(X\y) = ^
and the posterior mode 
 ^ _ a + d - 1
Xu~~bTT'
The posterior mode is the value of A which is in a sense 'most likely,' and the posterior 
mean is that which would on average be attained after repeating the experiment an infinite 
number of times (assuming the model and prior to be 'correct'). Note that these 
considerations are essentially ffequentist in character. Sometimes the mode is the preferred 
point estimate because of its relative insensitivity to the tail behaviour of an arbitrarily 
specified prior.
Decision-theoretic approach
From a decision-theoretic point of view, the posterior mean is also that value of A which 
minimizes posterior expected squared loss, in the sense that 
£ [ ( A - iE)2ly]S£[(A -Ä 0 )2ly] V X0 ,
where X0 denotes any other estimate of A. The proof of this result follows upon 
expressing the RHS of the inequality in terms of (A -  i E) and (AE -  Aö ), and noting that 
£(A - i E\y) = 0 and E[(iE -  A0 )2ly] = {XE -  X0 )2 > 0.
Although we will not pursue a decision-theoretic approach here, it should be kept in mind 
that such is therefore implicitly adopted whenever reference is made to a posterior mean. 
See Mehta (1981) and Tahir (1991) for a decision-theoretic treatment of censored 
exponentials.
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Confidence regions
As regards confidence regions, the one most widely used is the highest posterior density 
(HPD) region of content ( l - a ) ,  as defined in Box and Tiao (1973). For the class of priors 
considered, the (1 -  a) HPD region for A has no closed form. It can, however, be defined 
as [LB, UB], where LB and UB are such that:
LBa+d~xexp[-(h + v)LB] = UBa*d~x exp[-(h + v)UBl and 
xl(a+i)VUB(b + V)) -  x l(a+*)VLB(b + v)) = 1 -
where Xv()  is the c.d.f. of the X" distribution with t> d.o.f. The HPD region bounds can 
thus be obtained via an iterative search procedure.
Another interval with intuitive appeal is what we shall term the central posterior density 
(CPD) region of content ( l - a ) ,  or equivalently, the ( l - a )  CPD region. The (1 -a )  
CPD region for A is defined as [LB,UB], where LB and UB are such that a / 2 = 
Pr(A < LB\y) = Pr(A > UB\y). Solving for these bounds, we obtain
Xl(q+d)(a  / 2) Z2(a+d)(l ~ a  / 2) q  ^
2 (b + v) 2(6+ v)
1.33 Comparison
If the censoring is Type II and the Bayesian summary statistics are taken to be the posterior 
mean and CPD region, it will immediately be seen by comparison of (1-2) and 
(1-5) that the frequentist solution is in effect a special case of the Bayesian. In particular, 
use of the vague Jeffreys prior {a = b = 0) leads to identical conclusions concerning A. 
This equivalence can be seen as a reason for using CPD's rather than HPD's.
In the presence of other types of censoring, the complicated distribution of the m.l.e. 
generally precludes exact frequentist inference. Asymptotic maximum likelihood theory 
must then be invoked to obtain an approximate confidence interval. On the other hand, the 
posterior is the same regardless of the censoring mechanism, so that the Bayesian solution 
is unaffected.
A disadvantage of the Bayesian approach is that the parameterization of a model can affect 
the analysis. An example of this is given in the next subsection.
18
l .  3.4 Parameterization inconsistencies
Consider the equivalent problem of estimating the mean \ i - 1 / A of the underlying 
lifetime distribution, and assume that an appropriately inverted class of priors is specified 
for this mean (including the class of inverted gamma distributions). Then it can easily be 
shown that the m.l.e., frequentist Cl bounds and Bayesian CPD region bounds for p. are 
simply those for A but inverted. However, the same cannot be said of the HPD region 
bounds, nor of the posterior mode and mean. Furthermore, there is no prior in the class 
considered for which the dual identity
m.l.e. = posterior mean and (1 -  a ) Cl -  (1 -  a) CPD region
holds for f i . Remember that this identity occurs for X under the Jeffreys prior.
The question then arises whether there is any prior for which this identity is true for f J .. But 
the answer is no. This is because p(ji) 1 / p 2 is the only prior (proper or improper, inside
or outside of the class considered) which results in equality of the posterior mean and the
m. l.e. For a proof of this result, see Bhattacharya (1967).
1.3.5 Example
Taken from Lawless (1982), the following are the remission times in weeks of 30 leukemia 
patients undergoing a certain treatment; starred observations are censored: 1, 1, 2, 4, 4, 6, 6, 
6, 7, 8,9, 9, 10, 12, 13, 14, 18,19, 24, 26, 29, 31*, 42, 45*, 50*, 57,60,71*, 85*. 91. We 
will assume that the times to remission in the absence of censoring are i.i.d. exponentials. 
The following are frequentist and Bayesian inferences on the hazard X of the underlying 
exponential distribution. It will be observed that the two approaches yield very similar 
results.
Frequentist solution
Since d = 25 and v = 760, the m.l.e. of X is A = 25/760 = 0.03289. Assuming the 
censoring to be noninformative Type I, two approximate 95% Cl's for A are [0.02000, 
0.04579] and [0.0223, 0.04868], obtained using (1-3) and (1-4), respectively. The second 
Cl is the preferred one.
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Bayesian solution
*
Taking the usual vague prior (a = b = 0), we find that the posterior mode is XM = 0.03158. 
Also, the posterior mean is the same as the m.l.e. (0.03289). Finally, the 95% HPD and 
CPD regions for X are [0.02054,0.04601] and [0.02129, 0.04699], respectively.
1.3.6 Data augmentation
Markov Chain Monte Carlo methods are powerful tools which can be used to estimate 
entire posterior densities. One such method is the data augmentation algorithm', see Wei 
and Tanner (1990). Although redundant here (because the posterior is known), it will 
nonetheless be interesting to see how well this algorithm performs in the context of our 
example. A multivariate extension of data augmentation called the Gibbs sampler will be 
used in Section 1.5 to estimate a density not expressible in closed form, and what follows 
here is intended as an introduction to that technique.
The conditional distributions
Let z = (z\,--,zn_d) be the latent data, where z,- is the 'true' time to death of the zth 
censored individual. Then conditional on X and the data y, z has posterior
p(z\X,y) = J"lAeA(z‘"',), Zi>ti.
i=1
That is, the (z,IA,y) are i.i.d. truncated exponentials.
Also, the conditional posterior of X given the augmented data (y,z) is
p a iy ,2 )~ A a+V li,+w(z)1\
where w(z) is the sum of the uncensored times and the elements of z. Thus, 
(Aly,z) -  G(a + n,b + w(z)).
The algorithm
The data augmentation algorithm can now be defined as follows:
1. Decide on an initial estimate //°^(Aly) for the posterior of X (preferably a 
density from which it is easy to sample). Also decide on the number m of
20
distributions per mixture, the total number of iterations N, and the number of 
mixtures M to be used in estimating the posterior.
2. For y = 1 ,2 ,-,N :
a) Sample A(1),---,A(m)-i.i.d . p^~l\X \y).
b) Sample z(t) ~ p(zlA(t\y ), t = l,-**,m.
c) Let p0)(Aly) = —£p(A ly ,z(0).
m i=l
1 N
3. Estimate p(Aly) by p(Aly) = — ^ p (;*(Aly).
M  j= N -M +1
Thus the (marginal) posterior of A is estimated by the average of the last Af mixtures of m 
augmented posteriors. Note that each iteration involves sampling from m + m (n -d ) 
distributions.
The precision of p(Aly) obviously depends on the choice of m, N  and M as well as the 
model. We will not examine this issue in a theoretical vein, but see Tanner and Wong 
(1987) where the rate of convergence of the data augmentation algorithm is discussed 
generally.
Example
Applying the algorithm to the leukemia data with p (0)(Aly) «= exp(-(l /0.03)A) (an 
exponential distribution with mean approximately equal to the m.l.e.), m -  10 and 
a = b = 0, we obtained the series of posterior estimates shown in Figure 1-1 on page 21. 
The mixtures of augmented posteriors at iterations 1, 2 and 20 are plotted, as is the mean of 
the mixtures obtained at iterations 16 through to 20 (i.e., the final estimate p(Aly) defined 
by N = 20 and M -  5). Also shown are the true posterior p(Aly), our initial estimate 
p(0)(Aly), and the posterior ignoring censoring (i.e., the G(a + nyb + v) density).
Figures 1-2 and 1-3 on pages 22 and 23 present results obtained for the same experiment 
but with m increased to 100 and 1000, respectively. See Section A3.1 of Appendix 3 for the 
Splus code used to perform these simulations.
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1.4 COMPARISON OF TWO EXPONENTIAL DISTRIBUTIONS
Consider a study wherein two treatments T\ and 72 are applied to n\ and «2 individuals, 
respectively, and the n = nx + times to response or censoring are observed, whichever 
occurs first for each individual. It will be assumed that the times to response are 
independent exponentially distributed random variables with hazards and A2 (under 7 1 
and 72, respectively), and that the censoring mechanism is noninformative.
In what follows, we will derive and compare point estimates and confidence 
intervals/regions for the hazard ratio r = X2 /X l using several different approaches, namely 
the frequentist, Bayesian and fiducial. Note that r has two interpretations, the second being 
the ratio of the mean time to response under 7 1 to that under 72.
1.4.1 Frequentist solution
Denote the data by y = ( ^ , 3^ ), where:
yt- = (>7i»**•»>«.)» i = 1» 2 (treatment 7, being indicated by 1); 
yij -  (*ij y Sy), j  = 1, • • •, n,;
tij is the observed time for the /th individual in the 7/ group; and 
Sy is the indicator function for ttJ being a response time.
Also let:
di = H---- \-Sin^ (number of responses in the 7,- group);
d = di + dtf
vi = %+* * (total time on test for the 7/ group);
fi{t) = A,e_A'r (response time p.d.f. for individuals in the 7, group); and
Siit) = e_A,/ (response time survivor function for individuals in the 7, group).
Then the likelihood is
L -  LiXx,X2\y)
~piy\X^X2)
2 *
^  f i  itij) lJ Si itij) v by (1 -1) and independence
i=i j-\
= Xld'e~X'v'X2e~Xl'’2.
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Upon reparameterization to y  -  (A ß )' = logr)' (to facilitate the normal 
approximations we will employ), the likelihood can also be expressed as 
L = L( y\y) = exp {Ad + d ^  ~ e-A (Vi + v2e^ )}.
Then, setting the score U = dlogL / d y  to zero, we obtain the m.l.e.
m log )V1
U J l o g ^ -4 / v , J
and hence a point estimate for r, namely the m.l.e. 
? = eß = *2±Ü2'
d i / v 1 '
Note that this result could, by independence, have been obtained simply by dividing the 
individual m.l.e. of A2 by that of A^
Type I I  censoring
7In the case of Type II censoring, the result 2v,A,-= 2d,A,-/ A,-~ i.i.d. X2dL (from 
Subsection 1.3.1) implies that
( 1-6)
r F2d2,2dx
Hence an exact 100(1 -  a)% Cl for r is
(«  /  2)- (1 -  «  /  2)],
where (•) denotes the quantile function of the F distribution with Dj and v2 d.o.f. 
O ther types o f  censoring
To compute Cl's for r in situations where the censoring is other than Type II, one 
possibility is to use the large sample maximum likelihood result
ß±N<ß,I22( y ) \  (1-7)
where l 22(V) is the second diagonal element of the inverse of the observed Fisher
information I ( y )  = - d U / d y '  evaluated at the m.l.e. It is easily shown that 
I22(y )  = d l  (djd2), from which it follows that an approximate 100(1 -  a ) % Cl for r = e^ 
is
26
re x  i k-i ( l - a / 2 ) . (1-8)
Cox's approximation
Another possibility is to employ a suggestion by Cox (1953). This involves the 
approximation 2v, A, = 2dA,- /  A,- ~ i.i.d. Zid+\* and leads to a 100(1 -  a )  % Cl for r of the 
form
[?F(2d2+l)X2dx+\)(a  / 2), ^(2rf2+l).(2rf1+l)(l “ a  / 2)]. (1-9)
Type /  censoring with all censoring times known
In the case of Type I censoring where all n censoring times c^ are known, it may be better 
to use the result ß  ~ N(J3 ,322( i/r)), where 3 22( y )  = -EdU  /  <9yr' is the expected Fisher 
information. This approach leads to the approximate 100 (1 -  oc)% Cl
j =r  exp|±d>_1 (1 -  a  /  2)1
| ( / i i - f ) i ) - h ( / i 2 - r y 2 )
( n i - ^ K r t a - ^ )
where
Vi = £exp  
;=i
A cy
\
1.4.2 Bayesian solution
For the same reasons as in Section 1.3, we will consider the class of priors defined by 
p(Aj,A2) ~  x X2ai~le~bl?i'1, Aj ,A2 > 0,
where a, e  fc, > 0, and a, < 1 if fc, = 0. Note that a priori independence of the two 
hazards is thereby assumed.
The joint posterior of Aj and A2 is then
p(Ai,A2ly) ~  p(A1,A2)p(ylA1,A2)
oc 1 +^1 + V1 )^1  ^  0 2 + 4 2 - 1^ ” ^  + v2 )^ 2
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Hence the implied joint posterior of q -  and r = A2 / Aj is
p(q,r\y) ~ /KAj.A^y) , .
^ Aj = <7,A2 = qr
qax+ai+d-lra2+dt-l expH(fti + v1) + (b2+ v2)r]q}.
U a, x2r
•J d(q r)
It follows that r has implied marginal posterior
o o
p(r\y) = J p(q,r\y)dq 
o
+  ( 1- 10)/ I  * l + vi J
(upon seeing /?(<?,rly) as a p.d.f. in q and multiplying by the constant + vl )ai+a2+d after 
integration).
This last expression will be recognized as the kernel of the p.d.f. of some multiple of a 
random variable with an F distribution. After equating constants in the appropriate 
densities (e.g., see Spiegel, 1975), we find that
(1-11)— ~ F£ r Ul.V2
where:
k -  A2£ / Aj£,
~  (j[. -4- Q .
Ai£ = —--- L (the posterior mean of A. ),
v i+b i
t>! = 2(a2 + d2), and 
x>2 = 2 (flj + d{).
Compare (1-6) with (1-11) and observe that k - r  when a1=/?1=fl2 = ^2 =0. Also note 
that (1-11) could have been obtained by dividing two independent chi-square distributions. 
Inference about r can now proceed.
As regards point estimates, r has posterior mode
'•m =*  
and posterior mean 
rE = k
U - 2 Y V2 )
{  Vl A V2 + 2 >
(d2 + Ü2 ~  1) / (v2 + b i )
( d i  +1)/ (v! + t > i )
»2 A 
lv z - 2 .
(d2 + fl2) / (v2 + ^ )  
(d1+ a 1- l ) / ( v 1+^1)'
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Observe that these quantities are asymptotically equivalent to the m.l.e. 
r = (d2 /  v2) /( d 1 /  V!> for any finite 0 2 ,^2 -
To obtain confidence regions, first let / Ultl,2( ) and FUi ^  (■) denote the p.d.f. and c.d.f., 
respectively, of the distribution. Then, the (1 -  a)  CPD region for r is
^  (a  /  2), kF-1^  ( l - a /  2 »  
and the (1 -  a)  HPD region is [LB,UB], where: 
f Vi'V2(LB/k) = f Vi'V2(UB/k),  and 
F ^ tV2 (UB/ k ) - F ViX>2(LB/ k) = l - a .
It will be noted that under Type II censoring and vague priors, the (1 -  a)  CPD region is 
identical to the frequentist 100 (1 -  a) % CI.
1.43 Fiducial solution
Assuming reasonableness of the fiducial approach as originally proposed by Fisher (e.g., 
see Fisher, 1959), it is possible to switch the roles of the hazard ratio and its m.l.e., i.e. to 
think of f  as a constant and r as a random variable. In the case of Type II censoring, this 
leads to r having a fiducial distribution according to (1-6). This distribution will be exactly 
the same as the Bayesian posterior under the usual vague priors.
Asymptotically lognormal maximum likelihood-based fiducial inference
When the censoring is other than Type II, it is possible to switch the roles of ß  and ß  in
Ä  A A  A
(1-7) and thereby obtain ß  ~ where ß  and y  are thought of as constants.
The hazard ratio r -e ^  is then considered to have an asymptotically lognormal fiducial 
distribution. The mean and mode of this distribution are
d
and
r LFE =  rexP
rLFM =  rexP
r  - d ^
respectively (where LF stands for lognormal fiducial). It will be observed that these point 
estimates of r are in general different from the m.l.e. and Bayesian point estimates. In 
particular, note that rLFM < r < rjj:E.
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As regards confidence regions for r, the lognormal (1 -  
region can be defined as [LBtUB], where:
( M
r
v  d  r  J Vß f l o g ^V d r
1 -  a
( <I>( ) denoting the standard normal c.d.f.), and
a) highest fiducial density (HFD)
LBtx  p d\d2
2d
UBcx p d\di
2d
These relations are derived from r's asymptotically lognormal fiducial p.d.f.
PF(r) = ~
1 @ 5
2nd
exp<
4 ^  (log r - l o g  r ) 2 r > 0 .
Defined analogously to a CPD region, the lognormal (1 -  a) central fiducial density (CFD) 
region for r  is identical to the frequentist 100 (1 -  a ) % Cl as given by (1-8).
Fiducial inference based on Cox's approximation
A lternatively, Cox's suggestion can be used. This then leads to r  having a fiducial
distribution according to (r / r)~  F^ 2d2+\),(2^+1)’ where r  is thought o f as a constant. The 
mode and mean o f this distribution are
and
p = ~(2d2 - l ) ( 2 d l + l )  
FFM (242 + 1X24 + 3)
A A 24l +1
r FFE ~ r — 7’
respectively (FF standing for F-based fiducial). The corresponding F-based (1 -  a) CFD 
region is identical to (1-9); and the F-based ( 1 - a )  HFD region is defined by [LB,UB], 
where:
/(2 d 2+l),(2<*i+l)(^  ! ^  -  f (2 d 2+\),(2dl + \ ) ^ B  ! )^* and 
B(2d2+l)X2d^l)^B /  ?) ~  F(2d2+\)X2dl+l)^^B /  r) =  1 -  a.
1.4.4 Example
W e will now apply the three methods of inference described above to some lung cancer 
data. Kimura et al. (1993) list the survival times in months of 36 small cell lung cancer 
patients since com pletion of treatment. They also present some covariate inform ation,
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including the type of cancer, peripheral or proximal. See Table 1-1 for the portion of this 
data we will now use.
Table 1-1 Lung cancer survival times (* = censored)
Peripheral-. 13*, 12*, 3 1 ,1 0 ,7 ,2 0 ,4 1 * , 5, 18*. 8
Proximal: 19*. 7 ,19 ,23* , 7,16*, 14*. 3 ,12 , 8 ,30 ,11* , 15, 8 ,9 , 8 ,4 ,
10,6,16*, 1 3 ,1 8 ,7 ,5 ,7 ,1 1 *
Suppose there is interest, assuming it reasonable to fit an exponential model, in estimating 
the ratio r of the hazard A2 for patients with proximal small cell lung cancer to the hazard 
Aj for patients with the peripheral type.
Applying our frequentist method, we find the m.l.e. of r to be r = 1.7075. The 
corresponding approximate 95% Cl is [0.6820, 4.2754] if we employ the normal (i.e., 
lognormal) approximation, and [0.7564, 4.7540] if we use Cox's suggestion.
Taking the usual vague Jeffreys prior (aY = = a^  = &2 = 0), we obtain the following
results in the Bayesian analysis: 
rM = 1.3866, 
rE = 2.0490,
95% CPD region = [0.7400, 4.9782], and 
95% HPD region = [0.5312, 4.2229].
Finally, our fiducial approach yields:
?lfm ~ 1-3713, 
flfe = 1-9054,
lognormal 95% CFD region = [0.6820, 4.2754], and 
lognormal 95% HFD region = [0.4995, 3.7648] 
if we use the lognormal approximation; and 
fffm ~ 1- 4040, 
r pp£ — 2.0180,
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F-based 95% CFD region = [0.7564, 4.7540], and 
F-based 95% HFD region = [0.5554, 4.0714] 
if we apply Cox's suggestion.
See Figure 1-5 on page 38 for the densities ('basic' model) used to derive these results. As 
can be seen, the Bayesian and fiducial p.d.f.'s are very similar. Each has mode and mean 
roughly averaged by the ffequentist m.l.e.
1.4.5 Laplace's method
Suppose that p(r\y) was known only as proportional to (1-10), a functional we will denote 
by Pq(rly). (That is, suppose the F-form of the posterior had not been recognized.) Then, 
apart from numerical integration, one useful way of estimating the posterior mean would 
be via Laplace's method; see Tierney and Kadane (1986). It will be interesting to see how 
closely this approximates the true value obtained for the lung cancer data.
In particular, we will look at the second order form of Laplace's method, since the first 
order result simply returns the posterior mode.
Applying Result 3.2.2. in Tanner (1993), we have that
o~*exp[—nh*(r*)] 
<7 exp [-nh(rM)\
x (1 + 0(1/ n2)),
where:
-nh(r) = log Pq (rly), 
-nh*(r) = \og[rp0(r\y)l 
r* is the mode of rp0(r\y),
£2 _ d2PoWy)
2  ä  ’  d r  r = rM
bn = 0(an) means that 3 c > 0 s.t. \bn\/an <c V n = 1,2,
After some algebra, we obtain the estimator
2 _ r*p0(r*\y)J(rM,a,b,c) 
E Po(rM\y)J(r*,a + l,b,c)
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for the posterior mean rE> where: 
a = 02 + di ~ 1,
f t l + V ,
C =  0 ! +  02 +  d,
fl + 1
b ( c - a - 1) 
J(r,P\,Pt,Ps) =
, and
Pi Pi Ps 
IT1 (1 + p2r)2 '
Numerically, we find (see Section A3.2 of Appendix 3) that rE = 1.9886, which is within 
3% of the true value rE = 2.0490.
1.4.6 Monte Carlo inference
Let be m i.i.d. observations from the posterior p(rly). Then the mean r of these
values is an unbiased estimator of the posterior mean and is asymptotically normally 
distributed for large m by the Central Limit Theorem; e.g., see Mendenhall et al. (1986). 
Hence
I i " TV
r ± 0 - 1( l - « / 2 ) J  /  Y ( r - r ) 2 = l - a .1 ) "  JJ
The two values given by the expression within the square brackets define the upper and 
lower bounds of the Monte Carlo 100 (1 -  a )% Cl for the posterior mean.
It will be of interest to compare estimates of the posterior mean obtained in this manner 
(using various values of m) with the known exact value. As we shall see, this approach 
(like Laplace's method) has the advantage that the posterior need be known only up to a 
multiplicative constant.
The ratio of uniforms method of sampling
To sample from the posterior, we will not use the ready-made F distribution as available in 
Splus. Instead, we will demonstrate the ratio of uniforms method as defined in Ripley 
(1987). For our application, this can be taken as follows:
lim
m —»
r
Pr rEe
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1. First compute a = sup ^ p 0(r\y) and b = sup^r2p0(r\y).
2. Then, repeatedly generate U^U2 ~ i.i.d. t/(0,l) in pairs until 
aU^jpoibul/iaUJ).
3. Return bU2 / (aU{) as an observation from p(r\y).
Table 1-2 summarizes results obtained for the first m of 10000 observations sampled from 
the posterior in this manner, with m ranging from 1 to 10000. See Section A3.2 of 
Appendix 3 for the Splus code used.
Table 1-2 Monte Carlo estimates of the posterior mean
m r 95% Cl bounds for re
1 1.1368 - -
2 3.1868 -0.8312 7.2048
3 3.0792 0.7499 5.4086
10 2.1679 1.3836 2.9522
100 2.0979 1.8901 2.3058
1000 2.0247 1.9587 2.0908
2000 2.0531 2.0053 2.1010
5000 2.0456 2.0144 2.0768
10000 2.0400 2.0182 2.0618
True value: 2.0409
As can be seen, the true value lies within each of the 95% CTs. Figure 1-4 on page 34 is a 
probability histogram of the 10000 observations sampled. Shown also are the posterior 
density and the scaled expected frequencies derived from it. The standard x  test f°r 
goodness of fit (e.g., see Hogg and Craig, 1978) was applied to the frequencies of the 
histogram and yielded a value of 22.403 on 29 d.o.f. This corresponds to an attained 
significance level of 0.8031, implying consistency with the hypothesis that our sampling 
scheme was unbiased.
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1.4.7 A prognosis model
Enas et al. (1992) describe a sequential Bayesian clinical trial based on the approach of 
Berry (1989) and involving the follow-up times f,- of n = 81 patients with congestive heart 
failure syndrome (CHF). In addition to standard therapy, 40 of these received the drug 
Indolidan, and 41a placebo (the allocations being staggered at random). The times to death 
(without censoring) were modelled as independent exponentials.
Explicitly, the ith patient's hazard (i = 1,• *• ,81) was assumed to have the form 
w,Arz‘,
where:
Xx = A is the underlying hazard for the placebo group,
A2 = Ar is the hazard for the Indolidan group,
zi is the indicator function for the ith patient receiving Indolidan,
w; = — log(l -  $,-), and
Si is the ith patient's prognosis.
In this trial, a patient's prognosis was taken to be the estimated probability of his/her death 
during the 3-month randomized phase of the study, assuming standard therapy.
The two hazards were assigned independent lognormal priors with log A,- having mean 0 
and standard deviation <7 = 1.5 (considered noninformative).
The focus of this trial was on the posterior probability (PP) at each patient response that the 
ratio r of hazards (Indolidan to placebo) exceeds 1, and the stopping rule was to terminate 
the study if PP ever fell outside the range [0.05, 0.95]. As it turned out, PP never crossed 
these bounds, and the trial concluded with a final value of 0.738. Sensitivity analysis 
yielded a final PP of about 0.756 in the limiting case <7 = °° corresponding to improper 
vague priors.
It is not clear why the vague priors examined (in only an approximate manner) for the 
purpose of sensitivity analysis were not used throughout. Such would have been equivalent 
to the vague priors in our model (namely, p(A,) «= 1 / A,). Reanalyzing the CHF data with 
these priors and an appropriately modified version of our model, we obtained the final PP 
as 0.75697 by direct application of the F distribution. See Section A3.2 of Appendix 3 for 
our working.
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Reanalysis of the lung cancer data
It will be of interest to now apply the prognosis model used by Enas et al. to the lung 
cancer data. This will involve merely repeating the calculations of Subsection 1.4.4 after 
first redefining v,- as h » where wy = -log (l -Sy), and Sy is a prognosis for 
the yth individual in the 7,- group (i =1 indicating peripheral). Again, the usual vague priors 
will be used.
To define the prognoses, we will proceed in the spirit of Enas et al. and first give each 
patient a score subjectively based on selected predictors of mortality in the data of Kimura 
et al. Referring the reader to that document, let the scores be
Sij = 2 x (Age -  30) +10 x [Tumour size} + 25 x [Response to chemotherapy),
where:
Age is in years,
Tumour size is in cm (ranging from 2 to 10), and
Response to chemotherapy is either: 1 (Complete response), 2 (Partial response),
3 (No change), or 4 (Progressive disease). 
For example, S12 = 2 x (61 -  30) +10 x 8 + 25 x 3 = 217.
Then let s^ = -0.232 + 0.0018 xSy. Thus sn  =-0.232 + 0.0018x217 = 0.1586. This 
arbitrary transformation results in prognoses with about the same spread as those used in 
the CHF analysis. See Table 1-3.
loses (order corresponds to that in Table 1-1)
Peripheral: 0.0776,0.1586, 0.0326,0.0830, 0.1244,0.0938, 0.0830, 0.0542, 0.0848, 
0.1190
Proximal: 0.1352, 0.1280, 0.1100, 0.0344, 0.1388, 0.0812, 0.0092,0.1478, 0.0344,
0.1424, 0.1100, 0.0146, 0.0938, 0.0848, 0.1766, 0.1280, 0.1514, 0.0272, 
0.1208, 0.1550, 0.0884, 0.0596, 0.2054, 0.1964, 0.1082, 0.1298
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Note that the functional form by which the prognoses are computed is not important. What 
is important is that the same formula be used for all the patients. Even if high prognoses are 
assigned to patients likely to live longer, the analysis will still be valid, with possible 
improvement due to the incorporation of covariate information. See Berry (1989) for a 
fuller justification of this approach.
Results
Using the prognoses as given in Table 1-3, we obtained the following results in the 
frequentist and Bayesian analyses: 
r = 1.4283,
95% Cl = [0.5704, 3.5763], 
rM = 1.1598, 
rE = 1.7140,
95% CPD region = [0.6190, 4.1641], and 
95% HPD region = [0.4444, 3.5324].
(Incidentally, Laplace's method yielded an estimate for the posterior mean of 1.6635, which 
is again within 3% of the true value.)
As can be seen by comparison with the corresponding results obtained in Subsection 1.4.4, 
the estimates of r under the prognosis model are consistently lower than those obtained 
using the 'basic' model. This indicates that the apparent difference between the two types of 
small cell lung cancer may partly be explained by covariate information. Figure 1-5 on 
page 38 shows the posterior and fiducial densities for both models.
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1.5 A FRAILTY MODEL
1.5.1 Introduction and description
Consider a study wherein n individuals are put on test and observed until they have all 
either failed or been lost due to some noninformative censoring mechanism (such as Type 
I or Type II). To extend the theory of Section 1.3, suppose now that these can be grouped 
into a number /  of litters (or families), and that the individuals of a particular litter have a 
common time-constant hazard function.
Explicitly, we will model the hazard for the ith individual (/ = 1,•••,«) as
K -  ^  >
where:
A is the underlying hazard,
/,• is the index (/,• e  {1,-• •,/}) identifying the ith individual's litter, and 
Zj is the multiplicative frailty term common to all members of litter j.
The purpose of the frailty terms (or frailties) is to allow for heterogeneity in the form
of unobserved covariates which might be shared by members of the same litter. See Guo 
and Rodriguez (1992) and Clayton (1988) for a general discussion and examples.
In what follows, a Bayesian model and strategy are developed with the main objective 
being the estimation of A. All inference will be based on the marginal posterior of A, and 
the central problem is to compute or approximate this density, treating the frailties as 
nuisance parameters. Some other issues will also be addressed, such as estimation of the 
frailty terms and predicting future events. Note that the ffequentist treatment of frailty 
models has always been problematic.
The likelihood
Conditional on the frailties, the likelihood of A is 
L
~pOU,£)
- IJCV" A,'‘ ) s ‘
1=1
r n \ n
xi iw*
V »=1 )  »=1
40
exp
/= i y  i= i
where:
ki =  tj (the total time on test for the tth litter); 
j'-lj-i
qi -  ^  Sj (the number o f failures in the ith litter);
j:lj=i
§ = (5i * * • 5/ /  (the frailty vector);
tt is the observed time for the ith individual;
St is the indicator function for the ith individual failing (i.e., not being censored);
n I
d = ^  Si = ^  <7, (the total number of failures); and
i=l i=l
y denotes the data, i.e. (tltS1)t’--t(tniSn).
Prior distributions
Following Clayton (1991) who develops a similar model, the frailties t;y will be treated as 
conditionally independent gamma variates with mean 1 and variance 1 /a .  This is done 
mainly for mathematical convenience. See Aalen (1988) for some other possible frailty 
distributions.
The model is made hierarchical by treating a  as a random variable also. For convenience, 
this hyperparameter is assigned a hyperprior proportional to 
a v-le~Tai a >  0,
where ri e  SR and r  ^  0 are specified constants subject to the restriction r\ < 1 if  r  = 0.
Finally, A is given the same prior as in Section 1.3 (i.e., p(A) «= Xa~le~b^).
Note that A is thus assumed to be conditionally independent of £ and a  a priori in the 
sense that the joint prior of these parameters factors as 
p(A, £ , a )  = p( A) x p($\a)  x p{a).
Also note that 
p (£ la ) i\ no)
41
I W
( /  \ a ~ x
n&
^ »=i )
exp
V *=i
since (<!;,• I a )  ~ i.i.d. G (a,a).
Posterior distributions
(M 2 )
With these priors, the joint posterior of all 1+2 parameters and hyperparameter is 
p (X ,£ ,a \y )  oc p (X ,£ ,a)p(y\X ,% ,a)
= p(X )p(t, \a )p (a )p (y \X ,^)
J a  (  I A“ -1  (  l
~ [ r _1e 'w ]x r w expv  »=i )  v  *=i j
x[a’’-V t“]
 ^ 1=1 )  1=1
(1-13)
Hence the joint marginal posterior of A and a  is the integral of (1-13) with respect to £. 
That is,
p(X,a\y)  =  lp(X,^,a\y)d^
= /•••/ p(X,^,—,$h a\y)d$x-dZi
i a + d - 1 - b X  „ / a + T j - l  - r a  1 °° Ä. v „_ A— i—?—!— z—
;=1 0
x a+d-le- H a la+V- le- m  J r ( a  + 9 .)
r W (a  + Xki )a+qi' (1-14)
It follows that the (exact) marginal posterior of A is
n a  + q* d a d X
( a  + A*t)a+<7‘
(1-15)
Thus there is no closed form for the density required for inference on A. Consequently, 
either numerical quadrature, a Monte Carlo approach, or some other approximating 
technique such as Laplace's method must be employed if one is to proceed. In what 
follows, it is shown how a variety of Monte Carlo methods can be used to estimate A. We 
will then apply our theory to some kidney infection recurrence time data. Finally, results 
will be compared with their exact counterparts obtained via numerical quadrature, as well 
as with normal and lognormal approximations.
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The key references to our approach are Clayton (1991) and Tanner (1993). See also 
Smith and Roberts (1993), Besag and Green (1993), Gilks and Clayton et al. (1993) and 
the extensive discussion and references following this series of three papers for useful 
insight into the strengths and weaknesses of the statistical philosophy that follows.
Outline
The following is the 3-step procedure we propose for making inference about A:
1. Use the EM algorithm to find the mode of the joint marginal posterior density 
of A and a.
2. Starting with this mode, employ the Gibbs sampler to generate a large number of 
independent observations from the marginal posterior of A.
3. Use these observations to estimate quantities of interest relating to A, in 
particular the posterior mean and 95% CPD region.
1.5.2 The EM algorithm
To implement the EM algorithm (see Dempster et a l., 1977) with the aim of finding the 
mode of p(A, a \y ) , we will treat £ as the latent data. Each iteration ( j  = 1,2,- • •) will then 
involve two steps, the E-step and the M-step. In what follows, A(;) and denote the 
current estimates of A and a ,  respectively, at the beginning of the/th iteration.
The E-step
At iteration j , the E-step (E standing for expectation) requires the computation of the Q- 
function
Q(l) =Ei { l ( X ^ ,a \ y n {> \a {j\y }
= U (\,% ,a \y)p ($ \X {i) , a (j\y )d $ ,
where /(A,<j;,a,ly) = logp(A ,£ ,aly). That is, we need to find the expectation of the 
logposterior with respect to the distribution of the latent data given the observed data and 
current parameter estimates.
Firstly, we have from (1-13) that
/(A,<J,aly) = (a + d -  l)logA -  A
f i
&+2>,S;
 ^ »'=1 )
+ Ia \oga + (r j - \ ) \oga
- a T+Z(£;-log£;)
1=1
- /  log T(a).
43
Note that additive terms involving neither X nor a  have been left out. Including these 
would make no difference to the optimizing procedure.
Next, observe that
p(£\X,a,y) oc p($\a)p{y\X£,a)
i
oc ) - i e “ ( a +
i=1
This implies that ( IX , a ,y) ~ i. i. d. G(a  + , a  + Xkt), from which it follows that:
E(ti\X ,a,y)=  a  + , and
a  + Xki
£(log &I A, a,y) = ^ ( a  + <&)-log(a + A*,), 
where 'F(-) is the digamma function.
Thus ß (;) can be taken as 
(fl + d -l)logA  -  X * + 5 > i 0)
i=l
+ /a lo g a  + ( r / - l ) lo g a  
/
- a T +£ (r.<»-,.<»)
t=l
- /lo g T (a ) ,
where:
a (7) + <7, , and
n ~ a ^ + X (\
s.(j) -  xp(a O) + q.)~  log(a(;) + X^ki).
(1- 16)
(1-17)
The M-step
The M-step of the algorithm requires the maximization of ß (;). With respect to X this is 
straightforward, since d Q ^  / dX = 0 immediately yields the next estimate
Xu+1 ) _ _ £ + d - l _  ( 1- 18)
* + X * ir‘0)
Newton-Raphson iteration
To maximize with respect to a  is more difficult and requires an iterative technique. 
We will use the Newton-Raphson algorithm as follows:
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1. Let a (0) = a (;) (i.e., start at the current estimate).
2. For w = 1,2,
a (w )
• • • (until convergence to the limit a (oo)), let 
P (g (w -1 ) )
<W_1) DO(Vi))’
where:
D(a) = dQ(i) Ida
, /
= /[I + log a  -  T fa ) ]  + —— -  -  t-  £  (r/'>  -  i / » ),
® j-1
DD(a) = d2Qu) / d a 2
= /f--'F'(a)V^Ti, and V« y a
'F'(-) is the trigamma function.
3. Set a (y+1) = ct/w), where a(vy) = &(«,) to the required precision.
(1-19)
The EM algorithm is thus completely defined. Starting with arbitrary initial estimates 
A(0) and a (0) (which must, however, be sufficiently close to the mode for the algorithm 
to work), the E- and M-steps are repeated until convergence. At each iteration j, the 
r / 7) and are formed using the current estimates and a (;) via (1-16) and 
(1-17). Then is computed according to (1-18), and likewise a (y+1) by repeated
application of (1-19).
Note that we thereby arrive at the mode of p(A ,aly), not the values of A and a  which 
(together with a particular £) maximize p (A ,^ ,a ly).
1.5.3 The Gibbs sampler
The Gibbs sampler (see Geman and Geman, 1984, and Casella and George, 1992) is a 
powerful tool for estimating complex Bayesian models. It allows one to obtain an i.i.d. 
sample of any size from any marginal or joint marginal posterior distribution. By taking a 
large enough sample, inference on the param eters) of interest can be performed to any 
precision via Rao-Blackwell arguments.
The Bayesian model we have formulated defines a Gibbs distribution with cliques 
{A, £,y) and {£,«}. Accordingly, the Gibbs sampler can be taken to involve the following 
procedure at each iteration j  = 1,2, • • •:
1. Sample £ (y) -  p(£lA(-,“1\ a (;-1\y ) .
2. Sample A(;) ~  p(A l£(;),y).
3. Sample a ^  ~ p ( a \ ^ ) .
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Starting at some 'likely' values, such as the joint mode of p(A, a ly ) , the three conditional 
distributions are sampled from until stochastic convergence to the joint posterior 
distribution has been achieved. This is called the burn-in. A  further m cycles then yield m 
observations from p(A,<i;,aly). With a slight ambiguity o f notation, we will sometimes 
denote these m observations by (A(1\ £ (1\ a (1)),**s(A(m\ ^ m\ a (m)).
For inference on A, A(1\---,A (m) are 'peeled o f f  and constitute a sample from p(Aly). 
Note that although some serial correlation can be expected, the algorithm can be modified 
so that this is largely reduced. Moreover, the observations will be effectively i.i.d. if  m is 
sufficiently large.
The conditional sampling distributions
We have already seen that (<J,IA,a,y) ~ i.i.d. G (a  + <fr,a +  A/:,). Thus sampling from 
the first conditional distribution is straightforward.
The same applies to the second, since
P(A l£,y) ~ p (A )p (y lA ,£ )
A(a+JM exp -A b + t k&
V *=1
This implies that
W 4 , y ) ~ G a + d.b + ^ k ^ ,  .
< i=l J
However, to sample from the third conditional presents a challenge because o f this 
distribution's nonstandard density form. Explicitly, we have that 
p(al£) «p(a)p(£iar)
where k
„ W - l - r a  w Cta  1 e x
r W
(  I  \ a_1n&
v *=i
(  1 }
>
i=l J
exp [(/a  + 77 - 1 )  log a - a x -- / l o g  T (a)], 
i  i
t - l o g f l ^  + X ( a constant with respect to a). 
i=l i=1
by (1-12)
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The Metropolis algorithm
There are a variety of methods we could use to sample from the third conditional, such as 
the ratio of uniforms technique illustrated in Subsection 1.4.6. However, the simplest of 
these methods may not necessarily be the most efficient, and we will adopt a suggestion 
by Martin Tanner (personal communication, 1994) to sample from p(a\t;) by embedding 
a Metropolis random-walk subchain in the Gibbs sampler. This will involve the following 
procedure at the third step of each iteration j:
1. Compute the mode a  o f the function
f ( a)  = exp [(/a  + r/ - 1 )  log a -  a t e -  / l o g r ( a ) ] / ( a  > 0), 
i  i
where = r -  log ^
2, Set <2 (o) = a  (i.e., start the subchain at a 'likely' value)/ •
3. For w = 1,2,*••,7’:
(i) Sample a (w) ~ Nia^ ^yM )  (the driver distribution), 
where
M =  c d1 l o g / ( a )
da2 a -  a
- l
COL2
7] - 1  + Iä [öW \ä) - 1]
(i.e., where the curvature at the mode of the driver function is made to be c 
times the curvature at the mode of / ) .
(ii) Accept with probability
. /(«(W))min
/(«(w -l)).
otherwise, set a (w) = (i.e., repeat the last value).
4. Let a (y ) = (i.e., take the T'th observation in the Metropolis subchain as a
sample point from p (a l£ ^ ) ) .
Note that choice of c and T will in practise require some preliminary investigation into the 
rate of convergence to the required distribution.
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The Gibbs sampler is now fully defined. In the application which follows, however, certain 
problems arise, requiring some modification to the algorithm. These problems highlight 
some fundamental limitations of the approach we are taking as well as of the Bayesian 
paradigm in general.
1.5.4 An application
We will now apply our theory to the analysis of some recurrence time data as given in 
McGilchrist and Aisbett (1991). 28 female kidney patients using a portable dialysis 
machine were monitored and two times to censoring or recurrence of infection observed 
for each. The data is reproduced in Table 1-4.
Table 1-4 Kidney infection recurrence time data (* = censored)
Patient
number
Times to 
infection
Patient
number
Times to 
infection
1 23, 13* 15 402, 24*
2 447, 318 16 13, 66
3 24, 245 17 39, 46*
4 511, 30 18 113*, 201
5 53, 196 19 132, 156
6 7, 333 20 34, 30
7 141, 8* 21 130, 26
8 96, 38 22 27, 58
9 149*, 70* 23 5*, 43
10 536, 25* 24 152, 30
11 185, 177 25 190, 5*
12 292, 114 26 119, 8
13 22*, 159* 27 54*, 16*
14 15, 108* 28 6*, 78
Note that the litters' here are the patients. Also, recurrence times are assumed independent 
(apart from their common frailty component) by virtue of a 10-week interval which was 
enforced between an infection and reuse of a dialysis machine.
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The jo in t mode
Ignoring frailty, the m.l.e. of A (the underlying hazard for the time to recurrence, assumed 
exponentially distributed) is d / v  = 0.006118. Setting A(0) = 0.006 and a (0)= l  
(arbitrarily), as well as specifying the usual vague priors (i.e., a = b=  7J = t = 0), the EM 
algorithm converged to the required mode (A ,a) = (0.0065318, 5.2706) by about the 
100th iteration.
Using the Newton-Raphson algorithm to fin d  the jo in t mode
As a check, the Newton Raphson algorithm was used to obtain the same result. This 
involved iteratively computing
*<'-»
«Ü -» + / a ü-1), a ü "1)r 1i / a ° ' - l) , a (^ 1)).
where:
w > « ) = i M L £ ! z ) >and
7(A ,a) = -
<9(A a ) ' 
dU( X , a)  
<9(A a )
(1-20)
Explicitly, we have that
\U(X,a)  
I ( X , a)  = -
, and
a,
A^A ^Aa 
a^A laa
where:
/  _  (9 lo g p ( A ,a ly )  _  fl +  d - 1  y . ^ ( «  +  ^-)
A <9 A A a  +  A&,-
/a = — ------^  = /[l + lo g a -  yr(a)] + —-------r
/
;=i
^ ( a  + qx) -  log (a  + Afct-) - a  + qi
a  + Xk;
, _  ^ a _  + , 'irkiHa + qi)
i2 + , 01 v2 ’XL^{ ( a  + U i y
ft e  = U = ^  = £ ~ — ~ Qii \  and 
0,1 < ? a  ( a  +  A jt; ) 2
/ = ^ s .  = /  
“  eta
—-'{''(a) 
La
T )-l 1Tf/, x Q ; - C t -  2 Xk:
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Table 1-5 shows how the two algorithms fared in finding the required mode, starting from 
the same initial estimates. As can be seen, the Newton-Raphson algorithm found this 
mode faster than the EM algorithm. See Subsection A3.3.1 of Appendix 3 for the Splus 
code used.
Table 1-5 Comparison of Newton-Raphson and EM algorithms
Iteration
number
A a
EM NR EM NR
0 0.006 000 000 0.006 000 000 1.000 000 1.000 000
1 0.006 563 452 0.007 017 058 1.279 903 1.510 556
2 0.006 906 636 0.007 482 677 1.572 926 2.191 370
3 0.007 062 994 0.007 281 308 1.880 652 2.895 663
4 0.007 092 734 0.007 005 472 2.198 771 3.563 975
5 0.007 052 662 0.006 833 785 2.517 743 4.186 806
10 0.006 746 152 0.006 541 823 3.798 554 5.227 676
20 0.006 580 729 0.006 531 518 4.770 805 5.269 357
40 0.006 536 463 0.006 531 786 5.224 705 5.270 392
60 0.006 532 317 0.006 531 827 5.265 747 5.270 543
80 0.006 531 885 0.006 531 834 5.270 062 5.270 566
100 0.006 531 840 0.006 531 834 5.270 516 5.270 569
120 0.006 531 835 0.006 531 835 5.270 564 5.270 570
140 0.006 531 835 0.006 531 835 5.270 569 5.270 570
160 0.006 531 835 0.006 531 835 5.270 570 5.270 570
200 0.006 531 835 0.006 531 835 5.270 570 5.270 570
250 0.006 531 835 0.006 531 835 5.270 570 5.270 570
300 0.006 531 835 0.006 531 835 5.270 570 5.270 570
Gibbs sampling and problems with convergence
The Gibbs sampler was started from a range of values, including the mode just computed, 
and found to converge very rapidly as regards A. See Figure 1-6 on page 50 for the A 
values sampled on the first 100 iterations of two separate runs of the algorithm starting 
from 0.0001 and 0.014.
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However, a problem was encountered with the sampled values of a. These seemed to be 
very unstable and exhibited severe autocorrelation. Moreover, an absorbing state of 00 
(corresponding to all the frailty terms being unity) was invariably reached on repeated 
attempts by about j  = 1000.
Figures 1-7,1-8 and 1-9 on page 52 show the a, £2 and A values, respectively, obtained 
in one run of the Gibbs sampler for which the absorbing state was reached at about the 
100th iteration. Notice how the £2 values are initially centred at well below unity 
(corresponding to the second female having relatively high recurrence times), but then 
gradually cluster more and more tightly around 1 as a  approaches 00 (i.e., as the variance 
of the frailty terms tends toward zero). Also observe the corresponding movement of the A 
values toward the posterior mean ignoring frailty (i.e., the m.l.e. 0.006118).
Keeping this last point in mind, refer back to Figure 1-6 and notice how A was relatively 
low from about iteration 70 on in the run beginning with 0.014. Although this effect 
seems insignificant, it is in fact a consequence of the corresponding values of a  being 
high over this region. They later stabilized (temporarily), and the values of A increased 
accordingly.
Figure 1-10 on page 52 shows the values of a  in another run of the Gibbs sampler where 
absorption occurred even earlier.
The buffered stochastic substitution algorithm
To counter this problem, a suggestion by Clayton (1991) was adopted to implement a 
buffered stochastic substitution algorithm, along the lines of Tanner and Wong's (1987) 
imputation-posterior algorithm. Since Clayton used a model for the frailty terms identical 
to ours, we tried to emulate his approach as closely as possible. This entailed the 
following modification to our original sampling scheme at the yth iteration:
1. Draw a* at random from
2. Initially set A* = A^_1* and repeat 10 times:
(i) Sample ~ p (£ lA \a \y ) .
(ii) Sample A* -  /?(Al£*,y).
3. Let and A(;), respectively, be the last values of and A* 
generated in step 2.
4. Sample ~ p (a \£(;)).
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With this modification, the problem of autocorrelation was significantly reduced, and 
although high values of a  were occasionally sampled, it was possible to proceed past the 
j  = 1000 mark. As an additional measure against absorption (also in accordance with a 
suggestion by Clayton), a  was resampled whenever a value over 500 was obtained.
In one particular run for which these modifications to the Gibbs sampler were 
implemented from j  = 501, an equilibrium of sorts seemed to have been reached by about 
j  = 2500. But then a  began to gradually drift upward, and sampling was eventually 
stopped at j  = 5000. See Figure 1-11 on page 54 for the evolution of a  just described.
Improper posterior?
It is suggested that the failure to reach stochastic equilibrium may be due to an improper 
posterior. This would then most likely be the consequence of using an improper prior, i.e. 
p{A, a )  1 /  (Aa). Clayton (1991) seems to not have been aware of this possibility, and 
we wonder whether he would have encountered the same problem had he decided to 
sample past j  = 2500. It would appear that he stopped precisely at this point in his rat 
carcinogenesis example.
We hypothesized that changing the prior on a  (whilst retaining the improper prior on A) 
might improve the situation. Figure 1-12 on page 55 shows some of our findings. As 
expected, using the prior 1 / a  dampened the turbulence encountered with 1 / a, and 
using e~a , which is proper, reduced it even further. It would be interesting to try other 
priors and attempt to identify those which lead to an improper posterior.
Obtaining a sample from the joint posterior using a proper prior on a
In order to proceed, we arbitrarily decided to use the proper (and informative) density e~a 
as our prior for a  rather than the vague 1 /  a ,  as originally intended. The prior on A was 
kept as proportional to 1 /  A. Note that this specification of priors corresponds to setting 
(a,fr,77,T) = (0,0,1,1).
The Gibbs sampler was cycled through 11000 iterations in total with no problems, and 
Figures 1-13, 1-14 and 1-15 on pages 56, 57 and 58, respectively, show the values of 
a ,  A and <f;2 obtained. The mean of the £2 values is 0.5769, which compares favourably 
with the frailty estimate 0.5 obtained by McGilchrist and Aisbett using a very different 
approach. See Subsection A3.3.2 of Appendix 3 for the Splus code used to generate the 
sample.
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Sampling from the conditional distribution of a
To sample from p (a l£ ), we used c - 1 and T = 15 as the parameters of our Metropolis 
algorithm. To justify this choice, we present a simulation based on £^267\  arbitrarily taken 
from the run for which the a  values are displayed in Figure 1-11.
10000 independent Metropolis subchains of length 15 were generated, each starting at the 
mode of p (a l£ (267)), and the last observation taken from each. Figure 1-16 on page 60 
shows a probability histogram of these 10000 observations. Also shown are p (a l£ (267*), 
the scaled expected frequencies and the normal driver (centred at the mode). The standard 
X2 goodness of fit test yielded a p-value of 0.2282, which is consistent with our 
hypothesis that the sampling scheme is unbiased.
Inference on A
Taking the last 10000 values of A sampled (call these A(1\* • •, A(10000)), an estimate of the
marginal posterior mean XE is 
1 10000
A = — —  Y  A0) = 0.0073587,
10000 f t
with associated 95% Monte Carlo Cl
A±<D"1( l - 0 .0 5 /2 ) .
, 10000
----- ------Y a ^ - I )2
10000 x 9999 f v
[0.0073270,0.0073903].
The true posterior mean was computed via numerical quadrature and found to be 
0.0073274, which is just within the 95% Cl.
The 5th and 95th empirical percentiles of A ^ V * - , A ( 1 0 0 0 0  ^ are 0.004752 and 0.011063, 
respectively. The interval defined by these values is an estimate of the 95% CPD region 
for A. The exact CPD region is [0.004713, 0.011005]. Also, the true content of the CPD 
region estimate is 94.93%, with 2.73% and 2.34% being the exact marginal posterior 
probabilities of A lying below and above this estimate's lower and upper bounds, 
respectively.
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The Rao-BlackweU estimate o f  the marginal posterior
A nonparametric estimate of the whole marginal posterior density of A could be obtained 
by smoothing a histogram of the sampled observations. However, this would involve 
considerable arbitrariness. A better estimate, also in the sense of minimizing mean square 
error, is the Rao-Blackwell estimate; see Gelfand and Smith (1990). This is derived by 
applying the method of Monte Carlo to the identity
p(Aly) = lp(A,<Jly)^ = |p(AI<5,y)p(^ly)^.
Explicitly, the Rao-Blackwell estimate of p{Aly) is
iK A iy)
|>  / \a+d
M
\a+d-l
mT(a + d)r?AI
exp - A *+X«<0)
*=1
(1-21)
V *=1
i.e. a mixture of gamma densities. Note that here denote the first m of the
last 10000 £ vectors generated using the Gibbs sampler.
Figure 1-17 on page 62 shows this estimate for various values of m, as well as the true 
marginal posterior (obtained via numerical quadrature). Shown also are a probability 
histogram of A(1\---,A^10000\  and the corresponding true expected proportions. The / 2 
goodness of fit test yielded a p-value of 0.1593, which is consistent with the hypothesis 
that the 10000 observations were indeed sampled from the marginal posterior.
An alternative estimate of the 95% CPD region was computed by iteratively integrating the 
Rao-Blackwell estimator. This yielded the interval [0.004725,0.011118].
In a similar fashion, the Rao-Blackwell estimator was used to obtain [0.004437, 
0.010647] as an estimate of the 95% HPD region. Note that another estimate of this HPD 
region could have been obtained using the sample from the marginal posterior directly, as 
described in Tanner (1993). The exact HPD region was found to be [0.004432, 
0.010549].
Finally, the mode o f p(Aly) (using m=10000) was found to be 0.006832, which 
compares favourably with the true value, 0.006815.
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1.5.5 Normal and lognormal approximations
It will be of interest to see how normal and lognormal approximations of the marginal 
posterior of A perform in comparison to the Rao-Blackwell estimate. To this end, see 
Figure 1-18 on page 64. This figure shows four densities:
1. The true marginal posterior p(X\y ) as given by (1-15). This was obtained using 
numerical quadrature.
2. The Rao-Blackwell estimate p(X\y)  as given by (1-21) with m = 10000.
3. The normal approximation with density
r  ~ \
1
0
^in(i,a) WAX,«)
x - x
where:
(A ,d) is the mode of p(X ,a \y)  as given by (1-14), 
/ n (A ,a) is the first diagonal element of /(A ,a ) -1, 
/(A, a)  is as defined at (1-20), and 
0 0  is the standard normal p.d.f.
4. The lognormal approximation with density
/  - A
1
0
lo g A -0
where:
X^in(ß,r) U i u (ß,y)
ß  = \ogX , 
y = lo g a ,
111 iß, Y) is the first diagonal element of I iß,  y)-1, 
k o  V'  d1 logp(ß,y \y)
^  d(ß r)'d(ß r )’
p(ß,Y\y) p(X ,a \y)
X = e ^ , a  = e'
<9(A a ) f
d(ß  y)
(the implied joint marginal posterior density of ß  and y), and 
(ß , y) is the mode of p(ß, y\y).
As expected, the lognormal approximation outperforms the normal. Also, it does about as 
well as the Rao-Blackwell estimate using m = 10000. See Subsection A3.3.3 of Appendix 
3 for the Splus code used to compute and plot these four densities.
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The normal and lognormal approximations are based on the asymptotic results
and
"A"
y
/'r » ~
A
a ä
~ß~
\
y
/ a"
ß
_y_ / V.7 .
,/(A ,d )
,i(ß,rr
-1
respectively, the second of these being the more accurate one; see Carlin et cd. (1992).
The modes were obtained via the EM algorithm. Note that (ß, y) = (log A*,log a *), where 
(A \a * )  is the mode of p(A ,aly) with (a ,6, ry, r)  taken as (1,0,2,1). This is so because:
(i) the prior X~le~a used is defined by (a,b, tj, t) = (0,0,1,1), and
(ii) the Jacobian of the transformation from (A ,a) to (ß, y)  is e ^ r = Aa.
Thus the required maximization of p(ß ,y \y )  is effectively that of /?(A,aly), given the 
prior p ( X , a ) ~  X~'e~a x X a  = Xm ~xe~{a)xa a )~xe~m a .
Finally,
/ ( A r ) = -
Ißß Ißy 
}yß ,rr.
where:
, _ d 2 \ogp{ß,y\y) ß
w -  äp — e h I c yY
lßy ~
d 2p(ß, y\y) __ ^
d ß d y (er + kje^Y
l „  = -logP ^ ' y'y) = e7{ - r  +l[2 + y+  ¥ (e r)
+er t
1=1
'P (e r + <?,)-^ + +k J^ß ~ lo 8 ^ r + ki^ )
+ «2yX
i=l r(cr+,i)+J^ W
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1.5.6 Prediction
In addition to inference on the model parameters, the observations 
a (1), ^ 1), a (1)) , - , a (m)^ (m), a (m)> ~ i.i.d . p (A ,£ ,a ly ) 
obtained via the Gibbs sampler (or any other method) can be used to forecast events.
Predicting future observations from an existing titter
For example, suppose y* is a future observation for an individual from Litter 7. Then the 
predictive density of this observation is
p (y jy ) = / / / piy*, A, £, a\ y)dM$da
= / /  J P(yJ  A, , a ,  y )p( A, £, a\y )dXd£ da  
= J J J A£7 exp(-A £7y* )p( A, <5, a l y)dXd$da.
Applying the method of Monte Carlo, we obtain the Rao-Blackwell estimator of this 
predictive density, namely the mixture of exponential densities
1 m
P(y. ly) = —X  A0 )^7(-') exp(-A0 ,£7(-')y.)-
m ;=l
To sample m values from the exact predictive density, we apply the method of 
composition and (independently) draw
y.u) -  A<'>$7<;>exp(-A<'>S7<'>;y.), j  = 1 
The values constitute the required sample.
Predicting observations from a new litter
If y* is a future observation for an individual from a new litter, a modification is required
because the conditional predictive distribution of this observation is not simply 
exponential as before. To find this conditional distribution, first denote the new litter's 
frailty term by £*. Then,
p(yJA ,£,a,y) = Jp(y*,£jA,£,a,y)d£*
= J P(y+1 , A, £, a , y )p( § J  A, <!;, a , y )d£*
f a r  a- 1
J(A£,exp(-A|,;y.))
T ( a )
e x p ( - a | . )
Aag+1 
(a + Ay,)g+1
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Hence p (y jy )  can be estimated by
p(yJy)
1 m 
r X
;= i
& \ a W ) aU )+1 
(«<'> +
To obtain a sample from p(y*ly), sample y ^ ;) , y = l,---,m, from the distributions 
defined by the densities 
A 0 )(g< »)"0>*1 
(a«) + A<>V.)“°)+1'
Note that these results are expressible in terms of the F distribution. Each y ^  can be 
obtained by sampling from the F^  2aU) distribution and then dividing by Similarly,
1 m
P(y.ly) = - £ / 2i2ao,(A°,y.).
m i=1
Predicting the mean of a set of new observations from both existing and new litters
To conclude, we will show how to obtain m i.i.d. observations from the predictive 
distribution of the mean lifetime of s future observations generally. Denote this mean by
n+s
7. =  -  E ? ; .
where yn+i,-*-,yn+J are the new observations. Without loss of generality, let these be 
ordered so that the first r make up J new litters, indexed by /  +1, •••,/ + 7, and the rest are 
from litters 1 ,•••,/. Then the required sample is • • , y / m\  where:
! /+ /
K. U ) J  G (ö„A (»£< »), i =
.0 ')
iC^ ) p 2,2{aU)+Qi - \ y  
; and
i = /  + l ,•••,/ + / ;
a0 )( « 0) -+- a * —l)
f i  is the number of new observations in the zth litter, / = 1, •••,/ + 7.
Each gamma distribution here is simply the sum of i.i.d. exponentials. To derive the F 
distributions, denote the observations making up new litters by , and the frailty vector 
(£i+i'"£i+j Y by Then, the conditional predictive density of y+N is 
P(y*N IA, , a ,  y) = S  p ( y + u , IA, £, a ,  y
= I , A )p( I a ) d ^ N
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J
\i= n+1
I + J
r 5t V  rto ; a - L Xn (^«7~A«=/+i v ' j)
J] J Aa &(a+a Me-(«+«i >&a“r(a)_14,
*=/+! 0
where AT; = X y w
w:Lw=i,w>n
j4  Aa « gr ( a  + Q )
i i / i i  (®+ AXj)“+a r (a )
This expression will be recognized as the joint density of /  independent random variables, 
each being a multiple of a random variable with an F distribution. The sampling 
distributions follow upon equating constants in the relevant densities.
Note that the Rao-Blackwell estimator of p(y+\y) cannot in general be easily computed. 
This is because the joint conditional posterior density of the new observations is
p(yB+i.---.}’n+j|A ,^ a ,y ) r(a)T ex P yV *=1 J i= l+1
Transform ation to p([(yn+i+-••+>>,,+*) /  $]lA,<f;,a,;y) would require a nontrivial 
convolution due to the not being i.i.d.
Example
Suppose that the second female is put on test again and 8 independent recurrence times 
are observed. Then a sample from the predictive distribution of the mean of these 8 times 
is K2^  / 8,---,A'2(10000) /  8, where K2(;) is an observation sampled from the 
G(8, distribution. Figure 1-19 on page 69 shows a probability histogram of this
sample. Overlaid is the Rao-Blackwell estimator of the predictive density. This could be 
obtained in this special case, being simply a mixture of 10000 G(8,8A ^ § 2^ )  densities 
in the form
08 / »7110000
P(yJy)= 2 <a< W *7 exp(-u<^2o>*).
j- 1
The mean of the 10000 observations sampled was found to be 315.63 days, with 
associated 95% Monte Carlo Cl [310.50, 320.76] (for the mean of the mean time 
marginal predictive distribution).
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1.6 SOME OTHER MODELS
We now briefly review some other biostatistical problems which have been treated using 
Bayesian methods.
Bayesian proportional hazards model
The Bayesian paradigm is readily applied to the semiparametric Cox proportional hazards 
(PH) model (Cox, 1972). In an obvious notation, the partial likelihood
(Cox, 1975) is simply multiplied by a prior p(ß) to obtain the ’partial’ posterior pP(ß\y). 
This can be treated as an approximation of the exact posterior p(ß\y) and used to make 
inference on any parameter subset ß* = (/L • • -ßkM)' of ß  = ( f t  •••/?#)'. If the model has 
a large number of parameters N  in relation to the number of parameters M  one is 
interested in, numerical quadrature may be impractical, and Monte Carlo methods will 
prove invaluable for estimating the required ’partial’ marginals. In particular, the Gibbs 
sampler can be employed to generate a large number of observations from pP(ß\y). This 
is done by successively sampling from the full conditional distributions pP(ßi\ß -ß , ,y ) .  
Stochastic equilibrium is eventually reached, and m further iterations yield a sample of 
size m from the joint posterior. Finally, the values of ß* can be ’peeled o ff and used to 
construct Rao-Blackwell estimates of the densities and quantities of interest. See Carlin et 
cd. (1992) for a recent application of the Bayesian PH model to some ADDS data.
PH model with an independent increments process prior on the cumulative hazard
Basing his work on Ferguson (1973, 1974), Doksum (1974), Kingman (1975), and 
Cornfield and Detre (1977), Kalbfleisch (1978) developed a Bayesian extension of the 
PH model in a somewhat different spirit to that just described. Firstly, he considered a 
partition of [0,«») into the intervals [0,q ), [q,r2), where q, are the ordered times
of death. He then placed a prior on the underlying cumulative hazard function A it) in the 
form
where:
A* (t) is a specified cumulative hazard function (which may involve unknown 
parameters) corresponding to one’s a priori belief about A(f); 
c is a measure of this belief, with 0 corresponding to none and °° to certainty;
( 1-22)
ri ~ i.i.d. G i d A 'C V - A 'i t ^ U ) ,
r, =  - lo g ( l -< 7, ); and
<7, is the hazard contribution of the zth interval.
71
Finally, combining this independent increments process prior with the proportional 
hazards assumption Pr(7 ^ rlz,A) = exp[-A (r)e^z], Kalbfleisch obtained a likelihood of 
the form
exp
(  n-c^BiWxi
V i=l
(cX*(Xi)Bi)s‘, (1-23)
where:
xl ,-- ,x n are all the observed times (i.e., o f both death and censoring),
zi is the covariate vector for the individual failing or being censored at time xit
St is the indicator function for a death occurring at x,-,
A*(0 =  3 A *(f)/A ,
= - lo g  - f —  ,\ C + A i J
Aj =  , and
jeRi
Ri is the risk set just prior to time jcf.
It is of interest, as Kalbfleisch noted, that (1-23) reduces (at least to first order) to the 
standard partial likelihood (1-22) in the limit as c —>0 (corresponding to a priori 
ignorance concerning A). One also recovers the appropriate likelihood for a fully 
parametric survival model with A = A* in the limit as c ©o.
Kalbfleisch gives an example where A*(r) = At, z,- is a treatment indicator function, ß  is 
the corresponding (scalar) treatment effect parameter, and c takes on various values from 0 
to oo. However, his estimation of A and ß  is essentially frequentist in that it involves 
nothing more than maximizing (1-23) with respect to these parameters. A fully Bayesian 
treatment would base inference concerning A and ß  on these parameters' joint posterior 
distribution. The density o f this distribution could be taken as proportional to some prior 
p(A ,ß) multiplied by (1-23) with A*(jq) = Ax,- and A*(x,-) =  A.
Clayton (1991) describes how such a fully Bayesian version of Kalbfleisch’s approach 
can be extended to accommodate heterogeneity, and gives an example involving a 
noninformative prior on the treatment parameter ß. Burridge (1981) extends Kalbfleisch's 
model in another way by tailoring it to grouped data and using this data to estimate the 
variability parameter c.
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Bayesian extension o f the Kaplan-Meier estimator
Also working with an independent increments process prior, but one based on the 
Dirichlet distribution (rather than the gamma), Susarla and Ryzin (1976) developed a 
Bayesian extension of the Kaplan-Meier (or product-limit) nonparametric estimator (e.g., 
see Cox and Oakes, 1984). The effect was essentially a partial smoothing of the usual step 
function.
Morales et al. (1991) have recently extended the theory of Susarla and Ryzin to 
accommodate data which is censored on both left and right
Dynamic models
In all the examples so far considered, the parameters have been constant with respect to 
time. Because this may not always be a realistic assumption, dynamic models have been 
developed to account for the possibility of effects changing over the course of a study. 
Gamerman and West (1987) and Gamerman (1991) proposed a piecewise exponential 
Bayesian approach along these lines for the analysis of failure time data. The parameters 
are modelled as time series, and a system equation is made to provide the stochastic link 
between adjacent values.
Mixture models
In survival analysis, the underlying distribution is often not homogeneous, but may 
consist of several subpopulations mixed in unknown proportions. The model will then
involve a c.clf. of the form
AM f  AM ^
F « ) =  X a F1(/)+ 1 - £ p ,
i=l V i=1 )
FN(t\
where pt is the proportion for component c.d.f. F,( ). Sloan and Sinha (1991) applied 
Bayesian methods to the analysis of such mixture models which have exponential 
component distributions. Sinha and Sloan (1989) did likewise for mixtures of Weibull 
distributions.
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1.7 DISCUSSION
The Bayesian approach has long been seen as a valuable way - at least theoretically - of 
dealing with complex models involving a large number of parameters, especially nuisance 
parameters. Such models have largely eluded satisfactory analysis via classical frequentist 
techniques. Moreover, the Bayesian paradigm is attractive in that it is conceptually simple, 
consistently applicable, intuitively plausible and probabilistically elegant. Lacking a 
unified methodology, frequentist inference must often make do with ad hoc rules, 
asymptotic results and other approximations.
The major barriers to more widespread application of Bayesian methods have been 
computational. However, the situation has changed dramatically over the past few years. 
This is largely due to the increased availability of powerful tools in the form of Monte 
Carlo techniques and the computer technology which permits their implementation. We 
saw in Section 1.5 how, by application of these tools, an intractable integral required for 
Bayesian inference could be solved (in principle) to any degree of precision. Although 
numerical quadrature was an option in that simple case, use of Monte Carlo methods such 
as the Gibbs sampler may well be the only feasible way of dealing with Bayesian models 
involving a large number of parameters.
Biostatistical applications
An example of such a model is given in Gilks and Wang et al. (1993), where the analysis 
of long-term response to hepatitis B vaccination is undertaken in the presence of multiple 
random effects. Priors are assigned to these random effects as well as the data conditional 
on them, and the Gibbs sampler is used to generate a large sample from the marginal 
posterior distributions required for inference.
Another example is provided by Lange et al. (1992) who conduct a fully Bayesian 
analysis of the progression of HIV infection using longitudinal CD4 T-cell numbers with 
a high-dimensional model. Again, the Gibbs sampler is employed to provide inference 
where frequentist methods are not feasible.
Cowles et al. (1993) have used the Gibbs sampler together with data augmentation and a 
multivariate Hastings update step to implement a Bayesian hierarchical model for lung 
inhaler compliance data. The model is a longitudinal Tobit model which allows for 
missing data and incorporates individual-level random effects to account for correlations 
among repeated measures on the same participant.
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A random effects model has also been developed by Ten Have and Becker (1994) to deal 
with repeated categorical responses without the usual local independence assumption. 
This model is applied to some dysmenorrhea data and implemented via the Gibbs 
sampler.
These and other examples are indicative of the recent trend in biostatistics towards taking 
a Bayesian outlook. See Breslow (1990) for a good overview of this trend.
Convergence of the Gibbs sampler
Perhaps the greatest problem with the Gibbs sampler is assessing convergence. This is 
highlighted in Gilks and Wang et al. (1993), and has been addressed to some extent by 
Gelfand and Hills et al. (1990), Raftery and Banfield (1991) and Roberts (1992). Geweke 
(1992) suggests calculating and monitoring an arbitrary function of the model parameters 
at each iteration of a single run of the Gibbs sampler. However, as Gelman and Rubin 
(1992a) point out, convergence cannot reliably be assessed on the basis of one single run. 
Even with sophisticated techniques based on several parallel runs with widely dispersed 
starting values, such as advocated in Gelman and Rubin (1992b), one can never be quite 
sure that some important feature of the posterior has not been 'missed.' A good example 
of the convergence problem is provided by Tanner (1993). In his 'Witch's Hat' example, 
the Gibbs sampler is run for over 4000 iterations before the very narrow 'spike' of the 
posterior is 'found.'
The problem of nonconvergence (as distinct from assessing convergence) was 
encountered in the recurrence time example of Section 1.5. Use of an improper prior 
(p(a ) 1 / a) resulted, we believe, in an improper posterior. This could explain the 
unstable behaviour of the Gibbs sampler. Whether and to what extent inference based on 
an improper posterior has validity remains an open question. A more fundamental 
question is which priors lead to an improper posterior, in our model and generally.
Recently, Hobert and Casella (1993) examined one class of models and identified the 
priors which do and do not result in an improper posterior. Using the criteria established 
by these authors, it has been shown (personal communication from Martin Tanner, 1994) 
that Gelfand and Hills et al. (1990) (unknowingly) used improper posteriors when 
performing Bayesian inference. It is suggested that the same is true of Clayton (1991) in 
his rat carcinogenesis example. Possibly, many more such instances will come to light as 
research in the field of improper posteriors bears fruit.
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Chapter 2
A BAYESIAN PHASE nB  
CLINICAL TRIAL DESIGN
2.1 SUMMARY
This chapter firstly presents and examines Thall and Simon's (1992,1993) subjective Bayes 
method for obtaining stopping rules in continuously-monitored single-arm phase IIB 
clinical trials wherein patient response is binary and an experimental treatment is being 
evaluated relative to a standard therapy. Suitably related beta prior distributions are 
specified for the standard and experimental treatment success rates, and the stopping rules 
at each patient response are based on the posterior probability that the difference between 
these rates exceeds zero and a given targeted improvement, respectively. Conditional on 
fixed values of the experimental treatment success rate, the design is evaluated via 
frequentist operating characteristics.
Secondly, a generalization of Thall and Simon's method which accommodates priors of any 
shape is applied to a hypothetical clinical trial, and the results are discussed.
2.2 INTRODUCTION
Clinical trials
Clinical trials wherein an experimental drug or treatment E (e.g., a chemotherapeutic 
regimen) is being evaluated for its effect on some disease or condition (e.g., cancer) are 
generally carried out in four phases:
• Firstly, a phase I trial is conducted to determine the maximum tolerated dose of E 
(e.g., 3mg/day of some drug, the limit before unacceptably high levels of toxicity 
result).
• Then, a phase II trial seeks to ascertain - as efficiently as possible - whether E is 
worth further examination.
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• Thirdly {if E is deemed to be sufficiently promising at phase II), a large-scale 
randomized phase III trial is implemented to get accurate estimates of F s efficacy.
• Once the drug has been accepted for public use by the regulatory authorities, 
monitoring of its effects and safety are continued in ongoing phase IV studies.
Phase II trials
Phase II clinical trials are medical studies whose primary aim is to determine whether an 
experimental drug or treatment E (e.g., a chemotherapeutic regimen) has an effect on a 
disease (e.g., leukemia) sufficiently promising (defined in some way) to warrant further 
examination.
As a bridge between phase I and phase III trials, these studies are of considerable 
importance in sifting through the vast number of treatments continually suggested for any 
particular disease and identifying those worth the expense of an in-depth investigation. 
Also, a phase II trial may show a supposedly safe treatment to have undesirable side effects 
(e.g., toxicities) not picked up at the phase I stage.
Phase II trials may roughly be categorized into:
• phase IIA trials, which aim to determine whether E has any beneficial effect against 
the disease at all; and (assuming that it does)
• phase IIB trials, which estimate the magnitude of this effect.
Comparative phase IIB trials
The disease under study is usually known and already treatable to some extent. Hence, 
phase IIB trials are typically comparative, the primary focus being the degree by which E is 
better than some standard therapy S. Although S' s efficacy is hardly ever known exactly, it 
will generally be known accurately enough for a small-scale trial to make little difference. 
Thus, phase IIB trials are often single-arm, there being no control arm of patients treated 
with 5.
When implementing many of the frequentist designs for comparative phase IIB trials, such 
as those described in Gehan (1961), Fleming (1982), Simon (1989) and Storer (1990), the 
clinician is required to specify a single value for Rs , the success rate of S (for instance, Rs
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might be the probability that a cancer patient treated with S will achieve a 50% reduction in 
tumour size within two months).
As noted, however, there is virtually always some uncertainty regarding Rs . Failing to take 
this into account, and thereby treating an inherently variable quantity as if it were a 
constant, can result in an underestimate of the required sample size or to inflated type I and 
type II error probabilities. Ultimately, this can lead to large-scale randomized trials of 
inferior new treatments or to the discarding of superior new ones.
When reliable historical data on S is available, it can formally be incorporated into the 
design (and subsequent inference) using an empirical Bayes method; this deals with the 
above problems. Thall and Simon (1990) developed such a method, and demonstrated that 
ignoring the variability inherent in a point estimate of Rs (based on historical data) leads to 
bias in the trial results.
When no such data is at hand, one natural and convenient way of dealing with the problems 
associated with uncertainty regarding Rs is by employing a subjective Bayes approach.
Thall and Simon's subjective Bayes phase IIB design
Such an approach is adopted by Thall and Simon (1992, 1993). In their comparative phase 
ÜB design, Rs is treated as a random variable with a prior probability distribution based on 
current clinical experience, belief and uncertainty (rather than historical data).
To make for a fully Bayesian design, the experimental treatment response rate, which we 
will denote by RE, is also treated as a random variable and given a prior probability 
distribution. Unlike the prior on Rs , however, RE s prior is made at most only weakly 
informative so that it doesn't unduly dominate the data. It is also suitably centred so as to 
provide desirable operating characteristics.
Furthermore, RE s posterior distribution changes throughout the course of the trial so as to 
reflect the sample evidence at each patient response. The stopping rules are based on this 
evidence, permitting continuous monitoring. The design is thus fully sequential.
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Although Bayesian machinery is used to obtain the stopping rules, it is convenient to 
examine frequentist operating characteristics when evaluating the design. These are 
obtained by conditioning on RE.
2.2.1 Outline
The rest of this section is devoted to a general discussion of the Bayesian approach to 
clinical trial design.
In Section 2.3, Thall and Simon's phase HB design is described in its most general form. 
No assumptions or restrictions are made regarding the priors or the relationships between 
them.
Section 2.4 then deals with the special case where the priors on RE and Rs arc strictly beta 
in distribution. As well as being computationally efficient, this is convenient for the 
clinician who must specify these priors. Note that Thall and Simon concern themselves 
solely with this case.
As we shall see, however, restriction to beta priors is sometimes problematic, and Section 
2.5 presents an application of Thall and Simon’s philosophy to a hypothetical clinical trial 
using general non-beta priors.
Finally, Section 2.6 shows how the trial results can be used to make inference about RE, 
and suggests several design modifications.
2.2.2 Clinical trials and Bayes
Priors
Whereas the empirical Bayes approach is universally accepted as statistically valid (being 
after all frequentist and not truly Bayesian), the subjective Bayes approach has always been 
the source of much controversy. This is primarily because of uncertainty about what prior 
should be used. For instance, two clinicians could specify two different priors on Rs - with
79
p.d.f.'s /^1)(rs )a n d /52)(r5), say - and, after observing the same trial, come to 
contradictory conclusions about E's efficacy.
In such a case, however, it may be argued that the clinicians' priors should be combined, 
perhaps by a weighting procedure based on an assessment of the clinicians' relative 
knowledge and experience, to produce a single prior - namely, one with p.d.f. 
f s (rs ) = w f$ \rs)  + ( \ - w ) f ^ \ r s ). This prior would be the appropriate one to use, 
representing what is then honestly believed about S by the authority in charge of the trial.
The possibility of both these clinicians being severely 'wrong' is a potential problem not 
easily addressed, except by recommending that as many experts as possible be consulted 
for their views. This will tend to have a 'smoothing' effect and hopefully lessen the impact 
of unreasonably extreme opinions. An example of a Bayesian clinical trial design where 
several clinicians' priors are averaged is given in Carlin et al. (1992).
If there are many experts, another way of combining their beliefs is to independently ask 
each for a point estimate only (rather than a whole distribution), and then to treat these as 
sample points from some common underlying distribution. This approach has several 
attractive features and is discussed in Press (1989).
A more obvious solution to the problem of uncertainty about Rs might be to randomize a 
proportion of the patients in the study to a control arm treated by S. Thall and Simon (1990) 
show how this proportion can be chosen to maximize the precision of estimates in an 
empirical Bayes setting. However, we will assume that S's efficacy is known (or rather, 
'believed') accurately enough for a small-scale trial to make no significant difference. 
Consequently, only single-arm trials will be considered.
Robustness
Although choice of prior is often problematic because of the arbitrariness involved, the 
Bayesian approach is, by the same token, attractive in that it provides a conceptually useful 
framework for model sensitivity analysis (see Greenhouse, 1992). Greenhouse and 
Wasserman (1994) have recently developed methods for assessing the robustness of the 
posterior distribution to the specification of the prior. Their approach replaces the prior 
distribution with a class of prior distributions and investigate how inferences might change 
as the prior varies over this class. They illustrate their methods by application to clinical
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trials and show how a data monitoring committee can be helped to decide whether or not to 
stop a trial early.
Ethics and early termination
Perhaps the most distinguishing feature of medical trials in general is the host of ethical 
issues arising from the imperative that patients not be exposed to an inferior or harmful 
treatment for any longer than necessary. Also, a valuable treatment should not be withheld 
from the public any longer than necessary. These and associated issues necessitate very 
special consideration; see Jennison and Turnbull (1990).
In practice, many clinicians violate specified design protocols by terminating trials early if 
they observe what they deem to be an unacceptably long run of patient failures. 
Furthermore, aspects of patient response which are not formally part of the design, such as 
toxicity, as well as other factors (e.g., lack of funding, inconvenience, etc.) may be 
involved in the decision to terminate early. Such ad hoc early termination rules tend to 
reduce power in the design.
A good example of early termination and the associated problems is provided by the 
University Group Diabetes Program, as described in Meier (1975). A 10-year study was 
undertaken to assess the effect of the experimental oral drug Tolbutamide on the mortality 
(among other aspects) of a group of middle-aged and elderly diabetics. The classical 
frequentist design included a control arm given insulin (the standard treatment) as well as a 
placebo arm. With time, it became alarmingly clear that Tolbutamide was associated with 
excess mortality, and the decision to stop the trial was finally taken during the 8th year.
This decision, however, was made only after considerable and even heated debate. The 
point was made that early stopping had not been envisaged, and consequently there were 
serious methodological problems with any inference performed prior to the trial's 
conclusion, even with adjustment of significance levels.
If the trial design had been Bayesian rather than frequentist, these problems would not have 
arisen. This is because all Bayesian inference is based entirely on a prior multiplied by a 
likelihood, neither of which is affected by stopping rules; see Cornfield (1966) and Novick 
and Grizzle (1965).
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Another example of early termination is described by Korn et al. (1993) and Emerson 
(1993). A chemotherapy trial in which unexpectedly high leukopenia (a toxicity) in 3 out of 
4 patients led to the trial being stopped. The primary aim of the trial was to estimate the 
effectiveness of granulocyte colony-stimulating factor (a drug) in reducing the incidence of 
oral mucositis (another form of toxicity) in the patients receiving chemotherapy. The 
incidence of leukopenia was part of a planned secondary analysis of the trial results, but no 
formal interim analyses had been envisaged. The decision to stop and the subsequent 
reporting of results was again problematic because early termination had not been built into 
the design. Several different arguments for stopping were looked at, both frequentist and 
Bayesian. Whereas the Bayesian approach was seen as conceptually attractive, attention 
was drawn to the problem (already mentioned) of which prior to use.
Sequential clinical trials
Sequential clinical trials are trials which take into account the possibility of early 
termination; see Armitage (1975) and Peace (1992). Berry (1985) compares the classical 
and Bayesian approaches to designing such trials. In one example, the average sample 
number (ASN) decreases with the number of interim looks in the Bayesian design, but 
increases past an optimum in the frequentist. Since ethical considerations favour both 
minimizing the ASN and as many looks as possible (namely, the fully sequential design), 
Berry favours the Bayesian design over the frequentist.
He also criticizes the classical approach because it requires adjusted p-values (e.g., see 
Armitage et al., 1969, and Pocock, 1977), of which concept the consumer has such poor 
understanding. Note that adjusting p-values in a frequentist design because of early 
termination or the possibility of early termination is only problematic if that possibility is 
not considered in the design right at the start.
Finally, he makes the observation that many clinicians don't even understand what a p- 
value is, believing it to be the probability of the truth of a null hypothesis. The fact that this 
(latter) probability is a concept they feel comfortable with is an argument in favour of the 
Bayesian approach in general, since it cannot be calculated within a classical framework.
More recently, Freedman and Spiegelhalter (1992) applied Bayesian methods to the 
monitoring and analysis of a trial of treatment for patients with advanced colorectal
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carcinoma. Using a truncated normal prior with a probability mass at zero, they obtained 
stopping rules very similar to frequentist analogues.
Freedman and Spiegelhalter's contention is that Bayesian methods are ideally suited to 
sequential clinical trials. They make a number of points:
• Firstly, these methods are flexible, avoiding the need for 'adjustments' according to 
the number of looks at the data (or the number of looks which might have been had).
• Secondly, they can be adapted to suit many different types of trial simply by 
changing the prior (e.g., from vague to informative).
• Thirdly, estimation following Bayesian monitoring can be made via routine methods 
(e.g., by computing the posterior mean).
• Finally, interpretation of results using a posterior distribution is intuitively appealing, 
allowing conclusions to be made by way of simple probability statements (such as 
"Given the information gathered to date, the probability that Treatment A has less 
severe side effects than Treatment B is 93%").
Perhaps the most important of these four points is the first. This is because a frequentist 
design cannot take into account all possible contingencies which might lead to early 
termination. For example, had the Tolbutamide trial (mentioned above) been sequentially 
designed to accommodate the possibility of high mortality, inference would again have 
been problematic if the drug was found suspect for some other unexpected reason. 
'Adjustments' after the event are always dubious. Likewise, deciding beforehand on the 
contingencies worth consideration must typically be highly subjective (on a par with 
specifying a prior), and can lead to very biased conclusions.
However, the Bayesian approach is entirely free of these problems. This is because of its 
compatibility with the likelihood principle, which states that all inference should be based 
on the likelihood only and not on the stopping rules. Anscombe (1963) may have had this 
in mind when he wrote:
"Sequential analysis" is a hoax. The correct statistical analysis of the observations 
consists primarily of quoting the likelihood function. So long as all observations made 
are fairly reported, the sequential stopping rule that may or may not have been followed 
is irrelevant. The experimenter should feel entirely uninhibited about continuing or 
discontinuing his trial, changing his mind about the stopping rule in the middle, etc., 
because the interpretation of the observations will be based on what was observed, and 
not on what might have been observed but wasn't.
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2.3 THE GENERAL DESIGN
In this section, we present and define Thall and Simon’s general approach, as well as 
formulate the theory necessary for its implementation and analysis.
2.3.1 Description
Trial data
The phase DB clinical trial is assumed to be single-arm, consisting of a sequence Yl,Y2,‘ - 
of binary patient responses to E. For each n - 1,2,* • • , Yn = 0 indicates failure, and Yn = 1 
indicates success. Let he the realized values of these random variables (i.e., the
actual trial data).
Then, the total number of successes at the stage when n patients have been observed is 
Xn = y1+---+Yn, with realized value xn = yjH— \-yn, n = 1,2,*•*. For completeness, we also 
define X0 = Xq = Y0 = y0 = 0 with probability one.
We assume that, conditional on Re =^e (a constant), Y\,Y2>--' are exchangeable with 
Pr(y„ = 1) = rE = 1 —Pr(Tn =0), n = 1,2,-••. In particular, this precludes the possibility of 
Es effectiveness changing over the course of the trial.
Design parameters
Before the trial begins, the clinician specifies the following design parameters: 
nmax, the maximum number of patients (nmax € {2,3, • • ■});
«min» the minimum number of patients ('Wn e U»■• * *»^ max ~
d, the targeted improvement of RE over Rs (d e [0,1));
De , the prior probability distribution of RE (rE g [0,1]);
Ds , the prior probability distribution of Rs (rs g [0,1]);
pL, a small probability close to 0 (pL g (0,1)); and
pUt a large probability close to 1 {pv  g (0,1)).
As we shall see later, any particular combination of these parameters determines the 
operating characteristics according to certain patterns. To make for a useful design, the
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clinician should be aware of the interplay involved. This interplay is studied and 
summarized for the case restricted to beta priors in Subsections 2.4.3, 2.4.4 and 2.4.5.
Stopping criteria
The trial continues until at least patient responses have been observed. It finishes 
when E is declared to be either promising or not promising, or until nmax is reached. If 
rtmjm is reached and E is declared neither promising nor not promising at that stage, then 
the trial is declared inconclusive.
At the nth patient response, n = E is declared to be promising if and only if
K  (xn) = Pr(Re - R s > 0IXn = xn)> Pu
(i.e., iff there is a high enough posterior probability 
Pn(xn) that Re exceeds Rs ), 
and not promising if and only if
f*n (*»)s  Pr (Re ~ rs > d\Xn = x„ )<p L
(i.e., iff there is a low enough posterior probability 
Pn(*n) that Re exceeds Rs by at least d).
The rationale for the definition of not promising is that a treatment unlikely to provide an 
improvement of at least d over Rs does not warrant further consideration.
At the same time, the definition of promising addresses the question of primary interest, 
namely "Is E better than ST
Operating characteristics
Given a fixed experimental treatment success rate RE -  p E, the frequentist operating 
characteristics we will study are (primarily) P+, the unconditional probability of declaring 
E promising, P~, the unconditional probability of declaring E not promising, and 
and A/7 5 , the 25th, 50th and 75th percentiles, respectively, of the achieved 
sample size M.
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2.3.2 Bayesian stopping rules
Cutoffs
In application, the design consists of a sequence of stopping rules, these being simply upper 
and lower cutoffs based on P„ (xn) and P~(xn) at each step n =
Explicitly, we define the upper cutoffs to be * where for each n = un
is either:
(a) the smallest integer u such that P„ (u) > py,  if such an integer exists and n > nmin; 
or
(b) n+1, otherwise. (2-1)
Similarly, we define the lower cutoffs to be , where for each n = ln is
either:
(a) the largest integer / such that P~(/) < pL, if such an integer exists and n > 
or
(b) - 1, otherwise. (2-2) 
Decision rule
In full then, the decision rule at each stage n = 0,- • is as follows:
• If xn > then stop the trial and declare E promising.
• If xn < /„, then stop the trial and declare E not promising.
• If /„ < xn < un and n < then continue the trial, i.e. treat another patient, the 
(rt+l)th, with E.
• If /„ < xn < un and n = then stop the trial and declare it inconclusive. 
Computation of the cutoffs
To obtain general expressions for the cutoffs ln and un, first let fs(rs ) and f i { r E) be the 
prior p.d.f.'s of Rs and RE, respectively. Also let hn(rE\xn) be the posterior p.d.f. of RE 
given Xn = a:„.
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We then have that
Pn(x„) sPr(RE- R s ><XXK= x n)
l
= J Pr (Re~rs>  0IX« = xn)fs(.rs )drs 
0
1 1
= \[\K,(.rE\xn)drE]fs (rs )drs . (2-3)
0 rs
Similarly,
P„(xn) s Pt(Re -R $ >  d\Xn = xn)
1 -d
= l M R E- rS >dlXn = xn)fs(rs)drS 
0
1 -d 1
= J [ jK t(rE^ n)drE\ f s (rs )drs . (2-4)
0 (f+r
The cutoffs can then be obtained according to definitions (2-1) and (2-2) via an iterative 
search procedure, or else set to -1 or n+1, as appropriate.
Note that throughout this treatise, integrals are to be understood as appropriate summations 
if the context so demands, i.e. whenever the integrands are discrete functions.
Note also that
where
K,(r Eixn)
gn(xn\rE)
fFArF.)gn(xn\rF)
mn(xn)
\ XnJ
rEx' ( l - r E)-  T -V *.
is the conditional p.d.f. of Xn given RE = rE> and
l
m„(xn) = J f E(rE)gn(xn\rE)drE 
0
is the unconditional p.d.f. of Xn.
(2-5)
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2.33 Frequentist operating characteristics
Given a particular design with its associated cutoffs and operating characteristics and with 
Re fixed at some constant pE e  [0,1], let P„ and P~ be the unconditional probabilities of 
declaring E promising and not promising, respectively, just after the nth patient response,
^  “  ^ m in »' * ’ »^ m a x  *
Then, the (overall) unconditional probabilities of declaring E promising and not promising, 
respectively, are given simply by
r+= 2 K
n = n min
and
«=«min
It follows that the achieved sample size M has p.d.f.
and c.d.f.
m
W(m)=  £wO ), m = nmin, - , n m a.
J ^^ min
Hence the <rth percentile of Af s distribution is given by
Mq = min[f: W(t) Z q / 100, t e h w  ••,«„«}], Q G [0,100].
Computation
We first observe that
and
these sums being easily evaluable since ( X ^  IRE = pE) ~ B in C n ^ ,/^ ) .
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However, the calculation of P* and Pn for n > is more involved. We proceed by first 
defining:
Cft — Wn ' *»*fn — 1)» n ~~ ”  *» *^max
(the 'continuation set' just after the nth patient response);
A f t  —  {Xj  € C j  V j  0, • • •, n), n 0, • * •, n^^
(the event that the trial continues through the nth stage; and
Tn(xn) a  Pr(Xn = XftfAft^X xn = 0 ,n, ii = l f"',fin n
(the probability that the trial reaches the nth stage with a total of exactly xn 
successes observed at that stage).
Then,
K  = Pr(X„ > u .A _ i)  = i ,T n(xn) (2-6)
X*=un
and
U
P -  =  Pr(Xn s  / , A - i )  = £ r „ ( j t n). (2-7)
*.=o
Now 7 ^  (* ) = ( x ^  I p£ ), which is readily calculated.
It follows that if we can find a suitable recursive formula for the Tn(xn), then P„ and P~ 
can easily be computed for n = n ^  + l,-*-,nmax, and hence P+,P~, # 25*^50  andN75 
also. Such a formula is provided by the following theorem, the proof of which is given in 
Section A 2.1 of Appendix 2.
Theorem 2-1
Tn(xn) = Pe Tn-i(xn -  l)/(*n - 1  e Cn_j) + (1 -  PE)Tn-i(xn)I(xn e Cn_x\
Xn ~ 0 ," ‘,n, fl — I?” '>^ max>
where /(•) is the standard indicator function.
89
2.4 THE DESIGN WITH BETA PRIORS
In this section, we first describe the form of the design presented in Thall and Simon (1992, 
1993), and show how it simplifies computation. An example is then given, and this leads us 
to investigate how the design's operating characteristics behave for various combinations of 
its parameters.
2.4.1 The priors and design parameters
Retaining the notation so far developed, let Dj  = B e t a ^ ,^ )  for T = S,E, so that RT has 
concentration parameter cT = aT +br , mean mT =aT /c Tt and variance vT = 
rrvpil -  mj)  /  (1 + cT). Note that Dj's dispersion is thereby inversely proportionate to cT.
Also, denote the p.d.f., c.d.f. and quantile function of a Beta(a,fc) random variable by 
f{- \a ,b \  F(-;atb) and F~l(\a,b), respectively, so that RT has p.d.f. f j { r T) = 
f i r j ’.aj.bp)  andc.d.f. FT(rT) = Firj'.Op.bj).
The standard treatment prior
For convenience, we will describe Ds equivalently in terms of its mean and 
W9 0  = Fs~l (0.95) ~Fs~l (0.05), the width of the central 90% probability interval running 
from the 5th through to the 95th percentile of Ds .
The clinician first specifies ms and W9 0 . The density of the corresponding standard 
treatment success rate can then be drawn on a computer, and these parameters modified 
until the 'right' shape is achieved. Associated with this shape are unique values of 
as and bs , and thus Ds is determined. See Lindley and Philips (1976) for a discussion of 
this process.
The experimental treatment prior
As regards DE, there are two restrictions placed on it by Thall and Simon with the aim of 
achieving a useful design.
90
Firstly, mE is set to equal ms + d / 2. Thus, DE is centred at the average of the means of 
the priors corresponding to the most pessimistic view that E is on average identical to S, 
and the optimistic view that the targeted improvement d is provided.
And secondly, cE is restricted to the range [2, 10]. Thus DE s dispersion is made no greater 
than that of the standard uniform distribution (cE = 2) and no less than that of the posterior 
corresponding to a small pilot study of E (cE = 10).
In this latter regard, consider a Bayesian pilot study of size n wherein the response rate R 
has the noninformative prior
<p(r) = 1, re [0,1],
and X is the number of successes, with conditional p.d.f.
V
Y(x\r) rx( l - r ) ' x = 0,•••,«.
The posterior then, is
r\(r\x)~q><j)Y{x\r)
« l x r x( l - r ) n-x.
It follows that (R\X = jc)~Beta(;c + l,rt-jc  + l), with concentration parameter 
c = (x +1) + (n -  x +1) = n + 2. Thus c = 10 in this case corresponds to n = 8 (a small pilot 
study) and c - 2  corresponds to n -  0 (no study at all).
Once cE is specified, so also are aE and bE (through ms and d), and thus DE. Hence, the 
design parameters consist of d, ms , W ^ ,  cE, pL and pv .
2.4.2 Simplified computation
With Rs and RE being beta in distribution, the computation of the posterior probabilities 
needed for obtaining the stopping rules and operating characteristics is considerably 
simplified.
First observe that
“  / E ( rE ) « „ ( • * > £ )
“ [rE‘E~ \ 1" rE)^'1] xtr^'d -  rE)n~x- ],
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which implies that (RE\Xn = xn) ~ Beta(fl£ + xn,bE + n - x n).
Consequently, equation (2-3) reduces to
l
K  (**) = J[! -  F(rs ;aE + xn,bE + n-  xn)\f(rs ;as ,bs )drs , (2-8)
o
and equation (2-4) to
l - d
PnM  = J [ l - F(rs + d\aE + xn,bE + n - x n)]f(rs ;as ,bs )drs . (2-9)
o
Also, expressions (2-6) and (2-7) for P* and Pn simplify to 
K  =  PET n - \ ( “n -l -  =  *n- 1 “  D (2- 10)
and
^  = (1 -  P£Fn-l(/n-l + D/(/„ = /„-l +1). (2- 11)
respectively, n = nmin See Section A2.2 of Appendix 2 for a proof of these
results.
2.4.3 An example
Consider an experimental drug E which has been suggested as a possible alternative to S, 
the standard treatment for a certain disease. We assume that about 65 patients can be 
allocated to such an investigation, and that at least 10 would have to be treated with E 
before any conclusions drawn could convince the clinician and monitoring committee 
either way about E s therapeutic value, relative to 5 or otherwise.
Note that phase II trials involving more than 65 patients are rare, such studies usually being 
classified as phase III. Also note that there is no theoretical reason why a clinical trial 
should not be permitted to terminate very early. Refer back to Subsection 2.2.2 for the 
details of a trial which was stopped after only four patient responses.
Elicitation of design parameters and priors
Next suppose that S has a beneficial effect in approximately 20% of the patients to whom it 
is administered, and that an increase of 15% on this (so as to make 35%) would be
92
considered a minimal worthwhile improvement (all other things, such as toxicity and cost, 
being equal).
The clinician finds it difficult to express his uncertainty about Fs efficacy, and to help him 
visualize this, a beta density with mean 0.2 and ^  =0.1 is displayed on a computer 
screen. He comments, however, that this is 'too narrow' and represents him as being surer 
about the 20% value than he actually is. When a more disperse beta density is displayed, 
one with mean 0.2 and 1^90= 0.2, the clinician feels content with it as reasonably 
reflecting his belief and uncertainty about Fs effectiveness.
As regards F s efficacy, the clinician expresses total ignorance, and accordingly, its success 
rate is given a beta prior with concentration parameter 2 (see Subsection 2.4.1).
Note that total ignorance will in general not be the case, especially after a successful phase 
IIA trial. Moreover, encouraging studies involving animals will typically have been made 
prior to experimentation on human beings.
Finally, the clinician states that he would like to be at least 95% confident that F s success 
rate exceeds Fs before recommending that F be made the subject of a more extensive phase 
III trial. On the other hand, he would be hesitant to discard F as useless if there were at 
least a 5% chance that its success rate exceeds Fs by 15 percentage points.
The design and decision cutoffs
The above elicitations from the clinician translate into a phase HB design with parameters 
«max = 65, zimin = 10, d = 0.\5, ms = 0.2, 1*90=0.2, cE = 2, pL = 0.05 and Pu = 0.95. 
Figure 2-1 on page 93 shows the decision cutoffs corresponding to this design. These were 
computed using the Splus function bound.get, part of the code (accommodating beta priors 
only) provided with Thall and Simon (1993). See Section A3.4 of Appendix 3 for the Splus 
code corresponding to this section, and note that we do not list Thall and Simon's code, 
only our own.
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From Figure 2-1 we see, for instance, that if the trial continues through to the 37th patient, 
and 14 or more of these 37 have responded favourably to E by that stage, then the decision 
rule is to stop the trial and declare E promising. On the other hand, if 7 or less have 
responded favourably, the trial should be stopped and E declared not promising. Otherwise, 
another patient should be treated.
Beta densities
Also see Figure 2-2 on page 95 which shows five beta densities of varying dispersion, 
quantified in terms of W^q, including the two considered as priors for Rs .
Finally, see Figure 2-3 on page 96 which shows five beta densities with mean 0.275 and 
concentration parameter ranging from 2 to 10. Recall that in Thall and Simon's scheme, the 
prior on E is always given mean mE = ms + d /  2. Thus mE = 0.275 in this case.
Three questions relating to the operating characteristics
Given the cutoffs obtained, several questions naturally arise. Firstly, what is the probability 
of falsely declaring E promising if its success rate is only 20% (the same as Ss)7 Secondly, 
what is the probability of falsely declaring E not promising if its success rate is 35% (i.e., 
the targeted improvement has in fact been achieved)? Thirdly, given these two assumptions 
about Re individually, how long is the trial likely to last (i.e., how many patients are likely 
to be treated before the trial ends)?
Answers to these and some other questions about the design's operating characteristics are 
summarised in Table 2-1 (on page 97).
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Tabic 2-1 Operating characteristics
Pe 0.050 0.150 0.200 0.275 0.350 0.400 0.500 0.600 0.700
P+ 0.000 0.017 0.071 0.318 0.700 0.875 0.984 0.998 1.000
P~ 1.000 0.968 0.835 0.448 0.165 0.077 0.015 0.002 0.000
P# 0.000 0.015 0.094 0.234 0.135 0.048 0.001 0.000 0.000
* 1 0 10 10 10 10 10 10 10 10 10
* 2 5 10 10 10 10 10 10 10 10 10
* 5 0 10 10 14 21 16 13 10 10 10
* 7 5 10 19 32 60 38 25 13 10 10
M90 10 32 64 65 65 46 22 13 10
ASN 10.53 17.07 24.06 31.19 26.53 20.85 13.53 10.95 10.19
Note that P* =  1- P +- P~ here is the probability that the trial will be declared
inconclusive given the indicated value of pE. Also, A/10 and A/90 are, respectively, the 
10th and 90th percentiles of A/’s distribution. Finally, ASN denotes the average sample
number, otherwise known as the expected sample size. This quantity is defined and 
calculated according to
^^irux
ASN =  E(M\Re = pE) =  ^m w (m ),
^  nrmn
where w(m) is A/’s conditional p.d.f. given RE = pE (see Subsection 2.3.3).
As can be seen from Table 2-1, the answers to our first two questions are 
(P+\pE = 0.2) = 7.1% and (P+\pE = 0.35) = 16.5%, respectively (shown bold).
Type I and II errors
Note that these probabilities play a role similar (but not identical) to that of type I and type 
II error rates in classical frequentist hypothesis testing. In a similar way, the P+ row can be 
thought of as the power, i.e. the probability of rejecting the implied null hypothesis that E 
and S are equivalent, given certain fixed values of E's success rate. We will here loosely use 
these terms in this way.
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With the resemblance to frequentist theory in mind, we define a  to be the probability of a 
type I error, i.e. the probability that E is declared promising, given that its success rate is on 
average identical to S's. (Thus a  is the power at pE = ms + d.) Similarly, we define ß  to 
be the probability of a type II error, i.e. the probability that E is declared to be not 
promising, given that the targeted improvement d is exactly achieved. With this notation, 
then, a  = 0.071 and ß  = 0.165 for our design.
As regards the third question, we see that the trial can be expected to last about 24 and 27 
patient responses, respectively, for the two situations pE = 0.2 and pE = 0.35. 
Alternatively, we might say that there is an approximately 50% chance that the trial will 
terminate by the 16th patient response if pE = 0.35, but only by the 14th if pE = 0.2. As 
regards uncertainty about M (i.e., M's dispersion), we can say that there is about a 50% 
chance that the trial will terminate somewhere between the 10th and 32nd, and between the 
10th and 38th patient responses, respectively, for the two cases pE -  0.2 and pE = 0.35.
Although the ASN as well as Afi0 and M^q are given in Table 2-1 for completeness, we 
will find it convenient and sufficient for our purposes to henceforth focus solely on the 
other operating characteristics when evaluating a design. For simplicity, we will also only 
consider the two cases pE = ms and pE = ms + d.
Declaration probabilities at each patient response
Another question which arises about the above design has to do with the individual 
probabilities of declaring E promising and not promising at each patient response (denoted, 
respectively, by P„ and P~ in Subsection 2.3.3). Figure 2-4 on page 99 shows these 
probabilities for the cases pE = 0.35 and pE = 0.2. Note that some probabilities are zero. 
The reason for this can be seen by reference to Figure 2-1. For example, E cannot be 
declared promising at the 11th patient response (requiring at least 6 successes) because this 
would require there to have been at least 5 successes at the 10th, in which case the trial 
would already have terminated (since 5 out of 10 is itself an upper cutoff).
Varying the minimum number o f patients
Also observe that the highest probabilities occur very early on in the trial. This leads us to 
examine what happens if is varied. Table 2-2 (on page 100) gives the selected 
operating characteristics for the same design but with this parameter ranging from 2 to 20.
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Table 2-2 Varying
«min 2 5 10 15___________ 20
Pe 0.200 0.350 0.200 0.350 0.200 0.350 0.200 0.350 0.200 0.350
P+ 0.107 0.646 0.080 0.669 0.071 0.700 0.053 0.710 0.040 0.707
P~ 0.828 0.260 0.841 0.217 0.835 0.165 0.832 0.124 0.827 0.099
/># 0.065 0.094 0.079 0.115 0.094 0.135 0.115 0.166 0.133 0.193
« 2 5 4 4 5 7 10 10 15 15 20 20
« 5 0 10 10 10 13 14 16 19 22 23 28
« 7 5 23 25 28 32 32 38 40 46 44 52
We see that a  and ß  both decrease with increasing n ^ ,  but that the Mq and the 
probability of an inconclusive trial increase (as one would expect). Thus there is a trade-off 
involved when deciding upon in a design such as this: less probability of error has to 
be weighed up against having to treat more patients. One should also never lose sight of the 
ethical reasons for having as low as possible. Note also how the power at 0.35 
remains fairly constant.
Varying the maximum number of patients
Similarly, one might ask what happens if the maximum number of patients is varied. Table 
2-3 gives the operating characteristics for the same design again, but with fixed at 10 
and nmax ranging from 20 to 65.
Table 2-3 Varying
«max 20 40 50 60 65
Pe 0.200 0.350 0.200 0.350 0.200 0.350 0.200 0.350 0.200 0.350
P+ 0.055 0.430 0.068 0.611 0.070 0.655 0.071 0.691 0.071 0.700
P~ 0.567 0.130 0.747 0.156 0.785 0.160 0.825 0.164 0.835 0.165
p* 0.378 0.439 0.185 0.233 0.145 0.185 0.104 0.145 0.094 0.135
« 2 5 10 10 10 10 10 10 10 10 10 10
« 5 0 14 16 14 16 14 16 14 16 14 16
« 7 5 20 20 32 38 32 38 32 38 32 38
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It can be seen that a  and ß  both decrease as nmax decreases, but only slightly. At any rate, 
all improvement in this respect is more than cancelled out by the rate at which the power 
decreases (e.g., 0.700 at 0.350 when is 65 down to 0.430 at 0.350 when is 20). 
Furthermore (as one would also expect), the probability of an inconclusive trial increases. 
Note that the Mq do not change as they would in an analogous ffequentist design (due to 
significance levels having to be adjusted).
Varying the width of the 90% probability interval
We now turn our attention to the effect changing WgQ has on the operating characteristics. 
Table 2-4 gives these for our design with W90 varying from 0.05 to 0.4.
Table 2-4 Varying W90
WX) 0.05 0.10 0.20 0.30 0.40
Pe 0.200 0.350 0.200 0.350 0.200 0.350 0.200 0.350 0.200 0.350
P+ 0.131 0.768 0.122 0.783 0.071 0.700 0.024 0.461 0.005 0.153
P~ 0.865 0.228 0.866 0.202 0.835 0.165 0.703 0.097 0.467 0.044
P* 0.004 0.004 0.012 0.015 0.094 0.135 0.273 0.442 0.528 0.803
M 25 10 10 10 10 10 10 11 14 19 65
Mso 13 14 14 14 14 16 21 43 65 65
M 15 21 22 26 25 32 38 65 65 65 65
The best design seems to be that with W90 somewhere around 0.2 (out of those designs 
with the combination of the other parameters in our original example). For values greater 
than this, the probability of an inconclusive result becomes higher, and for smaller values, 
a  and ß  tend to become larger, although only slightly.
Note also that with W9q=0 .3 , the trial is likely to last substantially longer than if 1^90=0.2. 
But this situation is not one to arise, because if knowledge about the standard therapy is so 
limited (see the density with W90 =0.3 in Figure 2-2), a randomized control arm of 
patients treated with 5 should be included. This would deal with the problem more directly 
by obtaining empirical information on Ds . See Thall and Simon (1990) (mentioned earlier
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in Section 2.2) for an analogous situation in an empirical Bayes setting wherein an 
unbalanced two-arm design is formulated.
Varying the targeted improvement
Next, we examine the effect of varying d. Table 2-5 summarizes the operating 
characteristics for this parameter varying from 0.05 to 0.3. Note that we (again) compare 
the two cases pE = 0.2 and pE = 0.2 + d for each d.
d 0.05 0.10 0.15 0.20 0.30
Pe 0.200 0.205 0.200 0.300 0.200 0.350 0.200 0.400 0.200 0.500
P+ 0.072 0.081 0.072 0.463 0.071 0.700 0.070 0.832 0.074 0.886
P~ 0.322 0.298 0.595 0.146 0.835 0.165 0.920 0.150 0.926 0.114
P# 0.606 0.621 0.333 0.391 0.094 0.135 0.010 0.019 0.000 0.000
«25 19 22 12 12 10 10 10 10 10 10
A*50 65 65 28 35 14 16 12 13 10 10
M15 65 65 65 65 32 38 20 22 12 11
Observe that almost all the operating characteristics improve as d increases. However, a 
targeted improvement which is made artificially large simply for this reason will tend not to 
address the actual aims of the study. For example, E may be rejected due to not being better 
than S by d when it is better by d / 2, the latter being a gain which is actually significant.
Varying the concentration parameter of the experimental treatment response rate
We now look at the impact varying cE has on the design. Table 2-6 gives comparisons with 
this parameter ranging from 2 to 10.
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Table 2-6 Varying cE
ce________ 2____________4____________ 6____________ 8____________10
Pe 0.20 0.35 0.20 0.35 0.20 0.35 0.200 0.35 0.20 0.35
P+ 0.071 0.700 0.070 0.699 0.053 0.695 0.048 0.686 0.046 0.685
P~ 0.835 0.165 0.831 0.155 0.825 0.133 0.820 0.124 0.813 0.109
/># 0.094 0.135 0.099 0.146 0.122 0.173 0.132 0.190 0.141 0.206
« 2 5 10 10 10 10 11 12 11 12 12 12
« 5 0 14 16 15 18 20 22 20 24 20 26
« 7 5 32 38 36 40 40 47 41 50 45 55
We see that as c£ increases, a  and ß  decrease. However, the power at 0.35 decreases, if 
only slightly. Also, the trial is more likely to be inconclusive and last longer. This is 
because more data are required to reach a decision when the prior on Rs is more 
concentrated around its mean ms + d / 2.
Varying the mean of the prior on the standard treatment response rate
Table 2-7 shows the operating characteristics of our original design for values of ms 
ranging from 0.1 to 0.8. Observe how P+ and the power increase and P~ decreases 
uniformly as ms is increased. The achieved sample size tending to peak at ms =0.5 may 
be attributable to the binomial variance being largest for values of the binomial probability 
parameter close to a half.
Table 2-7 Varying ms
"'s 0.1 0.2 . 0.5 0.7 0.8
Pe 0.10 0.25 0.20 0.35 0.50 0.65 0.70 0.85 0.80 0.95
P+ 0.028 0.638 0.070 0.699 0.134 0.754 0.170 0.870 0.173 0.958
P~ 0.910 0.155 0.831 0.155 0.721 0.110 0.714 0.051 0.742 0.019
p* 0.062 0.207 0.099 0.146 0.145 0.136 0.116 0.079 0.085 0.022
« 2 5 10 10 10 10 11 10 11 11 10 10
« 5 0 14 18 15 18 18 18 17 11 13 10
« 7 5 29 50 36 40 42 39 35 28 28 18
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Varying the decision criteria
We finally look at varying py and p y . In each case we consider, these parameters differ 
from 0.5 by the same amount. Table 2-8 summarizes our results.
Table 2-8 Varying pL and py
Pl>Pu 0.10,0.90 0.08,0.92 0.05,0.95 0.02,0.98 0.01,0.99
Pe 0 . 2 0 0.35 0 . 2 0 0.35 0 . 2 0 0.35 0 . 2 0 0 0.35 0 . 2 0 0.35
P+ 0.139 0.738 0.125 0.754 0.134 0.754 0.022 0.506 0.007 0.337
P~ 0.855 0.254 0.852 0.216 0.721 0.110 0.670 0.060 0.533 0.033
p* 0.005 0.008 0.023 0.030 0.145 0.136 0.308 0.434 0.459 0.630
« 2 5 1 0 1 0 1 0 1 0 1 1 1 0 13 18 2 0 32
« 5 0 1 2 1 2 13 1 2 18 18 32 49 59 65
Mis 16 18 2 1 2 1 42 39 65 65 65 65
The first three combinations of py and py result in fairly good designs, the trial tending to 
last longer, of course, when there is greater stringency in the decision criteria. The last two 
combinations, however, exhibit a very poor power at 0.35 (0.506 and 0.337), with the trial 
also having a high probability of being inconclusive.
That concludes our study of the example which has been the topic of this section. Certain 
patterns and trade-offs were revealed in the behaviour of the operating characteristics by 
singly varying the design parameters. We will, however, defer a summary of our findings 
until after the next subsection wherein a more general investigation is undertaken.
2.4.4 Further investigation
Without making extensive tabulations, we will merely note that, generally speaking, the 
patterns which emerged in the previous subsection also occur for other base combinations 
of the design parameters. For instance, when ce =10 (rather than 2 in our example), then 
W90 = 0.2 still provides a much better design than does W90 = 0.3. We find that the power
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a tp e = ms + d is 0.685 for W90 = 0.2, which is significantly greater than 0.333, the same 
power for Ww = 0.3 (just as 0.700 > 0.461 in Table 2-4).
Stringent decision criteria
A notable exception is that for highly informative priors on the standard treatment response 
rate, more stringent decision criteria than p i  = 0.05 and pu  = 0.95 may result in good 
operating characteristics (unlike in Table 2-8). Table 2-9 gives an example of this, showing 
the operating characteristics for our original design but with W90 = 0.1 (rather than 0.2), p i  
= 0.02 and pu = 0.98.
Table 2-9 Stringent decision criteria
0.20 0.35
P+ 0.055 0.745
P~ 0.818 0.107
P# 0.127 0.147
M x 12 12
W 50 25 25
M 15 45 48
Compare these results with those in Table 2-4 wherein a  and ß  are worse, having values 
0.122 and 0.202, respectively. (However, the more stringent design is more likely to be 
inconclusive and last longer.)
This example suggests that pL and py be calibrated against W^q so as to obtain attractive 
operating characteristics when Ds is highly informative. That is, a table could be 
constructed showing 'optimal' values of p i  and pu  for any particular value of W^q. 
However, this would involve consideration of the other design parameters also, and we will 
not pursue the matter any further in this treatise.
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2.4.5 Conclusions
That concludes our study of Thall and Simon's design with beta priors. Although there are 
many combinations of parameters we did not examine, a fair idea has been gained 
regarding the design's sensitivity to these parameters changing, as well as what 
combinations are likely to result in a useful clinical trial. In broad summary, we make the 
following remarks:
• With consideration of the ethical issues, believability, and the trade off involved 
between low type I and II error rates and large achieved sample size, the minimum 
number of patients should be set at about 10.
• The maximum number of patients should be as high as other considerations will 
allow.
• High values of d are good, but this parameter should not be set artificially high just 
for this reason.
• Type I and II error rates are lower for high values of cE, but this is offset by the trial 
tending to last longer and being more likely to be inconclusive.
• For low ms , the probability of type I and type II error rates are low and high, 
respectively. When ms ~ 0.5, the trial tends to last longer and is more likely to be 
inconclusive than when this parameter is close to 0 or 1.
• Stringent decision criteria may be appropriate when the prior on Rs is highly 
informative.
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2.5 THE DESIGN WITH GENERAL PRIORS
In this section, we will apply the general philosophy already outlined in this chapter to a 
hypothetical phase IIB clinical trial wherein the clinician's priors on the standard and 
experimental treatment success rates do not conform very well to the beta constraints of 
Thall and Simon (1992, 1993).
To see how such a situation can arise, see Figure 2-2 and note that there is no beta 
distribution with =0.3 and both mode and mean equal to 0.2. Moreover, a clinician 
could conceivably have a bimodal prior in mind, and this would automatically rule out the 
beta family from consideration. Finally, Thall and Simon require the prior on RE to be 
centred in a very specific way (see Subsection 2.4.1 and Figure 2-3).
Before actually formulating the design for this trial, however, we will address the practical 
issues of computation and precision.
2.5.1 Discretization of the priors
Consider now the priors f s(rs ) and f E(rE) to be any continuous p.d.f.'s on the interval 
[0,1]. As before, let Fs (rs ) and FE(rE) denote the corresponding c.d.f.'s.
Although there are other feasible strategies (such as numerical quadrature), we will for 
illustrative purposes adopt a discretizing scheme along the lines of Evans and Nigm (1980).
Explicitly, we will approximate /$ (rs ) and f E(rE) by the discrete p.d.f.'s */s(rs) and 
respectively, these being defined by 
*fs(rs) = sk and y E(rE) = ek for rs ,rE =tk, k = l,•••,*, 
where tk = (2k - 1) / (2K) and K  > 2 is a suitable number of the equidistant points into 
which we thereby discretize [0,1].
The probabilities sk and ek are defined either by:
(a) sk = f s ( J l f s « i )  and ek = f E(tk) / ^ f E(ti);oTby
/  i=1 /  i=1
(b) sk = Fs (tk + - ) - F s (tk - — ) and ek = FE(tk + — ) ~ F E(tk - — )-
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In practise it turns out that these definitions of sk and ek are virtually equivalent. The first 
definition, however, has the advantage of convenience, in that it allows the clinician to 
draw an unnormalized continuous probability distribution function and then simply read off 
the height at points 1 / (2K),3/ (2K \ - -,(2K -1 ) / (2K). It is the one we will shortly use.
For completeness, the corresponding ’discretized' c.d.f.’s will be denoted by 
*F$(rs ) and *F£(r£ ), and the corresponding random variables by *RS and *RE.
Note that with this arrangement,
Ft (f j )  —► Fj {r j ) as K —> oo V r j  e [0,1], T = S,E, 
so that the approximation can be made arbitrarily close simply by taking K large enough.
Note also that the clinician may wish to choose K himself and specify the sk and ek 
directly, rather than derive these probabilities from continuous priors. He may even have 
discrete priors in mind to begin with. At any rate, it is unlikely that he will have such a 
highly refined notion of his own beliefs as to require anything more than relatively simple 
functions. We defer the issue of how K should be chosen to the next subsection.
With the discretizing scheme as defined, m„(a:n) is approximated via (2-5) by
Z^o-dr-.
\ Xn ) k=\
This permits /^(r£ lj:n) to be approximated by
\ ( T e \xh) =\ ( r E\ n)  M &
v vVW
f  n \ K
\ XnJk=i
ektkx* Q - tk)n x*
T  ’ r E
'Zejtf-d-tjr*'
» - h '
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Thus, P*(xn) is approximated by
* K ( * n )  =  P tCRe - R s >  0 \Xn =  Xn)
= ' Z M ’Re-rs >0\Xn = x f f a i r s )
rS
1
's
^ \ ( r £lx„)
\ f E > 'S
7 s  ('s)
K - 1
I
4=1
X \ W
7=4+1 
K - \  K
X** Xe/Z'd-O)'1'1’
4=1 ;=4+l________________
i=i
Similarly, P„ (xn) is approximated by 
*F~n{xn) =PrCRE- R s > d \ X n = xn)
= X P r CRe~rS > d\Xn = xn)'fs (rs ) 
rs
xj i \ ( r£|i.ir/s(rs)
rS [r E>r S +d  
K-d*
4=1
X  s* X e; ,/ " (1_ ,; )n’X”
4=1 )=4+d*________________
L/=*+<i*
Xe/f.-M l -»,■)" **
1=1
where d* is the smallest integer greater than Kd, with d assumed to be less than 
( K - \ ) / K .
2.5.2 Precision
We will now investigate the precision of the above discretizing approximation in terms of 
its effect on the cutoffs and operating characteristics of a design obtained using exact beta 
priors. The relevant Splus code is given in Section A3.5 of Appendix 3.
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Comparison o f a beta-based design with its discretized approximation
Consider the design with beta priors parameterized (arbitrarily) by = 20, = 5,
d -  0.15, ms = 0.30, W ^  = 0.2, c£ = 5, p i  = 0.1 and py = 0.9. Also consider exactly the 
same design but with the priors discretized into K -  30 points according to the first 
definition of ek and sk in the last subsection. The decision cutoffs for both these designs 
are shown in Table 2-10, and the operating characteristics corresponding to these cutoffs in 
Table 2-11.
Table 2-10 Comparison of cutoffs
Exact Approximate Exact Approximate
n ‘n “n In n ‘n Wn In “ n
5 0 4 0 4 13 3 7 3 7
6 0 4 0 4 14 3 7 3 8#
7 1 5 1 5 15 4 8 4 8
8 1 5 1 5 16 4 8 4 9#
9 1 5 1 6# 17 4 9 4 9
10 2 6 2 6 18 5 9 5 9
11 2 6 2 7# 19 5 9 5 10#
12 3 7 3 7 20 5 10 5 10
Table 2-11 Comparison of operating; characteristics
Exact Approximate
Pe 0.3 0.45 0.3 0.45
P+ 0.175 0.607 0.138 0.547
P~ 0.652 0.221 0.653 0.221
p 0.173 0.172 0.209 0.231
A /2 5 7 6 7 6
M50 10 9 10 10
M75 15 16 18 20
I l l
Discrepancies
In Table 2-10 we see 5 'approximate* cutoffs (marked by #) not in complete agreement with 
their 'exact' counterparts. The discrepancy appears minor, but is sufficient to make the 
impact on the operating characteristics which we see in Table 2-11. Note that although 
some of this impact is detrimental (e.g., there is a 0.231 -  0.172 = 0.059 greater probability 
of an inconclusive trial if /?£=0.45), there is also some improvement (e.g., there is
0.175 -  0.138 = 0.037 less chance of making a type I error).
It should be noted, however, that these differences are no greater than those one would 
expect to get by slightly varying the 'exact' design's parameters (e.g., by changing W9 0  
from 0.20 to 0.10, in relation to which see Table 2-4 in Subsection 2.4.3).
At any rate, if one is concerned about these discrepancies in the operating characteristics, K 
can always be taken large enough to get complete agreement once the exact cutoffs have 
been attained. However, this may be impractical. In our example, even though only 3 of the 
16 cutoffs differ when K = 50, complete agreement does not occur until K is about 1000 
(K = 500 still yields one discrepancy). Note that exactly the same results were obtained 
using definition (b) for s* and ek in the last subsection instead of (a).
Practical guidelines
In view of these findings, we suggest the following practical guidelines for choosing K and 
thereby formulating a design based on general continuous priors:
1. Construct the best-fitting design with beta priors.
2. Discretize each of these priors into an arbitrary number K of points (e.g., 20 or 30), 
and thereby obtain the corresponding 'approximate' design.
3. Compute and then compare the cutoffs and operating characteristics of these two 
designs.
4. If dissatisfied with the discrepancies, increase K and repeat, noting that it may be 
impractical to achieve complete agreement.
5. K having been thus decided, discretize each of the general continuous priors 
into that number of points and thereby arrive at the final required design with its 
associated decision cutoffs and operating characteristics.
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Note that the design with beta priors is here used only for the purpose of deciding upon a 
suitable K.
In the next subsection, these guidelines will be demonstrated by application to a 
hypothetical clinical trial.
2.53 Example
Consider a drug E which has passed the phase I stage and is now to be tested in a phase II 
study for its therapeutic effect on a disease with low patient accrual. Suppose that there are 
many drugs waiting for phase II evaluation, and that these and other considerations 
translate into a maximum sample size of 12. Also suppose that the minimum number of 
patients considered by the monitoring committee as sufficient to draw any conclusions is 4 
(in relation to which, recall the example given in Subsection 2.2.2 wherein the decision to 
stop a trial was taken after only 4 patients had been treated with the experimental 
chemotherapeutic regimen).
Finally, suppose that the standard treatment S achieves partial remission, defined by 
cessation of primary symptoms within one month, about 60% of the time, and that 10% 
more than this (so as to make 70%) would be considered a minimal worthwhile 
improvement
The clinician tries to express his beliefs about Rs and RE in the form of beta densities, but 
there are none that will fit to his satisfaction. To implement the guidelines offered in the 
last subsection, he decides to first construct a design with beta priors most closely 
corresponding to his beliefs. By discretizing these beta priors and studying the associated 
discrepancies, he hopes to obtain guidance on how many points his own priors should be 
discretized.
To begin with, he draws his own priors and discretizes them into an arbitrary K -  20 points 
according to definition (a) of Subsection 2.5.1. Suppose that his unnormalized e* and 
are those given in Table 2-12.
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Table 2-12 Unnormalized discrete priors
k 1 2 3 4 5 6 7 8 9 10
h 0.025 0.075 0.125 0.175 0.225 0.275 0.325 0.375 0.425 0.475
0 1 2 3 4 4 4 4 4 4
h 0 0 0 0 0 0 0 0 1 2
k 11 12 13 14 15 16 17 18 19 20
h 0.525 0.575 0.625 0.675 0.725 0.775 0.825 0.875 0.925 0.975
4 4 4 4 4 4 3 2 1 0
8 19 19 8 2 1 0 0 0 0
We see that the clinician's prior on Rs is (at least roughly) symmetric with mean 0.6 and a 
central 90% probability interval (W90) of about 0.2. Also, his prior on RE is symmetric 
about 0.5 and has a central 90% probability interval of about 0.7. We note that the unique 
beta distribution with these last two parameters is the Beta(2.23027, 2.23027) distribution. 
These parameters thus correspond to a concentration parameter of 4.46054.
Accordingly, the clinician formulates a design with beta priors defined by = 0.6, 
W90 = 0.2, cE = 4.46054, and d = 0.1. To completely specify the design, he also decides 
upon pL = 0.1 and Pu -  0.9, in addition to = 4 and - 12.
Table 2-13 shows the cutoffs for this design as well as those of the corresponding 
'approximate' design based on the same beta priors' densities each discretized into K = 20 
points.
T a b k 2 -n ^ C ^ g m so ^ ^ cu to fft^ = ^ 0
n 4 5 6 7 8 9 10 11 12
Exact In 1 1 2 2 3 4 4 5 5
“n 4 5 6 6 7 8 9 9 10
Approximate ‘n 1 1 2 3# 3 4 4 5 6#
“n 4 5 6 7# 7 8 9 10# 10
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The proportion of discrepancies (4/18) seems high and so another 'approximate' design is 
formulated, one with K -  80. The cutoffs for this design are shown in Table 2-14.
Table 2-14 Approximate design cutoffs, K -  80
n 4 5 6 7 8 9 10 11 12
In 1 1 2 2 3 4 4 5 5
“ n 4 5 6 7# 7 8 9 9 10
This is better (only one discrepancy), but there is still some concern about the effect on the 
operating characteristics. Table 2-15 shows a selection of these for the 'exact' design as well 
as the 'approximate' one obtained using K = 80.
Table 2-15 Comparison of operating characteristics, K -  80
Exact Approximate
P e 0.5 0.6 0.7 0.8 0.5 0.6 0.7 0.8
P+ 0.089 0.210 0.419 0.695 0.089 0.210 0.419 0.695
P~ 0.582 0.339 0.146 0.040 0.604 0.361 0.159 0.044
P* 0.329 0.451 0.435 0.264 0.307 0.429 0.422 0.261
M 25 4 4 4 4 4 4 4 4
8 11 11 8 8 9 11 8
m 15 12 12 12 12 12 12 12 12
The agreement is very close, and accordingly, the clinician deems it sufficient to use K = 
80. Hopefully, discretizing his own priors into that number of points will lead to no greater 
'error' (in terms of cutoffs and operating characteristics) than that suffered by discretizing 
the beta priors.
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The design
For simplicity, he decides to use discrete step functions for his priors of the form ek = 0, 0, 
0, 0, 1, 1, 1, 1, 2, 2, with sk defined similarly (using Table 2-12). (He states that step 
functions of this form reflect his views no less accurately than any 'smoothed' discrete 
functions derived from his originals with K  = 20.) Note that the clinician could alternatively 
have read off 80 points from each of his continuous drawn priors and used these instead.
With ek and sk so defined, in addition to d -  0.1, pE = 0.1, pu = 0.9, >1^  = 4, and 
nmBX =12, the required 'discretized' design is fully specified. The cutoffs corresponding to 
it are given in Table 2-16, and Table 2-17 shows the associated operating characteristics.
Table 2-16 Cutoffs
n 4 5 6 7 8 9 10 11 12
In 1 2 2 3 3 4 5 5 6
“ n 5 6 6 7 8 9 9 10 11
Table 2-17 Operating characteristics
Pe 0.5 0.6 0.7 0.8
P+ 0.021 0.071 0.190 0.423
P~ 0.731 0.490 0.247 0.079
p* 0.247 0.439 0.563 0.498
« 2 5 4 5 6 6
« 5 0 5 10 12 10
M15 12 12 12 12
Comparing Table 2-17 with the 'best' beta-based design's operating characteristics in Table 
2-15, we see that for high values of pE, the final 'discretized' design does worse. For 
example, ß  is 0.247 -  0.146 = 0.101 higher. On the other hand, the 'discretized' design
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fares better for values of pE lower than 0.7. For example, a  is 0.210 -  0.071 = 0.139 
lower.
With these comparisons in mind, as well as the poor operating characteristics in general 
(due to so few patients being available), the trial is begun. It terminates on the 10th patient 
response after the sequence of results (^»...»Xjo) = (1,2,3,4,5,5,6,7,8,9).
We see that jc10 has hit an upper cutoff, and accordingly, E is declared promising. The 
phase II stage of its testing is therefore at an end, and the drug will now be passed on for 
phase IE evaluation.
Note that had the 'best' design employing only beta priors been used, the trial would have 
stopped after only 4 patient responses (see Table 2-13). This shows how imposing 
constraints on the priors can result in decision rules quite different to those which the 
clinician implicitly has in mind. On the other hand, a clinician may well renounce his priors 
(a controversial decision) when he sees the stopping rules and operating characteristics 
logically implied by them.
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2.6 DISCUSSION
In clinical trials where patient response is binary and the data is monitored continuously, 
we have investigated a subjective Bayesian method for obtaining stopping rules when 
attempting to decide whether an experimental treatment E is promising relative to a 
standard therapy 5.
Note that these stopping rules are practical guidelines only, since phase n  trials inherently 
require (and in practice do receive) continual subjective input on the part of the monitoring 
clinician(s). As pointed out earlier, there is no possibility in these settings of hard and fast 
rules (such as a fixed sample size), simply because ethical considerations demand that the 
trial stop as soon as the results begin to get interesting and a clear picture starts to emerge 
in any way regarding the experimental treatment's value (or harm).
If a trial is inconclusive using this method, the disposition of E will depend on what other 
treatments are available, the results which have been obtained for them, and other 
considerations such as cost and toxicity. But regardless of this, the trial will have been of 
value in having produced a useful and intuitively appealing estimate of E's efficacy. By 
contrast, estimation following frequentist sequential trials is often problematic; e.g., see 
Emerson and Fleming (1990).
Inference on RE
Inference on RE is based on its final posterior distribution. Recall that for 
Re ~ Beta(fl£,^£), this distribution is simply Beta(fl£ + xn,bE + n - x n). For example, if 
aE = bE = 1 (a flat prior) and jc16 =11, then (RE\X16 = *16) ~ Beta(12,6). It follows that 
two point estimates of RE are the posterior mean 12 / (12 + 6) = 0.6667 and the posterior 
mode (12-1)/(12+  6 - 2 )  =0.6875. A central Bayesian 95% confidence region is 
[F-1 (0.025; 12,6), F -1 (0.975; 12,6)] = [0.440,0.858].
Alternatively, results can be reported in terms of the (1 -  a) HPD region, defined in this 
case by [L,£7], where L and U are such that:
F~l(U;aE + xn,bE + n - x n)-F~\L-,aE + xn,bE + n - x n) = \ - a ,  and 
f{L\aE +xn,bE + n -  xn) = f(U;aE + xn,bE + n - x n).
The 0.95 HPD region for RE in our example is [0.454, 0.869].
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Negative targeted improvement
Although we did not examine the possibility, note that d could conceivably be negative. 
This might reflect a situation where S has certain undesirable side effects or 'costs' (e.g., 
toxicity, expense, travel time, etc.) more severe than those of E. In such a case, it might 
also be appropriate to change RE - R S > 0 to RE -  Rs > d' in the definition of promising 
(refer back to Subsection 3.3.1), with d'<d.  Another situation is represented by 
0 <d' <d. See Spiegelhalter and Freedman (1986) for a general discussion of this issue.
Decision-theoretic approach
Instead of tailoring the targeted improvement d to represent 'cost' differences between S and 
E, Thall and Simon's phase ÜB design could be modified via a decision-theoretic approach. 
Sylvester (1988) presents such an approach to the design of phase II clinical trials 
generally. His Bayesian strategy involves not only prior opinion but also consideration of 
the 'costs' of treating a patient with a new drug. In addition, he takes into account the 'gains' 
and 'losses' resulting from the decisions taken at the end of the trial.
Additional early termination rule based on predictive probabilities
To conclude, we will briefly describe another possible modification. As suggested by 
Herson (1979), it may be desirable in some phase II designs to have an early termination 
rule based on predictive probabilities. This would be in addition to any other stopping 
criteria.
Although there are many possibilities in the Bayesian setting considered here, a convenient 
form for this rule might be to terminate the trial at any stage n when there is a high enough 
conditional predictive probability of E being declared inconclusive, given that the trial 
continues to the maximum number of patients.
This rule can formally be stated as follows:
• At each stage n = ,• • •,nm&x - 1, stop the trial and declare it
inconclusive if the predictive probability
P P n (*n ) =  ^  <  X nmMX <  1X n = x n)
exceeds some cutoff p close to 1.
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Note that
PP»(*n)=
where y/n(t\xn) is the conditional p.d.f. of given Xn = xn. For designs with a strictly 
beta prior on RE, this p.d.f. is beta binomial of the form given by the following theorem. 
The proof of this theorem is provided in Section A2.3 of Appendix 2.
Theorem 2-2
If Re ~ Beta(fl£,b£), then
/n max
‘ ~ x n j
Bff + Oß^n^ - t  + fcg) 
B(xn + aE,n - x n + bE) ’
where is the beta function.
A subtle but significant variation on this rule is to stop at any stage when there is a high 
enough unconditional predictive probability that the trial will be declared inconclusive. 
The computation of this probability is outlined in Thall and Simon (1994) and involves 
excluding paths from n to nmax which hit a cutoff.
Appendix 1
NOTATION AND ABBREVIATIONS
Probability distributions
120
X ~ D  
X  ~ N ( f l , h )
X  has the D distribution asymptotically or approximately 
X is normally distributed with mean ß  and variance/covariance 
matrix Z
X  ~ Beta(o.ß) 
*  -
X  -  G ( a , ß )
X  -  Bin(n,p)
X has the beta distribution with mean a  / ( a + ß )
X  has the F  distribution with and cLo.f., respectively 
X has the gamma distribution with mean a  /  ß  
X  is binomially distributed with probability of success p  and 
number of trials n
X ~ U ( a , b )
X, ~ i.i.d. p( )
X  has the chi-square distribution with v  d.o.f.
X is uniformly distributed on the interval [a , b ]
X is a sample point from the distribution with p ( )  as p.d.f. 
X1,X2,--- are i.i.d. sample points from the distribution 
with p ( )  as p.d.f.
X, ~i.i.d. D X1,X2,--- are i.i.d. sample points from the D  distribution
Functions
*(•), <&■*(•) p.d.f., c.cLf. and quantile function of the standard normal 
distribution
2 —2X v (•), X v  (*) c.d.f. and quantile function of the chi-square distribution 
with v  d.o.f.
/ o j ,v 2 (•). F V] ,V2 O. < U 2 O P-d.f, c.cLf. and quantile function of the
F.u „ distribution
v l»v 2
f (  ',a,ß), F(;a,ß) ,  F_1( ;a,j3) p.d.f., c.cLf. and quantile function of the
r ( ) ,  ¥ ( • ) ,¥ '( )
5 (v ), /(•)
L, L( ); U, C/O 
/(•),3()
P()
Beta(a,/J) distribution 
gamma, digamma and trigamma functions 
beta function, standard indicator function 
likelihood function; score function 
observed and expected Fisher information 
p.d.f. of (•)
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<5, indicator function for the ith individual failing (i.e., not being
censored)
f\(0 )  «= / 2(0) function f \  is proportional to function / 2 with respect to the
variable 6
Other notation
Pr(A), Pr(AIB) probability of (the event) A, probability of A given B
A -B set of elements in (the set or vector) A which are not in B
E(X), Var(X) expected value and variance of (the random variable) X
Ey(X\Z) expected value of X given Z with respect to the distribution of Y
p , p-  value attained significance level
X the whole real line, i.e. ( - 0 0 , 0 0 )
V, 3 for all, there exist(s)
the (U)th element of the inverse of the matrix M
a, ß type I error rate, type II error rate
* right-censored
d , v, y number of failures, total time on test, the data
OII 3 c > 0  s.t. \bn\/an <c  V n = 1,2,--*
Abbreviations
ASN average sample number (or expected sample size)
Bay. Bayes, Bayesian
CFD central fiducial density
CHF chronic heart failure (syndrome)
Cl confidence interval
CLT Central Limit Theorem
CPD central posterior density
EM expectation-maximization
FF F-based fiducial
GOF goodness of fit
HFD highest fiducial density,
HPD highest posterior density,
LF lognormal fiducial
MC Monte Carlo, Markov Chain
ML maximum likelihood
NR Newton-Raphson
O C s operating characteristics
PH proportional hazards
PP predictive probability, posterior probability
RB Rao-Blackwell
RHS right hand side
Subs. Subsection
alg. algorithm
approx. approximation, approximate(ly)
ave. average
b.s.s. buffered stochastic substitution
c.d.f. cumulative distribution function
coord. coordinate
cov. covariance
d.o.f. degrees of freedom
dsn, dsns distribution, distributions
ed.; eds edition, editor, editions, editors
e s t estimate, estimator
fn, fhs function, functions
iff if and only if
i.i.d. independently and identically distributed (as)
indep. independently)
info. information
init initial
iter. iteration
m at matrix
m.l.e. maximum likelihood estimate/estimator
no. number
p.d.f. probability density function
post. posterior
prop. proportional
pt, pts point, points
ref. reference
resp. respective(ly)
r.v. random variable
s.t. such that
var. variance
w .r.t with respect to
Appendix 2 
PROOFS
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A2.1 PROOF OF THEOREM 2-1
The following proof is outlined in Thall and Simon (1993).
n-1
T„(xn) sP r(X „ = x „ A -i)=  XPr(XB = x,,,X ,,-i=X n-iA -i)
— Pr(^n ~ *n*^n- 1 “  ~ — *n*^n—1 ~
since Xn =xn => Xn_x = xn or xn -1  (note that Pr(Xn_! = -1) = 0)
= Pr(*„ = *B,X„_, = xn - 1 , V 2)/(j:„ -1  s  C„_j)
+ — Xn»^ n-l ~ Xn*An_2)I(xn € CB_j)
= Pr(X„ = A:„IXn_, = xB -1 , V 2 )Pr(X„_, = -1  e C„_,)
+ Pr(X„ = XnIXM_! = I „ V 2 ) W , - 1  = A - 2  )*(*» s  c *-l)
= Pr(X„ = *„IXB_, =xn -  l)Pr(X„_, = -  1 , V l ) - i )/(•*» “ 1e Cn_,)
+ Pr(X„ = = J.IPK 4-1 = Jt.. V i h )'*1« e  C»-i)
by the Markov property of the random walk Xl,X2,--- 
= PETn-\(xn -  !)/(•*„ - 16 CB_,) +  (1 -  PE)Tn-\(xn)I(x„ € C„_,), as required. (|
A2.2 PROOF OF RESULTS (2-10) AND (2-11)
The following proofs are outlined in Thall and Simon (1993).
Lemma A2-1 F(r;a,b)> F(r,a + \,b).
Proof
F(r\a,b)
By 26.5.16 of Abramowitz and Stegun (1965),
r(a + fc)
r(a+i)r(*>) ra (1 -  ry +  F(r\ a + l,b)
> F(r;a +1 >b) since the gamma term is nonnegative,
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Lemma A2-2 F(r;a,b)£ F(rya,b + 1).
Proof Since f(r,a,b) = /(I  -  r,b,a), it follows that
F(r,a,b) = l - F ( l - r ; M )
< 1 - F (\-r ,b  + lya) by Lemma A2-1 
= 1 — [1 — F(ryayb +1)]
= F(r;a,b + 1). fl
Theorem A2-1 ^n+l (-*n (■*«)> ~ rt ~ m^in ’ * * *»**max — ^
Proof By equation (2-8), 
1
K + \ ( x n + 1) = J[! — F(rs ;aE + (*» +1 \  + (n + 1) +
0
1
ä J[1 -  F(rs ;aE + xn,bE + n -  xn)]f(rs ;as ,bs )drs 
0
by Lemma A2-1
= ^ U „)- 1
Theorem A2-2 J C „ = 0 , •••,/!, n = nmin,--,nmax- l .
Proof By equation (2-8), 
1
K+  i(*„) = J[1 -  F(rs \aE + xn,bE + (« + ! ) -  xn)]f(rs ;as ,bs )drs
0
i
£ J [1-F(rs ;a£ + *n,*>ß + n - x n)] f ( r s \as  ,bs )drs 
0
by Lemma A2-2
= K ( * n)- i
Theorem A2-3 (•*«) — ^n+1 )» *n —  ^~ ^*min»* *’»^ max ~
Proof By equation (2-9),
1 -d
p n ( * n )  = \ [ \ - F ( r s + d\aE + xn,bE + n - x n)]f(rs \as ,bs )drs 
o
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i-d
Z J[1 -  F(r5 + d\aE + + (* + 1) -
0
by Lemma A2-2
= C i(*„). n
Theorem A2-4 ^n+l(*n+l) — (*n+l — 1)> *n ~ rt ~ m^in>**'»^ max — ^
Proof By equation (2-9),
1 -d
^ n + iU n + i)  = J[1 -  F(rs + d;aE + x„+l,bE + (« + ! ) -  x n+1 )]f(rs ;as ,bs )drs
0
i-<*
ä J[1 - F(rs + d;a£ + (*„+1 - \),bE + n - (x„+1 - l)) l/,(r.s;as ,fts )(l/-5 
0
by Lemma A2-1
= 11
Theorem A2-5 W^+i^Wn+l* tl — Wmin»'*‘»^inax —
Proof By definition, either wn = n + lorwrt<n.
First suppose un = n +1.
Then wn+1 < +1, since un+1 <(n + 1) +1 by definition.
Alternatively, suppose < n. Then P* (un) > py.
^n+i (un +1)  ^Pu by Theorem A2 -1. m„+1 < u„ +1 by the definition of w„+1. U
Theorem A2-6 n^+1  ^  ^ ^^min»* ”»^ *max
Proof By definition, either w„+1 = (n +1) +1 or un+1 <n + 1.
First suppose wn+1 = (n +1) +1. Then u„ < w„+1, since un < n +1 by definition.
Alternatively, suppose w„+1 <n + 1. Then F*+1 (w„+1) >
F* (wn+1) > pu by Theorem A2 - 2. un < m„+1 by the definition of
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Theorem A2-7 ln+i>/„,  n = nmin,---,nm!ix- l
Proof By definition, either ln = -1 or ln > 0.
First suppose /„ = -1. Then /n+1 > ln, since /n+1 > -1 by definition.
Alternatively, suppose /„ > 0. Then P~(/n) -  Pl •
Pn+\(/») -  Pl by Theorem A2 - 3. /n+1 > /„ by the definition of /n+1. H
Theorem A 2 S  /n+1</„ + l, * = “ i-
Proof By definition, either /n+1 = -1 or /n+1 > 0.
First suppose /n+1 = -1. Then /n+1 < /n +1, since ln ^ -1 by definition.
Alternatively, suppose /n+1 £ 0. Then F“+1(/n+1) <
.*. P~(Ln+l - \ ) < p L by Theorem A2 - 4. ln ^ l n+l- \  by the definition of ln. ^
Result (2-10) K  = PETn-\(un-\-W (M n = Un_.i- 1), /I = ^  + 1,"
Proof Recall by Theorem 2-1 that
Tn(x„) = pET„-i(xn -  l)/(x„ -1  e C„_,) + (1 -  pE)T„-i(xn)I(xn e C„_,).
Now Theorems A2-5 and A2-6 imply that either un = Un-\ or +1.
Also, C„_! = {/„.j +1,•••,«„_! -1).
Thus if xn > Un, then xn -1  > -1 , so that *n, - 1 € Cn_x. Also,
Un > Un-i -1 , so that un * Cn-i* Finally, u„ e Cn-\ iff = Un-v
It follows that
[0 , =1^4- !,•••,«.
Hence P+ = P£T„_i (w„_i -1  )I(un = w„_i) by equation (2-6).
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Result (2' l l )  Pn = (1 -/?£)7'„_1 (/„_! + l)/(/n = /„_!+1), « = *min +
Proof Recall by Theorem 2-1 that
Tn(xn) = PETn-\(xn - l ) / u n - l e  +  G C n_ !).
Now Theorems A2-7 and A2-8 imply that either ln = /n_j or ln = /„_! +1. Also,
C f i - l  — { ^ n - l 1» * * *»^ n - 1  —
Thus if xn <ln, then xn < ln_i +1, so that xn,xn -1  € Cn_i. Also,
/„ -1  < (/n_! +1) -1  < /n_! +1, so that /„ -1  e Cn_!. Finally, 
e C»-i iff In = (*-i +1-
It follows that
Tn(xn) = f(l -  PE^n-itfn-i + 1)/(/„ = /n_i +1), *n = ln
[0 , *„=(),•••,/„-1.
Hence P~ = (1 -  Pe ) ^  (/„_! + !)/(/„ = ln_x +1) by equation (2-7). U
A2.3 PROOF OF THEOREM 2-2
For convenience, first define
a = aEi b = &£, = Xn, zl = mj = n,
Z 2 ~  X nTMX ~  X n> z2 ~  -Xnm,x ~~
^*2 ^max n, Z  Z j ■+■ Z 2 , Z Zi -H Z2 , 
m = m! + m2, P = RE, and r -  rE.
Also, let
01(z1,z2,r), <f>2(r),
03(z1,z2lr), ^ (z jlr), 05(z2lr),
06(zltz2), 07(Z!), 08(z2lzi), and ^(zlzj)
be the p.d.f.'s of 
(Zj,Z2,P), P,
(Z1,Z2IP), (ZjlP), (ZjlP),
(Zj,Z2), Zj, (Z2IZj), and (ZIZj),
respectively.
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Then,
01 (Zj, z2, r) = 02 (003 (zi .■z2!1-r)
^2(r )04(zi*r )^5(z2*r ) by independence of the trials
ra- \ \ - r ) b~w
B(a,b)
m x
^ zi
r Zl ( l - r ) mi_Zl
' m ?  
Z2 )
r Z2( l - r ) m2_Z2.
Therefore,
l
06(z1,z2) = J 0 1(z1,z2,r)dr
o
miVmi^BCa + Z! +z2,Z? + m1 -  zt -t- ^  -  z2)
zi A z2 ;  ß(a , fe )
Now
0 7 ( z i )  =  J  0 2 ( r ) ^ 4 ( z i l r ) r f r
o
_ [■r ‘l~1( l - r ) i>~Y m, 
- J  B(a,b) U i
(1 -  r)m,~h dr
m \ \B(a +zx,b + mi -Z j)
zi J B(a,b)
Hence,
0 g ( z2 lzi )
<t> 6 ( zl»z2)
07 (zl)
^m2^ß(fl + Zj + z2,b + ml -  z{ + m2 -  z2)
k Z2 J  Z^a  +  Zj . b +  m j - Z j )
It follows that
^(rl^„) = 09(/lz1)
— Pr(Zj + Z2 — t\Z-y — Zj)
= Pr(Z2 = r -  ZjIZj = Zj)
=  ^ 8( f - Z i l Z i )
—Zj +  +  - Z i ) ’
which completes the proof,
Appendix 3 
Splus CODE
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A3.1 CODE FOR SECTION 13
The function AUG (for implementing the data augmentation algorithm of Subs. 1.3.6)
AUG <- function(m,N,outvec=0,xvec,data){
# This function performs N iterations of the data
# augmentation algorithm. It outputs a matrix, where:
# row 1 = xvec (a specified vector of x coordinates),
# row 2 = true posterior y coordinates (G(d,v)),
# row 3 = y coord.'s of post, ignoring censoring (G(n,v)),
# row 4 = y coord.'s of init. est. of post. (G(1,1/0.003)),
# row (4 + j) = y coord.'s of the mixture at iter. outvec[j],
# row 5 = y coord.'s of the final mixture if outvec=0.
# data is a matrix whose first and second columns
# are the failure times and corresponding statuses, resp.
# m is the no. of dsns per mixture.
times <- data[,l]; status <- data[,2] cens.times <- times[status==0] v <- sum(times); vd <- sum(times[status==l]) 
n <- length(times); d <- sum(status); cc <- n-d 
npts <- length(xvec)
if(sum(match(outvec,0,nomatch=0)) > 0) outvec <- N
outmat <- matrix(0,length(outvec)+4,npts)
outmat[l,] <- xvec # x coordinates
outmat[2,] <- dgamma(xvec*v,d)*v # true posterior
outmat[3,] <- dgamma(xvec*v,n)*v # as if no censoring
outmat[4,] <- (1/0.03)*dgamma((1/0.03)*xvec,1) # first guess
lamvec <- rgamma(m,1)/(1/0.03); ct <- 5
SAMP.Z <- function(lamvec,cens.times,cc,m){
# Sample from the conditional dsn of the latent data, 
zmat <- matrix(0,cc,m)
for(j in l:m) for(i in l:cc)
zmat[i,j] <- rgamma(1,1)/lamvec[j]+cens.times[i] zmat 
}
SAMP.L <- function(zmat,m,n,vd){
# Sample from the conditional dsn of lambda, 
lamvec <- l:m
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for(j in 1:m){
index <- ceiling(runif(1))*m 
par2 <- vd+sum(zmat[,index]) 
lamvec[j] <- rgamina (1, n) /par2 
}lamvec
}
OUT.V <- function(zmat,xvec,vd,n,npts){
# Output a vector of y coordinates, 
yvec <- xvec; vzvec <- apply(zmat,2, sum) 
par2vec <- vd+vzvec 
for(i in l:npts)
yvec[i] <- mean(par2vec*dgamma(xvec[i]*par2vec,n)) 
yvec 
}
for(i in 1:N){
zmat <- SAMP.Z(lamvec,cens.times,cc,m)
lamvec <- SAMP.L(zmat,m,n,vd)
if(sum(match(outvec,i,nomatch=0)) > 0){
outmat[ct,] <- OUT.V(zmat,xvec,vd,n,npts); ct <- ct + 1 
}
}
outmat
Code for Figure 1-1
aug <- AUG(10,20,1:20,seq(0.01,0.07,0.0001),leuk.data) 
par(mai=c(1.4,0.7,1,0.7))
plot (c(0.01,0.07) , c (0,7 0) , type="n", xlab=" lambda", 
ylab="density",sub=
"\n\n\nFigure 1-1 Mixtures of 10 augmented posteriors")
lines(aug[1,],aug[2,],lty=l) # true
# ignoring censoring
# initial guess
# j = l# j=2
lines (aug[1,],aug[24,],lty=5) # j=20
lines(aug[1,],apply(aug[20:24,],2,mean),lty=2) # ave. j=16-20 
legend(c(0.047,0.07),c (67,42),c("True posterior",
"Ignoring censoring","Initial guess","Iteration 1", 
"Iteration 2","Iteration 20",
"Iterations 16 to 20"),lty=c(1,6,7,3,4,5,2))
lines (aug[1,],aug[3,],lty=6) 
lines (aug[1,],aug[4,],lty=7) 
lines (aug[1,],aug[5,],lty=3) 
lines(aug[1,],aug[6,],lty=4)
# NB: leuk.data is a matrix (see Subs. 1.3.5) with:
# column 1 = observed times (1,1,2,4,...,85,91), and
# column 2 = statuses (1,1,1,1, ..., 0,1) .
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A3.2 CODE FOR SECTION 1.4
Some calculations (Subsection 1.4.4)
dl <- 6; d2 <- 19; vl <- sum (c (13,12,31,10,7,20,41,5, 18, 8) ) 
v2 <- sum (c (19, 7, 19,23, 7, 16, 14,3, 12, 8,30, 11, 15, 8, 9, 8,4,
10,6,16,13,18,7,5,7,11))
r.mle <- (d2/v2)/ (dl/vl); r.mle 
[1] 1.707516
r.mle*exp(c(-1,1)*qnorm(1-0.05/2)*sqrt((dl+d2)/ (dl*d2))) # Cl 
[1] 0.6819511 4.2753976
((d2-l)/v2)/ ( (dl+1)/vl) # mode 
[1] 1.386555
Laplace's method (Subsection 1.4.5)
LAPLACE <- function(dl,vl,d2,v2,al=0,bl=0,a2=0,b2=0) { 
fnl <- function(r,a,b,c){ rAa/(l+b*r)Ac } 
fn2 <- function(r,a,b,c){ sqrt(a/rA2-c*bA2/(l+b*r)A2) }
a <- a2+d2-l; b <- (b2+v2)/ (bl+vl); c <- dl+d2+al+a2 
r <- a/(b* (c-a)); rs <- (a+1)/(b* (c-a-1))
(fn2 (r, a, b, c) /fn2 (rs, a+1, b, c) ) *rs*fnl (rs, a, b, c) / fnl (r, a, b, c) 
}
LAPLACE(dl,vl,d2,v2)
[1] 1.988647
Monte Carlo inference (Subsection 1.4.6)
SAMPLE.R <- function(numb=l,dl,d2,vl,v2,al,a2,bl,b2){
# This fn uses the ratio of uniforms method to output a
# sample of numb obs.'s from the p.d.f. prop, to pO.fn.
pO.fn <- function(r,dl,d2,vl,v2,al, a2,bl,b2) { 
rA (a2+d2-l)/(1+((b2+v2)/ (bl+vl))*r)A (al+a2+dl+d2)
}
a. val <- sqrt(p0.fn(r.mode,dl,d2,vl,v2,al,a2,bl,b2))
r.hash <- (d2+l)*vl/ ( (dl-1)^v2) # maximizes rA2 * pO.fn
b. val <- sqrt(r.hashA2*pO.fn(r.hash,dl,d2,vl,v2,al,a2,bl,b2)) 
samp <- rep(0,numb)
for(ii in l:numb){
UU <- a .val*runif(1); W  <- b.val*runif(1)
compar <- sqrt (p0 . fn (W/UU, dl, d2, vl, v2, al, a2, bl, b2) )
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while(UU > compar){
UU <- a .val*runif(1); W  <- b.val*runif(1) 
compar <- sqrt (pO . fn (W/UU, dl, d2, vl, v2, al, a2,bl,b2) ) 
}
samp[ii] <- W / U U
}
samp
r.sample.10000 <- SAMPLE.R(10000,dl, d2,vl,v2,0,0,0,0)
Computation o f the \'final PP' (Subsection 1.4.7)
chf.vl <- 429.8; chf.v2 <- 353.3; chf.dl <- 2; chf.d2 <- 3 
chf.nul <- 2*chf.d2; chf.nu2 <- 2*chf.dl
chf.k <- (chf.d2/chf.v2)/ (chf.dl/chf.vl) # See Enas et al.
1-pf(1/chf.k,chf.nul,chf.nu2)
[1] 0.7569719
A3.3 CODE FOR SECTION 1.5
Some functions
DIGAMMA <- function(xx,prec=0.000001){
# Computes the digamma fn at xx (xx > 0 only) to a precision
# of plus or minus prec. Ref.: Abramowitz and Stegun (1965). 
nn <- floor(xx); zz <- xx-nn
if (zz > 0) {
KK <- 50
while((KK+zz)* (KK+1)/ (KK*(KK+zz+1)) > exp(2*prec))
KK <- KK+50
Sum <- zz*sum(1/((1:KK)*((1:KK)+zz)))+
0.5*log((KK+zz+1)* (KK+zz)/ (KK*(KK+1)))
}
Res <- -0.577215664901532860606512 # -1 * Euler's constant 
if((zz==0) && (nn>l)) Res <- Res+sum(1/(1:(nn-1))) 
if(nn==0) Res <- Res+Sum-l/zz 
if((zz>0) && (nn==l)) Res <- Res+Sum
if((zz>0) && (nn>l)) Res <- Res+Sum+sum(1/((1:(nn-1)+zz))) 
Res 
}
DIGAMMA.VEC <- function(xvec,prec=0.000001){
# Computes the digamma fn at each element xx of the vector
# xvec (xx > 0 only) to a precision of plus or minus prec.
133
num <- length(xvec); resvec <- l:num for(j in l:num) resvec[j] <- DIGAMMA(xvec[j],prec)) 
resvec 
}
TRIGAMMA <- function(xx,prec=0.000001){
# Computes the trigamma function at xx (xx > 0 only) to a
# precision of plus or minus prec.
KK <- 50
while((KK+xx)* (KK+xx+1) < 1/(2*prec)) KK <- KK+50 
sum(1/((0:KK)+xx)"2)+0.5*(1/(KK+xx+1)+1/(KK+xx))
}
TRIGAMMA.VEC <- function(xvec,prec=0.000001){
# Computes the trigamma fn at each element xx of the vector
# xvec (xx > 0 only) to a precision of plus or minus prec. 
num <- length(xvec); resvec <- l:num
for(j in l:num) resvec[j] <- TRIGAMMA(xvec[j],prec) 
resvec 
}
LOG.GAMMA <- function(arg){
# Computes log(gamma(xx)) for each element xx in arg. Values
# of xx may be ’large.'num <- length(arg); resvec <- l:num 
for(i in 1:num){ 
argval <- arg[i]
if(argval < 165); res <- log(gamma(argval)) 
if(argval >= 165){
upto <- floor(argval)-160; vec <- argval-(1:upto) 
res <- sum(log(vec))+log(gamma(argval-upto))
}resvec[i] <- res
}resvec
}
A3.3.1 Computing the joint mode
The function EM.ALG (for implementing the EM algorithm of Subsection 1.5.2)
EM.ALG <- function(data,lam,alp,aa=0,bb=0,eta=0,tor=0,alp.prec=0.000001,num.iters=2){
# This function performs num.iters iterations of the EM
# algorithm starting at lambda=lam and alpha=alp.
tvec <- data[,l] # observed time
dvec <- data[,2] # status (l=death, 0=censored)
lvec <- data[,3] # litter no. (1,2,...,11)
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II <- max(lvec) # no. of litters 
dd <- sum(dvec) # no. of deaths
qvec <- 1:11; for(ii in 1:11) qvec[ii]<-sum(dvec[lvec==ii]) 
kvec <- 1:11; for(ii in 1:11) kvec[ii]<-sum(tvec[lvec==ii]) 
lam.vec <- (1:(num.iters+1)); lam.vec[l] <- lam 
alp.vec <- (1:(num.iters+1)); alp.vec[l] <- alp
ALP.NEW <- function(alp,rvec,svec,eta,tor,II){
# Use the NR alg. to max. the Q-fn w.r.t. alpha.
Q.A <- II*(l+log(alp)-DIGAMMA(alp))+(eta-1)/alp-
(tor+sum(rvec-svec))
Q.AA <- II*(l/alp-TRIGAMMA(alp))-(eta-1)/alpA2 alp-Q.A/Q.AA 
}
for(iter in 1:num.iters){
rvec <- (alp+qvec)/(alp+lam*kvec)
lam <- (aa+dd-1)/(bb+sum(kvec*rvec)); svec <- (1:11) 
for(ii in 1:11)
svec[ii] <- DIGAMMA(alp+qvec[ii])-log(alp+lam*kvec[ii]) 
alp.delta <- 100; xx <- alp 
while(alp.delta > alp.prec) {
xx2 <- ALP.NEW(xx,rvec,svec,eta,tor,II) 
alp.delta <- abs(xx2-xx); xx <- xx2 
}alp <- xx # alpha(j+1)lam.vec[iter+1] <- lam; alp.vec[iter+1] <- alp 
}
list (lam.vec,alp.vec)
The function NR. ALG (for implementing the Newton-Raphson algorithm of Subs. 1.5.4)
NR.ALG <- function(Lam,Alp,Num,Data=fem.data,Aa,Bb,Eta,Tor){
# This function performs Num iterations of the Newton-Raphson
# algorithm starting at lambda=Lam and alpha=Alp.
Tvec <- data[,l]; Dvec <- data[,2]; Lvec <- data[,3]
Ii <- max(lvec); Dd <- sum(dvec)
Qvec <- 1:11; for(ii in 1:11) Qvec[ii]<-sum(Dvec[Lvec==ii]) 
Kvec <- 1:11; for(ii in 1:11) Kvec[ii]<-sum(Tvec[Lvec==ii]) 
Lamvec <- c(Lam,1:Num); Alpvec <- c(Alp,l:Num)
NEW <- function(Lam,Alp,Aa,Bb,Eta, Tor,Dd,Qvec,Kvec) {
L <- (Aa+Dd-1)/Lam-Bb-sum(Kvec*(Alp+Qvec)/(Alp+Lam*Kvec)) LL <- - (Aa+Dd-1)/LamA2+
sum(Kvec^2*(Alp+Qvec)/(Alp+Lam*Kvec)A2)
A <- Ii*(1+log(Alp)-DIGAMMA(Alp))+(Eta-1)/Alp-Tor+ 
sum(DIGAMMA.VEC(Alp+Qvec))-
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sum((Alp+Qvec)/(Alp+Lam*Kvec))-sum(log(Alp+Lam*Kvec)) 
LA <- sum(Kvec/(Alp+Lam*Kvec))-sum(Kvec*(Alp+Qvec)/(Alp+Lam*Kvec)*2)
AA <- Ii*(l/Alp-TRIGAMMA(Alp))-(Eta-1)/AlpA2+
sum(TRIGAMMA.VEC(Alp+Qvec))+sum((Alp+Qvec)/ 
(Alp+Lam*Kvec)^2)-2*sum(1/(Alp+Lam*Kvec))
Mat <- matrix(c(LL,LA,LA,AA),2,2)
Vecl <- c(Lam,Alp); Vec2 <- c(L,A)
Vecl-solve(Mat)%*%Vec2}
for(i in 1:Num){Res <- NEW(Lam,Alp,Aa,Bb,Eta,Tor,Dd,Qvec,Kvec)
Lam <- Res[l]; Alp <- Res[2]
Lamvec[i+1] <- Lam; Alpvec[i+1] <- Alp 
}
rbind(Lamvec,Alpvec)
}
Demonstration o/EM.ALG and NR.ALG (compare output with Table 1-5)
EM.ALG(data=fem.data,lam=0.006,alp=l,num.iters=3)
[ d l  1 s[1] 0.006000000 0.006563452 0.006906636 0.007062994 
[[2] ] :[1] 1.000000 1.279903 1.572926 1.880652
NR.ALG(0.00 6, 1,Num=3,Aa=0,Bb=0, Eta=0, Tor=0)
[,1] [ / 2 ] [, 3] [ f 4 ]Lamvec 0.006 0.007017058 0.007482677 0.007281308 
Alpvec 1.000 1.510556190 2.191369865 2.895662552
# NB: fern.data is a matrix (see Table 1-4) with:
# column 1 = recurrence times (23,13,447,318,24,...,108),
# column 2 = statuses (1,0,1,1,1,...,0), and
# column 3 = patient numbers (1,1,2,2,3,...,28).
A3.3.2 Obtaining a sample from the joint posterior
The function GIBBS (for implementing the Gibbs sampler of Subsection 1.5.3)
GIBBS <- function(lam.start,alp.start,num.iters.1,
num.iters.2,data=fem.data,aa=0,bb=0,eta=0,tor=0){
# This fn performs (num.iters.1+num.iters.2) iter.’s of the
# Gibbs sampler, starting at lambda=lam.start and alpha=
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# alp.start, with buffered stochastic substitution for the
# last num.iters.2 iterations. Sampling of alpha is
# restricted to (0,500] from iteration (num.iters.1+1) on.
# The output is a 4-member list:
# [[1]] = vector of lambda values sampled,
# [[2]] = vector of alpha values sampled,
# [[3]] = matrix whose ith row is the vector of the
# of xi[i] values sampled, and
# [[4]] = number of times alpha had to be resampled.
lam <- lam.start; alp <- alp.start
tvec <- data[,l]; dvec <- data[,2]; lvec <- data[,3]
II <- max(lvec); dd <- sum(dvec)
qvec <- 1:11; for (ii in 1:11) qvec[ii] <- sum(dvec[lvec==ii])
kvec <- 1:11; for(ii in 1:11) kvec[ii] <- sum(tvec[lvec==ii])
num.iters <- num.iters.1+num.iters.2
lam.vec <- (1:num.iters); alp.vec <- (1:num.iters)
xi.mat <- matrix(0,II,num.iters); ct.gr.500 <- 0
SAMPLE.LAM <- function(xi,aa,bb,dd,kvec){
# Sample lambda given xi and the data, 
pari <- aa+dd; par2 <- bb+sum(xi*kvec) 
rgamma(l,parl)/par2
}
SAMPLE.XI <- function(lam,alp,II,qvec,kvec){
# Sample xi given lambda, alpha and the data.
vec <- 1:11; pari <- alp+qvec; par2 <- alp+lam*kvec 
for(ii in 1:11) vec[ii] <- rgamma(1,pari[ii])/par2[ii] 
vec 
1
KAP <- function(xi,tor){ tor+sum(xi)-log(prod(xi)) }
FN <- function (alp,xi,II,eta,tor){ (II*alp+eta-l)*
log(alp)-KAP(xi,tor)*alp-II*LOG.GAMMA(alp) }
H.FN <- function(alp,xi,II,eta,tor){
# Compute at alp a function H(.) prop, to p(alpha|xi). 
exp(FN(alp,xi,II,eta,tor))
}
FN.D <- function (alp,xi,II,eta,tor) {
# Derivative of the function H(.) evaluated at alp. 
(II*alp+eta-l)/alp+II*(log(alp)-DIGAMMA(alp))-KAP(xi,tor)}
FN.DD <- function(alp,II,eta) {
# Second derivative of the function H(.) evaluated at alp. 
II*(1/alp-TRIGAMMA(alp))-(eta-1)/alpA2
}
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H.MODE <- function(xi,II,eta,tor,
precl=0.01,prec2=0.0001,pos=0.000001,incr=10){
# Find the mode of the function H(.), first approximately
# using a 'Golden Section' method, and then via NR iter, 
dir <- 1
while(incr > precl){ 
pos <- pos+dir*incr deriv <- FN.D(pos,xi,II,eta,tor)
if(dir*deriv < 0){ dir <- dir*(-l); incr <- incr/2 }
}pos <- pos+dir*incr; delta <- 100 
while(delta > prec2){pos2 <- pos-FN.D(pos,xi,II,eta,tor)/FN.DD(pos,II,eta) 
delta <- abs(pos2-pos); pos <- pos2 
}pos
}
METROP <-function(xi,II,eta,tor,num=15,output.num=l,cc=l){
# This function returns the last output.num values of
# a Metropolis subchain of length num. This subchain
# starts at the mode of H(.) and is generated using a
# a normal driver with curvature at the mode equal to
# cc times the curvature at the mode of H(.).
Mode <- H.MODE(xi,II,eta,tor)
MM <- -cc/FN.DD(Mode,II,eta); mm <- sqrt(MM)
val <- Mode; val.vec <- rep(0,num+1); val.vec[l] <- val
for (ii in 1:num){
val2 <- mm*rnorm(1)+val 
if(val2 < 0) val2 <- val if(val2 > 0){
ratio <- H.FN(val2,xi,II,eta,tor)/H.FN(val,xi,II,eta,tor) 
if(ratio < 1){
prob <- runif(l)
if(prob > ratio) val2 <- val # i.e., reject val2
}}val.vec[ii+1] <- val2 
val <- val2 
}
val.vec[(num-output.num+2):(num+1)]
}
SAMPLE.ALP <- function(xi,II,eta,tor){
# Sample alpha given xi.
METROP(xi,II,eta,tor,num=15,output.num=l,cc=l)}
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for(ii in 1:num.iters.1){ # burn-in
xi <- SAMPLE.XI(lam,alp,II,qvec,kvec); xi.mat[,ii] <- xi 
lam <- SAMPLE.LAM(xi,aa,bb,dd,kvec); lam.vec[ii] <- lam 
alp <- SAMPLE.ALP(xi,II,eta, tor); alp.vec[ii] <- alp 
}
for(ii in (num.iters.1+1):num.iters){ # b.s.s. 
ran <- ceiling(runif(1)*100) # 1,...,100
alp <- alp.vec[ii-ran] # select an alpha from the last 100 
for(jj in 1:10){
xi <- SAMPLE.XI(lam,alp,II,qvec,kvec) 
lam <- SAMPLE.LAM(xi,aa,bb,dd,kvec)
}xi.vec[,ii] <- xi; lam.vec[ii] <- lam alp <- SAMPLE.ALP(xi,II,eta,tor) 
while(alp > 500){
alp <- SAMPLE.ALP(xi,II,eta,tor) 
ct.gr.500 <- ct.gr.500+1 
}alp.vec[ii] <- alp
}
list (lam.vec,alp.vec,xi.mat,ct.gr.500)
Obtaining the sample o f 11000 (Subsection I S .4)
gibbs.11000 <- GIBBS(lam.start=0.006948,alp.start=2.4599,num.iters.1=500,num.iters.2=10500,aa=0,bb=0,eta=l,tor=l)
lam.samp.11000 <- gibbs.11000[[1]] # see Figure 1-14 alp.samp.11000 <- gibbs.11000[[2]] # see Figure 1-13 
xi.samp.11000 <- gibbs.11000[[3]] # see Figure 1-15 (row 2)
# NB: EM.ALG was used to obtain (0.006948,2.4599) as the mode
# of p(lambda,alpha I data) for a=b=0 and eta=tor=l.
A3.33 Code for the densities in Figure 1-18
The Rao-Blackwell estimate
RAO <- function(xi.mat,Num.pts,data,From,To,aa,bb,eta,tor){
# Outputs lists of the x and y coordinates
# of the Rao-Blackwell estimator of p(lambda|data).
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tvec <- data[,l]; dvec <- data[,2]; lvec <- data[,3]
II <- max(lvec); dd <- sum(dvec)
kvec <- 1:11; for(ii in 1:11) kvec[ii] <- sum(tvec[lvec==ii]) 
NN <- length(xi.mat[1,]) # number of sample pts to be used 
par2.vec <- bb+t(xi.mat)%*%kvec; pari <- aa+dd 
xvec <- seq(From,To,(To-From)/ (Num.pts-1)) 
yvec <- xvec
for(i in l:Num.pts)
yvec[i] <- mean(par2.vec*dgamma(xvec[i]*par2.vec,pari)) 
list(xvec,yvec)
}
rao <- RAO(xi.mat=xi.samp.11000,
Num.pts=300,From=0.002,To=0.016,aa=0,bb=0,eta=l,tor=l) 
plot(rao[[1]],rao[[2]],type="l")
The normal approximation
NORM.VAR <- function(Lam,Alp,Data=fem.data,Aa,Bb,Eta,Tor){
# Outputs the cov. mat. used for the normal approx.
Tvec <- data[,l]; Dvec <- data[,2]; Lvec <- data[,3]Ii <- max(lvec); Dd <- sum(dvec)Qvec <- (1:11); for(ii in 1:11) Qvec[ii]<-sum(Dvec[Lvec==ii]) Kvec <- (1:11); for(ii in 1:11) Kvec[ii]<-sum(Tvec[Lvec==ii])
mil <- - (Aa+Dd-1)/LamA2+
sum(KvecA2* (Alp+Qvec) / (Alp+Lam*Kvec) A2)
ml2 <- sum(Kvec/(Alp+Lam*Kvec))-
sum(Kvec*(Alp+Qvec)/(Alp+Lam*Kvec)A2)
m22 <- Ii*(1/Alp-TRIGAMMA(Alp))-(Eta-1)/AlpA2+
sum(TRIGAMMA.VEC(Alp+Qvec))+sum((Alp+Qvec)/ 
(Alp+Lam*Kvec)A2)-2*sum(l/(Alp+Lam*Kvec))
solve(-matrix(c(ml1,ml2,ml2,m22),2,2))
}
st.dev <- sqrt(NORM.VAR(Lam=0.0069476,Alp=2.4599,
Aa=0,Bb=0,Eta=l,Tor=l) [1,1])
xvec <- seq(0.002,0.016,0.0001)
plot(xvec,dnorm(xvec,0.0069476,st.dev),type="l")
# NB: EM.ALG was used to obtain (0.0069476,2.4599) as the
# mode of p(lambda,alpha|data) for a=b=0 and eta=tor=l.
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The lognormal approximation
LOG.NORM.VAR <- function(Lam,Alp,Data=fem.data,Bb=0,Tor=l){
# Outputs the cov. mat. used for the lognormal approx.
Tvec <- data[,l]; Dvec <- data[f2]; Lvec <- data[,3]
Ii <- max(lvec); Dd <- sum(dvec)
Qvec <- 1:11; for(ii in 1:11) Qvec[ii]<-sum(Dvec[Lvec==ii]) 
Kvec <- 1:11; for(ii in 1:11) Kvec[ii]<-sum(Tvec[Lvec==ii])
ml2 <- Lam*Alp*(sum(Kvec*(Alp+Qvec)/(Alp+Kvec*Lam)A2)- 
sum(Kvec/(Alp+Kvec*Lam)))
mil <- -Lam*(Bb+sum(Kvec*(Alp+Qvec)/(Alp+Kvec*Lam))- 
Lam*sum(KvecA2*(Alp+Qvec)/ (Alp+Kvec*Lam)A2))
m22 <- Alp* (-Tor+Ii*(2 + log(Alp)-DIGAMMA(Alp)-
Alp*TRIGAMMA(Alp))+sum(DIGAMMA.VEC(Alp+Qvec))- 
sum ( (Alp+Qvec)/(Alp+Kvec*Lam))-sum(log(Alp+Kvec*Lam)) + 
Alp*(sum(TRIGAMMA.VEC(Alp+Qvec))+sum((Alp+Qvec)/ 
(Alp+Kvec*Lam)A2)-2*sum(l/(Alp+Kvec*Lam))))
solve (-matrix (c (ml 1 ,11112, ml2, m22) , 2 , 2 )  )
}
st.dev <- sqrt(LOG.NORM.VAR(Lam=0.0071340,Alp=2.9279) [1,1]) 
xvec <- seq(0.002,0.016, 0.0001)yvec <- dnorm(log(xvec),log(0.0071340),st.dev)/xvec 
plot(xvec,yvec,type="l")
# NB: EM.ALG was used to obtain (0.0071340,2.9279) as the
# mode of p(lambda,alpha I data) for a=l,b=0,eta=2,tor=l.
The exact marginal posterior
tvec <- fern.data[,1]; dvec <- fem.data[,2] 
lvec <- fern.data[, 3] ; II <- max(lvec); dd <- sum(dvec) 
qvec <- 1:11; for(ii in 1:11) qvec[ii]<-sum(dvec[lvec==ii]) 
kvec <- 1:11; for(ii in 1:11) kvec[ii]<-sum(tvec[lvec==ii])
ALP.FN <- function(Alpvec,Lam=Lam.def,Dd=dd, Ii=II,
Kvec=kvec,Qvec=qvec,Aa=0,Bb=0,Eta=l,Tor=l){ 
num <- length(Alpvec); resvec <- l:num for(j in 1:num){
Alp <- Alpvec[j]
resl <- (Ii*Alp+Eta-l)*log(Alp)-Tor*Alp-Ii*LOG.GAMMA(Alp) 
vecl <- l:Ii
for(i in l:Ii) vecl[i] <- LOG.GAMMA(Alp+Qvec[i])-
(Alp+Qvec[i])*log(Alp+Lam*Kvec[i]) res2 <- resl+sum(vecl)
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resvec[j] <- exp(res2)*LamA(Aa+Dd-1)*exp(-Bb*Lam)*le+113 
}resvec
}
POST.X <- seq(0.0010,0.0300,0.0001); POST.Y <- POST.X 
for(i in 1:length(POST.X)){
Lam.def <- POST.X[i]
POST.y[i] <- integrate(ALP.FN,0.005,50)$integral 
} # Each integral took about 5 minutes.
POST.FIT <- smooth.spline(POST.X,POST.Y)
POST.SPLINE.FN <- function(x){ predict.smooth.spline(POST.FIT,x)$y }
POST.INTEG <-
integrate(POST.SPLINE.FN,0.0010,0.0300)$integral 
plot (POST .X, POST. Y/POST . INTEG, type="l")
A3.3.4 Code for Figure 1-19
RAO.PRED <- function(xi2.vec,lam.vec,Num.pts,From,To){
# Outputs lists of the x and y coordinates for the
# Rao-Blackwell estimator of Subsection 1.5.6.
NN <- length(xi2.vec)
pari <- 8; par2.vec <- 8*lam.vec*xi2.vec
xvec <- seq(From,To,(To-From)/(Num.pts-1)); yvec <- xvec 
for(i in l:Num.pts)
yvec[i] <- mean(par2.vec*dgamma(xvec[i]*par2.vec,pari)) 
list(xvec,yvec)
}
rao.pred<-RAO.PRED(xi2.vec=xi.samp.11000[2,1001:11000],
lam.vec=lam.samp,11000[1001:11000] , 
Num.pts=500,From=0,To=1200) 
predict.samp.10000 <- rgamma(10000,8)/
(8*lam.samp.11000[1001:11000]*xi.samp.11000[2,1001:11000]) 
par(mai=c(1.4,0.8,1.1,0.5) )
hist(predict.samp.10000[predict.samp.10000 <= 1200],48, 
probability=T,xlab=
"mean of 8 new recurrence times for the second patient", 
ylab="density / scaled frequency", 
xlim=c(0.00,1200),ylim=c(0,0.004),
sub="\n\n\nFigure 1-14 Rao-Blackwell estimate of the
predictive density")
lines(rao.pred[[1]],rao.pred[[2]] )
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A3.4 CODE FOR SECTION 2.4
Computation of the cutoffs shown in Figure 2-1, using Thall and Simonfs (1993) code
testboundl <- bound.get() # Note that a graph is displayed. 
OUTER BOUNDARY COMPUTATION MENU
(1) Derive parameters (W90, mu) of beta prior on ThetaS 
using graphical display, then compute boundaries
(2) Specify parameters (W90, mu) of beta prior on ThetaS 
without using graphical display, then compute boundaries
(3) Specify parameters (a, b) of beta prior on ThetaS 
without using graphical display, then compute boundaries
(4) Fetch existing boundaries from file
Enter the number of your choice: 1 
Enter the prior mean (mu) of ThetaS: 0.2
Enter the width (W90) of the 90% probability interval aroundmu: 0.1
Is this an accurate representation of your prior?
Enter ((1) Yes (2) No - I'd like to change the parameters: 2
Enter the prior mean (mu) of ThetaS: 0.2
Enter the width (W90) of the 90% probability interval aroundmu: 0.2
Is this an accurate representation of your prior?
Enter ((1) Yes (2) No - I'd like to change the parameters: 1
You have chosen the following beta parameters. aS= 8.14782 bS= 32.59126
Enter the targeted improvement (deltaO): 0.15
Enter the prior concentration parameter (cE=aE+bE) ofThetaE: 2
Enter the minimum # patients (nMin): 10 
Would you like to:
(1) Specify nMax (2) Use the beta posterior to calculate nMax: 1
Enter the maximum # patients (nMax): 65 Enter pL: 0.05 
Enter pU: 0.95
Your outer boundaries have been retrieved or computed.Hit [RETURN] to continue.
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testboundl$UpperBnd
[1] 2 3 4 5 6 7 8 9 10 5 6 6 6 7 7 7 8 8 8[20] 9 9 9 10 10 10 11 11 11 12 12 12 12 13 13 13 14 14 14
[39] 15 15 15 16 16 16 17 17 17 18 18 18 18 19 19 19 20 20 20
[58] 21 21 21 22 22 22 23 23
testboundl$LowerBnd
[1] -1 -1 -1 -1 -1 -1 -1 -1 -1 1 1 1 1 2 2 2 2 2 3[20] 3 3 3 4 4 4 4 4 5 5 5 5 6 6 6 6 7 7 7
[39] 7 8 8 8 8 9 9 9 9 10 10 10 10 11 11 11 11 12 12
[58] 12 12 13 13 13 13 14 14
The function OCS (for computing operating characteristics)
OCS <- function(nl,n2,IV,uV,pE){
#
#
#
#
#
#
#
#
#
#
#
#
#
#
#
#
#
#
#
#
For the associated phase IIB design and specifications, 
this function outputs operating characteristics in the 
form of a list comprising:
(1) a vector named $probs consisting of P.pos, P.neg 
and P.inc, the overall probabilities of declaring 
the experimental treatment promising and not 
promising, and the overall probability of 
declaring the trial inconclusive, respectively;
(2) a matrix named $all.probs with first column 
consisting of n, and second and third columns 
consisting of P.pos.n and P.neg.n, the 
probabilities of declaring the experimental treatment promising and not promising, respectively, at each stage n of the 
trial, for n=nl, ...,n2; and
(3) a vector named $size consisting of MIO, M25, M50, 
M75, M90, and ASN,
where Mq is the qth percentile of the achieved 
sample size, and ASN is the average sample number 
or expected sample size.
#
#
#
#
#
#
#
#
#
The specifications required are:
n2, the maximum number of patients (n2 > 1);
nl, the minimum number of patients (0 < nl < n2);
IV, a vector consisting of the lower cutoffs 
(at each step n=nl,...,n2); 
uV, a vector consisting of the upper cutoffs 
(at each step n=nl,...,n2); and 
pE, the fixed experimental treatment response rate 
(in [0,1]).
NN <- n2-nl+l; T.mat <- matrix(0,NN,n2+l) 
T.mat[l,] <- dbinom((0:n2),nl,pE)
for(n.var in 2:NN)
if((0 < uV[n.var-1]) && (0 > IV[n.var-1]))
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T.mat[n.var,1] <- (1-pE)*T.mat[n.var-1,1]
for(n.var in 2:NN)for(x.var in 2:(nl+n.var)){ 
val <- 0if(((x.var-1) < uV[n.var-1]) &&((x.var-1) > IV[n.var-1])) 
val <- (1-pE)*T.mat[n.var-1,x.var] 
if(((x.var-2) < uV[n.var-1]) &&((x.var-2) > IV[n.var-1])) 
val <- val+pE*T.mat[n.var-1,x.var-1]
T.mat[n.var,x.var] <- val
}
P.pos.V <- rep(0,n2); P.neg.V <- rep(0,n2) 
for (nn in nl:n2){if(uV[nn-nl+1] < (nn+1)) P.pos.V[nn] <-
sum(T.mat[nn-nl+1,(uV[nn-nl+1]+1):(n2+l)]) 
if(IV[nn-nl+1] > -1) P.neg.V[nn] <-
sum(T.mat[nn-nl+1,1:(IV[nn-nl+1]+1)])}
P.pos <- sum(P.pos.V); P.neg <- sum(P.neg.V)
P . inc <- 1-P.pos-P.neg
w.vec <- P.pos.V+P.neg.V # p.d.f. of achieved sample size 
w.vec[n2] <- 1-sum(w.vec[-n2])
W.vec <- cumsum(w.vec) # c.d.f. of achieved sample size 
ASN <- sum((nl:n2)*w.vec[nl:n2])
Ml0 <- nl; M25 <- nl; M50 <- nl; M75 <- nl; M90 <- nl 
pr <- W.vec[M90]
while(pr < 0.90) {
if(pr < 0.10) MIO <- M10+1; if(pr < 0.25) M25 <- M25+1 if(pr < 0.50) M50 <- M50+1; if(pr < 0.75) M75 <- M75+1 
M90 <- M90+1; pr <- W.vec[M90]
}
P.neg.V <- P.neg.V[nl:n2]; P.pos.V <- P.pos.V[nl:n2]
list(probs=matrix(cbind(P.pos,P.neg,P.inc),nrow=l,
dimnames=list(' ',c('P.pos',
'P.neg','P.inc'))),all.probs=matrix(rbind(nl:n2,P.pos.V,P.neg.V), 
ncol=NN,
dimnames=list(c('n ','P.pos.n ',
'P.neg.n '),rep(' ',NN))),
size=matrix(cbind(MIO,M25,M50,M75,M90,ASN),nrow=l, 
dimnames=list(' ',c ('MIO','M25','M50','M75','M90','ASN'))))
}
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Demonstration of OCS (compare output with Table 2-1, column 4)
ocs <- OCS(10,65,testboundl$LowerBnd[10:65],testboundl$UpperBnd[10:65],0.2)
ocs$probs
P.pos P.neg P.inc
0.07117385 0.8350319 0.09379428
ocs$size
MIO M25 M50 M75 M90 ASN
10 10 14 32 64 24.06398
Code for Figure 2-4
par(mai=c(1.3,0.9,0.9,0.7)); par(mfrow=c(1,1)) 
ocsl <- OCS(10,65,testboundl$LowerBnd[10:65],testboundl$UpperBnd[10:65],0.2) 
ocs2 <- OCS(10,65,testboundl$LowerBnd[10:65],testboundl$UpperBnd[10:65],0.35) 
prsUl <- ocsl$all.probs[2,]; prsU2 <- ocs2$all.probs[2,] 
prsLl <- ocsl$all.probs[3,]; prsL2 <- ocs2$all.probs[3,] 
outUl <- (1:56)[prsül==0]; outU2 <- (1:56)[prsU2==0] 
outLl <- (1:56)[prsLl==0]; outL2 <- (1:56)[prsL2==0] 
plot(c(10,65),c (-11,0),type="n",lab=c(11,8),sub=H\n \nFigure 2-4 Declaration probabilities",
xlab="number of patients treated", ylab="logarithm of probability when nonzero") points((10:65)[-outUl],log(prsUl[-outUl]),pch=0,cex=l) 
points((10:65)[-outLl],log(prsLl[-outLl]),pch=2,cex=l) 
points((10:65)[-outU2],log(prsU2[-outU2]),pch=15,cex=l) 
points((10:65)[-outL2],log(prsL2[-outL2]),pch=17,cex=l) 
legend(c(20,65),c(0,-2.3),c ("Probability of declaring E promising for pE = 0.2",
"Probability of declaring E not promising for pE = 0.2",
"Probability of declaring E promising for pE = 0.35",
"Probability of declaring E not promising for pE = 0.35"),
marks=c(0,2,15,17), cex=l)
text(10,-9,"If the probability is nonzero,",adj=0) 
text(10,-9.5,"the number of patients is given below each symbol,",adj=0) 
text(10,-10,"and the probability, to 3 decimal places, above.",adj=0) 
delta <- 0.165
text((10:65) [-outUl],log(prsUl[-outUl])-delta,
labels=(10:65)[-outUl],cex=0.3) 
text((10:65)[-outLl],log(prsLl[-outLl])-delta,
labels=(10:65)[-outLl],cex=0.3) 
text((10:65)[-outU2],log(prsU2[-outU2])-delta,
labels=(10:65)[-outU2],cex=0.3) 
text((10:65)[-outL2],log(prsL2[-outL2])-delta,
labels=(10:65)[-outL2],cex=0.3)
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text ( (10:65) [-outUl] , log(prsUl[-outUl])+delta,
labels=round(prsUl[-outUl],3),cex=0.3) 
text ( (10:65) [-outLl],log(prsLl[-outLl])+delta,
labels=round(prsLl[-outLl],3),cex=0.3) 
text ( (10:65) [-outU2],log(prsU2[-outU2])+delta,
labels=round(prsU2[-outU2],3),cex=0.3) 
text ( (10:65) [-outL2],log(prsL2[-outL2])+delta,
labels=round(prsL2[-outL2],3), cex=0.3)
A3.5 CODE FOR SECTION 2.5
The function CUTOFFS (for computing cutoffs based on discrete priors)
CUTOFFS <- function(sV,eV,nl,n2,pL,pU,dd){
# For the phase IIB design specified, this function outputs
# a matrix with first row consisting of n, and with second
# and third rows consisting of l.n and u.n, the lower and
# upper cutoffs, respectively, at each stage n of the# clinical trial, for n=nl,...,n2.
The specifications required for the design are:
sV, a vector consisting of any multiple of the p.d.f. 
of the standard treatment's discrete prior 
distribution defined exclusively on (2k-l)/(2K), 
k=l,...,K, where K is any integer greater than 1; 
eV, a vector consisting of any multiple of the p.d.f. 
of the experimental treatment's discrete prior 
distribution defined exclusively on (2k-l)/(2K), k=l,...,K;
n2, the maximum number of patients (n2 > 1);
nl, the minimum number of patients (0 < nl < n2);
pL, a 'small' probability (in (0,1));
pU, a 'large' probability (in (0,1)); and
dd, the targeted improvement (in [0,(K-l)/K)).
CALC.P.POS <- function(sV,h.array,nl,KK,nn,xx){ 
hV <- 1-cumsum(h.array[xx+1,1:(KK-1),nn-nl+1]) 
sum(sV[1:(KK-1)]*hV)
}
CALC.P.NEG <- function(sV,h.array,nl,KK,d.star,nn,xx){ 
hV <- 1-cumsum(h.array[xx+1,1: (KK-1),nn-nl + 1]) 
sum(sV[1: (KK-d.star)]*hV[d.star: (KK-1)])
}
NN <- n2-nl+l; IV <- rep(-l,n2) # vector of lower cutoffs 
uV <- (l:n2)+l # vector of upper cuttofs
KK <- length(eV); eV <- eV/sum(eV); sV <- sV/sum(sV) 
tV <- (2*(1:KK)-1)/(2*KK); d.star <- floor(KK*dd)+1
#
#
#
#
#
#
#
#
#
#
#
#
#
#
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h.array <- array(0,c(n2+l,KK,NN)) # array of E's post.
for(n.var in 1:NN) # update E's posterior
for(x.var in 1:(n.var+nl)) 
for (kk in 1:KK) {
val <- eV[kk]*tV[kk]A(x.var-1)*
(l-tV[kk])A(n.var+nl-x.var) 
h.array[x.var,kk,n.var] <- val 
}
for(n.var in 1:NN) # normalize E's posterior
for(x.var in 1:(n.var+nl)) h.array[x.var,,n.var] <-
h.array[x.var,,n .var]/sum(h.array[x.var,,n.var])
for(nn in nl:n2){ # upper cutoffs 
xx <- nn # search down
pr <- CALC.P.POS(sV,h.array,nl,KK,nn,xx) 
while((pr >= pU) && (xx > 0)){ 
uV[nn] <- xx; xx <- xx-1
pr <- CALC.P.POS(sV,h.array,nl,KK,nn,xx)}
for(nn in nl:n2){ # lower cutoffs 
xx <- 0 # search up
pr <- CALC.P.NEG(sV,h.array,nl,KK, d.star,nn,xx) 
while((pr <= pL) && (xx < nn)){ lV[nn] <- xx; xx <- xx+1
pr <- CALC.P.NEG(sV,h.array,nl,KK,d.star,nn,xx)
}
matrix(rbind(nl:n2,IV[nl:n2],uV[nl:n2]),ncol=NN,
dimnames=list(c('n ','l.n ','u.n '),rep(' ',NN)))
}
The function TEST.CUTOFFS (for assessing the precision of a discretizing scheme)
TEST.CUTOFFS <- function(aS,bS,deltaO,cE,
nMin,nMax,pL,pU,KK,pdfORcdf=l){
# This function uses the function CUTOFFS to test the
# precision of the discretizing
# scheme defined in Section 2.5.1 in approximating the
# cutoffs which have been computed using continuous beta
# priors via Thall and Simon's philosophy and code.
# It outputs the cutoffs calculated for [0,1] discretized
# into the KK points tk=(2k-l)/(2KK) , k=l, ...,KK, where
# KK is any integer greater than 1. The approximating# p.d.f.'s are either:
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# (a) the beta p.d.f. ordinates at each tk, in which case
# pdfORcdf should be specified as 1; or
# (b) the beta probabilities between tk-1/(2KK) and
# tk+1/(2KK) for each k, in which case pdfORcdf=2.
The other specifications required are:
aS and bS, the parameters of the beta distribution
for the standard treatment response rate; 
deltaO, targeted improvement
(0 <= deltaO < (KK-D/KK);
cE, concentration parameter of the experimental
treatment beta dsn (2 <= cE <= 10); 
nMin, min. no. of patients (0 < nMin < nMax);
nMax, max. no. of patients (nMax > 1);
pL, a small probability (0 < pL < 1); and
pU, a large probability (0 < pU < 1).
aE <- cE*(aS/(aS+bS)+delta0/2) ; bE <- cE-aE
tK <- (2*(1:KK)-1)/ (2*KK)
if(pdfORcdf == 1){ # 1 = pdf
eV <- dbeta(tK,aE,bE)/sum(dbeta(tK,aE,bE)) 
sV <- dbeta(tK,aS,bS)/sum(dbeta(tK,aS,bS))
}
if(pdfORcdf == 2){ # 2 = cdf
eV <- pbeta(tK+1/(2*KK),aE,bE)-pbeta(tK-1/(2*KK), aE,bE) 
sV <- pbeta(tK+1/(2*KK),aS,bS)-pbeta(tK-1/(2*KK),aS,bS)}
CUTOFFS(sV,eV,nMin,nMax,pL,pU, deltaO)
}
Demonstration o/TEST.CUTOFFS and CUTOFFS (see Tables 2-10 and 2-16)
TEST.CUTOFFS(tb$aS,tb$bS,tb$delta,tb$cE,5,20,.1,.9,30,1)
n 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 201. n 0 0 1 1 1  2 2 3 3 3 4 4 4 5 5 5u . n 4 4 5 5 6 6 7 7 7 8 8 9 9 9 10 10
ek <- 
sk <-
c (0, 1,2, 3, rep (4, 
c (rep (0, 8) ,1,2,8
12),3,2,1 
,19,19,8,
,0)
2,1,0, 0,0,0)
ek80 <- rep(ek,c(rep(4,20))); sk80 <- rep(sk,c(rep (4,20)))
CUTOFFS(sk80,ek80,4,12,0.1,0.9,0.1) 
n 4 5 6 7 8 9 10 11 12
l.n 1 2 2 3 3 4  5 5 6
u.n 5 6 6 7 8 9  9 10 11
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